(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 13 February 2003 (13.02.2003)

(10) International Publication Number WO 03/012082 A2

- (51) International Patent Classification7: 15/11, A61K 48/00, 31/70
- (21) International Application Number: PCT/GB02/03409
- 25 July 2002 (25.07.2002) (22) International Filing Date:
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0118223.7

26 July 2001 (26.07.2001) GB

- (71) Applicant (for all designated States except US): AXOR-DIA LIMITED [GB/GB]; Firth Court, Western Bank, Sheffield S10 2TN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ANDREWS, Peter [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB). WALSH, James [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB). GOKHALE, Paul [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB).

- C12N 5/06, (74) Agent: HARRISON GODDARD FOOTE; 31 St Saviourgate, York YO1 8NQ (GB).
 - (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
 - (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR MODULATING STEM CELL DIFFERENTIATION USING STEM LOOP RNA

(57) Abstract: This invention relates to a method to promote the differentiation of stem cells, typically embryonic stem cells, through the use of RNA interference, by the introduction of stem loop RNA into a cell.

Method for Modulating Stem Cell Differentiation Using Stem Loop RNA

The invention relates to a method to modulate stem cell differentiation comprising introducing stem loop containing RNA into a stem cell to ablate mRNA's which encode polypeptides which are involved in stem cell differentiation; stem loop RNA's; and nucleic acid molecules and vectors encoding stem loop RNA's.

A number of techniques have been developed in recent years which purport to specifically ablate genes and/or gene products. For example, the use of anti-sense nucleic acid molecules to bind to and thereby block or inactivate target mRNA molecules is an effective means to inhibit the production of gene products. This is typically very effective in plants where anti-sense technology produces a number of striking phenotypic characteristics. However, antisense is variable leading to the need to screen many, sometimes hundreds of, transgenic organisms carrying one or more copies of an antisense transgene to ensure that the phenotype is indeed truly linked to the antisense transgene expression. Antisense techniques, not necessarily involving the production of stable transfectants, have been applied to cells in culture, with variable results.

In addition, the ability to be able to disrupt genes via homologous recombination has provided biologists with a crucial tool in defining developmental pathways in higher organisms. The use of mouse gene "knock out" strains has allowed the dissection of gene function and the probable function of human homologues to the deleted mouse genes, (Jordan and Zant, 1998).

25

30

5

10

15

A much more recent technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to

form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding sequence of the gene which is to be ablated.

Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

The exact mechanism of RNAi action is unknown although there are theories to explain this phenomenon. For example, all organisms have evolved protective mechanisms to limit the effects of exogenous gene expression. For example, a virus often causes deleterious effects on the organism it infects. Viral gene expression and/or replication therefore needs to be repressed. In addition, the rapid development of genetic transformation and the provision of transgenic plants and animals has led to the realisation that transgenes are also recognised as foreign nucleic acid and subjected to phenomena variously called quelling (Singer and Selker, 1995), gene silencing (Matzke and Matzke, 1998), and co-suppression (Stam et. al., 2000).

Initial studies using RNAi used the nematode Caenorhabditis elegans. RNAi injected into the worm resulted in the disappearance of polypeptides corresponding to the gene sequences comprising the RNAi molecule (Montgomery et. al., 1998; Fire et. al., 1998). More recently the phenomenon of RNAi inhibition has been shown in a number of eukaryotes including, by example and not by way of limitation, plants, trypanosomes (Shi et. al., 2000) Drosophila spp. (Kennerdell and Carthew, 2000).

Recent experiments have shown that RNAi may also function in higher eukaryotes. For example, it has been shown that RNAi can ablate c-mos in a mouse ooctye and also E-cadherin in a mouse preimplanation embryo (Wianny and Zernicka-Goetz, 2000).

The use of RNAi to ablate stem cell RNA is disclosed in our co-pending application, WO 02/16620, which is incorporated by reference.

5

10

During mammalian development those cells that form part of the embryo up until the formation of the blastocyst are said to be totipotent (e.g. each cell has the developmental potential to form a complete embryo and all the cells required to support the growth and development of said embryo). During the formation of the blastocyst, the cells that comprise the inner cell mass are said to be pluripotential (e.g. each cell has the developmental potential to form a variety of tissues).

Embryonic stem cells (ES cells, those with pluripotentiality) may be principally derived from two embryonic sources. Cells isolated from the inner cell mass are termed embryonic stem (ES) cells. In the laboratory mouse, similar cells can be derived from the culture of primordial germ cells isolated from the mesenteries or genital ridges of days 8.5-12.5 post coitum embryos. These would ultimately differentiate into germ cells and are referred to as embryonic germ cells (EG cells).

Each of these types of pluripotential cell has a similar developmental potential with respect to differentiation into alternate cell types, but possible differences in behaviour (eg with respect to imprinting) have led to these cells to be distinguished from one another.

- Typically ES/EG cell cultures have well defined characteristics. These include, but are not limited to;
 - i) maintenance in culture for at least 20 passages when maintained on fibroblast feeder layers;
- 25 ii) produce clusters of cells in culture referred to as embryoid bodies;
 - iii) ability to differentiate into multiple cell types in monolayer culture;
 - iv) can form embryo chimeras when mixed with an embryo host;
 - v) express ES/EG cell specific markers.
- 30 Until very recently, in vitro culture of human ES/EG cells was not possible. The first indication that conditions may be determined which could allow the establishment of

human ES/EG cells in culture is described in WO96/22362. The application describes cell lines and growth conditions which allow the continuous proliferation of primate ES cells which exhibit a range of characteristics or markers which are associated with stem cells having pluripotent characteristics.

5

10

15

20

25

30

More recently Thomson et al (1998) have published conditions in which human ES cells can be established in culture. The above characteristics shown by primate ES cells are also shown by the human ES cell lines. In addition the human cell lines show high levels of telomerase activity, a characteristic of cells which have the ability to divide continuously in culture in an undifferentiated state. Another group (Reubinoff et. al., 2000) have also reported the derivation of human ES cells from human blastocyts. Shamblott et. al., 1998 have also described EG cell derivation. In Lake et al J Cell Science 2000, 113:555-66 and Rathjen et al J Cell Science 1999, 112: 601-12, ectodermal stem cells are disclosed. The above references are each both incorporated by reference in their entirety.

A feature of ES/EG cells is that, in the presence of fibroblast feeder layers, they retain the ability to divide in an undifferentiated state for several generations. If the feeder layers are removed then the cells differentiate. The differentiation is often to neurones or muscle cells but the exact mechanism by which this occurs and its control remain unsolved.

In addition to ES/EG cells a number of adult tissues contain cells with stem cell characteristics. Typically these cells, although retaining the ability to differentiate into different cell types, do not have the pluripotential characteristics of ES/EG cells. For example haemopoietic stem cells have the potential to form all the cells of the haemopoietic system (red blood cells, macrophages, basophils, eosinophils etc). All of nerve tissue, skin and muscle retain pools of cells with stem cell potential. Therefore, in addition to the use of embryonic stem cells in developmental biology, there are also adult stem cells which may also have utility with respect to determining the factors which govern cell differentiation. Further recent studies have suggested

that some stem cells previously thought to be committed to a single fate, (e.g neurons) may indeed possess considerable pluripotentcy in certain situations. Neural stem cells have recently been shown to chimerise a mouse embryo and form a wide range of non-neural tissue (Clark et. al., 2000).

5

10

A further group of cells which have relevance to developmental biology are pluripotent embryonal carcinoma cells (EC cells) which are stem cells of teratocarcinomas, also referred to as teratomas, which are able to differentiate into all cell types found in these tumours. A teratocarcinoma also includes teratocarcinoma cells which do not have the full pluripotential characteristics of an EC cell but nevertheless can differentiate into a restricted number of differentiated tissues. These cells have many features in common with ES/EG cells. The most important of these features is the characteristic of pluripotentiality.

15 Teratomas contain a wide range of differentiated tissues, and have been known in humans for many hundreds of years. They typically occur as gonadal tumours of both men and women. The gonadal forms of these tumours are generally believed to originate from germ cells, and the extra gonadal forms, which typically have the same range of tissues, are thought to arise from germ cells that have migrated incorrectly during embryogenesis. Teratomas are therefore generally classed as germ cell tumours which encompasses a number of different types of cancer. These include seminoma, embryonal carcinoma, yolk sac carcinoma and choriocarcinoma.

The similar biology of EC cells with ES/EG cells has been exploited to study the developmental fates of cells and to identify cell markers commonly expressed in EC cells and ES/EG cells. For example, and not by way of limitation, the expression of specific cell surface markers SSEA-3 (+), SSEA-4 (+), TRA-1-60 (+), TRA-1-81 (+) (Shevinsky et al 1982; Kannagi et al 1983; Andrews et al 1984a; Thomson et al 1995); alkaline phosphatase (+) (Andrews et. al., 1996); and Oct 4 (Scholer et. al., 1989; Kraft et. al., 1996; Reubinoff et. al., 2000; Yeom et. al., 1996).

25

We have accumulated expression studies which identify a number of genes thought to be involved in determining the developmental fate of stem cells, particularly embryonic stem cells. By northern blotting we have identified the expression of human homologs of two signalling pathways believed to be critical in cell fate determination. Expression of ligands, receptors and downstream components of the Notch and Wingless signalling cascades have been elucidated. Using the model system NTERA2/D1 embryonal carcinoma cells we have recorded changes in the expression of some of these components as the cells differentiate. Bearing in mind the role these cascades play in embryonic development throughout the animal kingdom, these changes suggest a significant role for both the wingless and Notch signalling pathways in differentiation of stem cells. Furthermore the activity of some genes are required for differentiation to occur along specific pathways e.g. the myogenic gene MyoD1. Other genes have activity which inhibits cellular differentiation along particular pathways. We envisage regulation of stem cell differentiation to yield a specific cell type could be achieved by:

- (i) inhibition of certain genes that normally promote differentiation along particular pathways; therefore promoting differentiation to alternate cell phenotypes;
- 20 (ii) inhibition of gene activity that prevents differentiation into particular cell types; and
 - (iii) a combination of (i) and (ii), see figure 1
- In our co-pending application, WO02/16620, we introduce RNAi molecules homologous to genes encoding factors involved in stem cell differentiation. The differentiation of stem cells during embryogenesis, during tissue renewal in the adult and wound repair is under very stringent regulation; aberrations in this regulation underlie the formation of birth defects during development and are thought to underlie cancer formation in adults.

·5 ·

10

Generally, it is envisaged that stem cells are under both positive and negative regulation which allows a fine degree of control over the process of cell proliferation and cell differentiation: excess proliferation at the expense of cell differentiation can lead to the formation of an expanding mass of tissue – a cancer – whereas express differentiation at the expense of proliferation can lead to the loss of stem cells and production of too little differentiated tissue in the long term, and especially the loss of regenerative potential. Certain genes have already been identified to have a negative role in preventing stem cell differentiation. Such genes, like those of the Notch family, when mutated to acquire activity can inhibit differentiation; such mutant genes act as oncogenes. On the contrary, loss of function of such genes on their inhibition results in stem cell differentiation.

We propose to use EC cells has a model cell system to follow the effects of perturbations in stem cell differentiation. We further propose an alternative approach to introduce double stranded RNA molecules into stem cells to ablate mRNA's.

The invention relates to the provision of stem-loop RNA structures which can either be synthesised *in vitro* followed by transfection into a stem cell, or alternatively, synthesised *in vivo* by the stem cell from vectors which are provided with expression cassettes which include a DNA molecule which includes the coding sequence for the stem-loop RNA.

The DNA molecule encoding the stem-loop RNA is constructed in two parts, a first part which is derived from a gene the regulation of which is desired. The second part is provided with a DNA sequence which is complementary to the sequence of the first part. The cassette is typically under the control of a promoter which transcribes the DNA into RNA. The complementary nature of the first and second parts of the RNA molecule results in base pairing over at least part of the length of the RNA molecule to form a double stranded hairpin RNA structure or stem-loop. The first and second parts can be provided with a linker sequence.

5

10

15

20

25

According to a first aspect of the invention there is provided a method to modulate the differentiation state of a stem cell comprising:

- (i) contacting a stem cell with at least one nucleic acid molecule comprising a sequence of a gene which mediates at least one step in the differentiation of said cell which nucleic acid molecule consists of a first part linked to a second part wherein said first and second parts are complementary over at least part of their length and further wherein said first and second parts form a double stranded region by complementary base pairing over at least part of their length;
- 10 (ii) providing conditions conducive to the growth and differentiation of the cell treated in (i) above; and optionally
 - (iii) maintaining and/or storing the cell in a differentiated state.

In a preferred method of the invention said first and second parts are linked by at least one nucleotide base.

The provision of first and second sequences which are complementary to one another and which comprise at least part of the coding sequence of a gene involved in stem cell differentiation means that when the sequence is transcribed into RNA the complementarity between first and second sequences allows base pairing between first and second sequences to form a double stranded RNA structure, see Figure 1. The optional provision of a linking region bewteen first and second parts results in the formation of a so called "hair-pin" loop structure. The transcription of the nucleic acid provides many copies of the hair-pin loop RNA which effectively functions as a RNAi molecule.

In a preferred method of the invention said nucleic acid molecule is a stem loop RNA molecule. Alternatively, said nucleic acid molecule is a DNA molecule which encodes said stem loop RNA. Ideally said DNA molecule is a vector adapted for expression of said stem loop RNA.

5

20

25

The stem cell in (i) above may be a teratocarcinoma cell.

In a preferred method of the invention said conditions are in vitro cell culture conditions.

5

10

15

20

In a further preferred method of the invention said stem cell is selected from: pluripotent stem cells such as embryonic stem cell; embryonic germ cell and embryonal carcinoma cells; and lineage restricted stem cells such as, but not restricted to; haemopoietic stem cell; muscle stem cell; nerve stem cell; skin dermal sheath stem cell; liver stem cell; and teratocarcinoma cells.

It will be apparent that the method can provide stem cells of intermediate commitment. For example, embryonic stem cells could be programmed to differentiate into haemopoietic stems cells with a restricted commitment. Alternatively, differentiated cells or stem cells of intermediate commitment could be reprogrammed to a more pluripotential state from which other differentiated cell lineages can be derived.

In a further preferred method of the invention said stem cell is an embryonic stem cell or embryonic germ cell.

In a yet further preferred method of the invention said stem loop RNA molecule is derived from a gene which encodes a cell surface receptor expressed by a stem cell.

In a further preferred method of the invention said cell surface receptor is selected from: human Notch 1(hNotch 1); hNotch 2; hNotch 3; hNotch 4; TLE-1; TLE-2; TLE-3; TLE-4; TCF7; TCF7L1; TCFFL2; TCF3; TCF19; TCF1; mFringe; lFringe; rFringe; sel 1; Numb; Numblike; LNX; FZD1; FZD2; FZD3; FZD4; FZD5; FZD6; FZD7; FZD8; FZD9; FZD10; FRZB.

In an alternative preferred method of the invention said stem loop RNA molecule is derived from a gene which encodes a ligand.

Typically, a ligand is a polypeptide which binds to a cognate receptor to induce or inhibit an intracellular or intercellular response. Ligands may be soluble or membrane bound.

In a further alternative preferred method of the invention said ligand is selected from: D11-1; D113; D114; D1k-1; Jagged 1; Jagged 2; Wnt 1; Wnt 2; Wnt 2b; Wnt 3; Wnt 3a; Wnt5a; Wnt6; Wnt7a; Wnt7b; Wnt8a; Wnt8b; Wnt10b; Wnt11; Wnt14; Wnt15.

Alternatively, said gene is selected from: SFRP1; SFRP2; SFRP4; SFRP5; SK; DKK3; CER1; WIF-1; DVL1; DVL2; DVL3; DVL1L1;mFringe; IFringe; sel11; Numb; LNX Oct4; NeuroD1; NeuroD2; NeuroD3; Brachyury; MDFL

In a further preferred method of the invention said stem loop RNA molecule is derived from at least one of the sequences identified in Table 4 or Figures 4-54.

In a yet futher preferred embodiment of the invention said sequence is derived from Oct 4. Preferably the Oct 4 sequence corresponds to nucleotide sequence about 610 to about 1032 of the Oct 4 sequence found in GenBank accession number NM_002701.

Many methods have been developed over the last 30 years to facilitate the introduction of nucleic acid into cells which are well known in the art and are applicable to the stem loop RNA structures disclosed herein or the vectors which encode said stem loop structures.

Methods to introduce nucleic acid into cells typically involve the use of chemical reagents, cationic lipids or physical methods. Chemical methods which facilitate the uptake of DNA by cells include the use of DEAE -Dextran (Vaheri and Pagano Science 175: p434). DEAE-dextran is a negatively charged cation which associates

5

10

and introduces the nucleic acid into cells. Calcium phosphate is also a commonly used chemical agent which when co-precipitated with nucleic acid introduces the nucleic acid into cells (Graham et al Virology (1973) 52: p456).

The use of cationic lipids (eg liposomes (Felgner (1987) Proc.Natl.Acad.Sci USA, 84:p7413) has become a common method. The cationic head of the lipid associates with the negatively charged nucleic acid backbone to be introduced. The lipid/nucleic acid complex associates with the cell membrane and fuses with the cell to introduce the associated nucleic acid into the cell. Liposome mediated nucleic acid transfer has several advantages over existing methods. For example, cells which are recalcitrant to traditional chemical methods are more easily transfected using liposome mediated transfer.

More recently still, physical methods to introduce nucleic acid have become effective means to reproducibly transfect cells. Direct microinjection is one such method which can deliver nucleic acid directly to the nucleus of a cell (Capecchi (1980) Cell, 22:p479). This allows the analysis of single cell transfectants. So called "biolistic" methods physically shoot nucleic acid into cells and/or organelles using a particle gun (Neumann (1982) EMBO J, 1: p841). Electroporation is arguably the most popular method to transfect nucleic acid. The method involves the use of a high voltage electrical charge to momentarily permeabilise cell membranes making them permeable to macromolecular complexes.

More recently still a method termed immunoporation has become a recognised techinque for the introduction of nucleic acid into cells, see Bildirici et al Nature (2000) 405, p298. The technique involves the use of beads coated with an antibody to a specific receptor. The transfection mixture includes nucleic acid, antibody coated beads and cells expressing a specific cell surface receptor. The coated beads bind the cell surface receptor and when a shear force is applied to the cells the beads are stripped from the cell surface. During bead removal a transient hole is created through which nucleic acid and/or other biological molecules can enter. Transfection

15

20

25

efficiency of between 40-50% is achievable depending on the nucleic acid used. In addition the specificity of cell delivery of RNAi's can be enhanced by association or linkage of the RNAi to specific antibodies, ligands or receptors.

There are also a number of commercially available transfection kits which purport to provide high efficiency transfection of cells. A kit which is particularly preferred is sold under the tradename ExGen 500tm by MBI Fermentas, Lithuania. ExGen is a polyethylenimine, non-liposomal transfection reagent.

According to a further aspect of the invention there is provided a stem loop RNA molecule derived from a coding sequence of at least one gene involved in stem cell differentiation comprising a first part linked to a second part wherein said first and second parts are complementary over at least part of their length and further wherein. said first and second parts form a double stranded region by complementary base pairing over at least part of their length.

In a preferred embodiment of the invention said first and second parts are linked by at least one nucleotide base. In a further preferred embodiment of the invention said first and second parts are linked by 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide bases. In a yet further preferred embodiment of the invention said linker is at least 10 nucleotide bases.

In a preferred embodiment said coding sequence is an exon.

Alternatively said RNA molecule is derived from intronic sequences or the 5' and/or 3' non-coding sequences which flank coding/exon sequences of genes which mediate stem cell differentiation.

In a further preferred embodiment of the invention the length of the RNA molecule is between 10 nucleotide bases (nb) -1000nb. More preferably still the length of the

RNA molecule is selected from 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb. More preferably still said RNA molecule is 21nb in length.

In a further preferred embodiment of the invention said RNA molecule is 100nb; 200nb; 300nb; 400nb; 500nb; 600nb; 700nb; 800nb; 900nb; or 1000nb. More preferably still said RNA molecule is at least 1000nb.

In a further preferred embodiment of the invention said RNA molecule comprises sequences identified in Table 4 or Figures 4-54.

10

5

In yet a further preferred embodiment of the invention said RNA molecules comprise modified nucleotide bases.

It will be apparent to one skilled in the art that the inclusion of modified bases, as well as the naturally occurring bases cytosine, uracil, adenosine and guanosine, may confer advantageous properties on RNA molecules containing said modified bases. For example, modified bases may increase the stability of the RNA molecule thereby reducing the amount required to produce a desired effect. The provision of modified bases may also provide stem-loop structures which are more or less stable.

20

25

According to a further aspect of the invention there is provided a nucleic acid molecule encoding at least part of a gene which mediates at least one step in stem cell differentiation comprising a first part linked to a second part which first and second parts are complementary over at least part of their length, wherein said nucleic acid molecule is operably linked to at least one further nucleic acid molecule capable of promoting transcription of said nucleic acid linked thereto and further wherein said first and second parts form a double stranded region by complementary base pairing over at least part of their length as or when said nucleic acid molecule is transcribed.

In a preferred embodiment of the invention said first and second parts are linked by linking nucleotides as hereinbefore described.

It will be apparent to one skilled in the art that the synthesis of RNA molecules which form RNA stem loops can be achieved by providing vectors which include target genes, or fragments of target genes, operably linked to promoter sequences. Typically, promoter sequences are phage RNA polymerase promoters (eg T7, T3, SP6). Advantageously vectors are provided with multiple cloning sites into which genes or gene fragments can be subcloned. Typically, vectors are engineered so that phage promoters flank multiple cloning sites containing the gene of interest.

Alternatively target genes or fragments of target genes can be fused directly to phage promoters by creating chimeric promoter/gene fusions via oligo synthesising technology. Constructs thus created can be easily amplified by polymerase chain reaction to provide templates for the manufacture of RNA molecules comprising stem loop RNA's.

15

5

According to a further aspect of the invention there is provided a vector including an expression cassette comprising a first sequence linked to a second sequence wherein said first and second sequences are complementary over at least part of their lengths and further wherein the expression cassette is transciptionally linked to a promoter sequence.

In a preferred embodiment of the invention said first and second parts are linked by linking nucleotides as hereinbefore described.

Vectors including expression cassettes encoding stem-loop RNA's are adapted for eukaryotic gene expression. Typically said adaptation includes, by example and not by way of limitation, the provision of transcription control sequences (promoter sequences) which mediate cell/tissue specific expression. These promoter sequences may be cell/tissue specific, inducible or constitutive.

Promoter elements typically also include so called TATA box and RNA polymerase initiation selection sequences which function to select a site of transcription initiation. These sequences also bind polypeptides which function, *inter alia*, to facilitate transcription initiation selection by RNA polymerase.

5

10

15

Adaptations also include the provision of selectable markers and autonomous replication sequences which both facilitate the maintenance of said vector in either the eukaryotic cell or prokaryotic host. Vectors which are maintained autonomously are referred to as episomal vectors. Further adaptations which facilitate the expression of vector encoded genes include the provision of transcription termination sequences.

These adaptations are well known in the art. There is a significant amount of published literature with respect to expression vector construction and recombinant DNA techniques in general. Please see, Sambrook et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory, Cold Spring Harbour, NY and references therein; Marston, F (1987) DNA Cloning Techniques: A Practical Approach Vol III IRL Press, Oxford UK; DNA Cloning: F M Ausubel et al, Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994).

20

According to a further aspect of the invention there is provided a cell transfected with the nucleic acid or vector according to the invention. Preferably said cell is an embryonic stem cell or embryonic germ cell. Alternatively said cell is an embryonal carcinoma cell.

25

According to a further aspect of the invention there is provided a method to manufacture stem loop RNA molecules comprising:

(i) providing a vector or promoter/gene fusion according to the invention;

(ii) providing reagents and conditions which allow the synthesis of the RNA molecule comprising a stem loop RNA molecule according to the invention; and

(iii) providing conditions which allow the RNA molecule to base pair over at least
 5 part of its length, or at least that part corresponding to the nucleic acid sequence encoding said stem cell gene which mediates stem cell differentiation.

Preferably said gene, or gene fragment is selected from those genes represented in table 4 or Figures 4-54.

10

In vitro transcription of RNA is an established methodology. Kits are commercially available which provide vectors, ribonucleoside triphosphates, buffers, Rnase inhibitors, RNA polymersases (eg phage T7, T3, SP6) which facilitate the production of RNA.

15

According to a further aspect of the invention there is provided an *in vivo* method to promote the differentiation of stem cells comprising administering to an animal an effective amount of stem loop RNA molecule, or vector encoding a stem loop RNA molecule according to the invention, sufficient to effect differentiation of a target stem cell.

stem cell.

Preferably said method promotes differentiation in vivo of endogenous stem cells to repair tissue damage in situ.

25 It will be apparent to one skilled in the art that stem loop RNA relies on homology between the target gene RNA and double stranded region of the stem loop in a similar way to conventional RNAi. This confers a significant degree of specificity to the stem loop RNA molecule in targeting stem cells. For example, haemopoietic stem cells are found in bone marrow and stem loop RNA molecules may be administered to an animal by direct injection into bone marrow tissue.

Stem loop RNA molecules may be encapsulated in liposomes to provide protection from an animals immune system and/or nucleases present in an animals serum.

Liposomes are lipid based vesicles which encapsulate a selected therapeutic agent which is then introduced into a patient. Typically, the liposome is manufactured either from pure phospholipid or a mixture of phospholipid and phosphoglyceride. Typically liposomes can be manufactured with diameters of less than 200nm, this enables them to be intravenously injected and able to pass through the pulmonary capillary bed. Furthermore the biochemical nature of liposomes confers permeability across blood vessel membranes to gain access to selected tissues. Liposomes do have a relatively short half-life. So called STEALTH^R liposomes have been developed which comprise liposomes coated in polyethylene glycol (PEG). The PEG treated liposomes have a significantly increased half-life when administered intravenously to a patient. In addition STEALTH^R liposomes show reduced uptake in the reticuloendothelial system and enhanced accumulation selected tissues. In addition, so called immuno-liposomes have been develop which combine lipid based vesicles with an antibody or antibodies, to increase the specificity of the delivery of the RNAi molecule to a selected cell/tissue.

The use of liposomes as delivery means is described in US5580575 and US 5542935.

It will be apparent to one skilled in the art that the stem loop RNA molecules can be provided in the form of an oral or nasal spray, an aerosol, suspension, emulsion, and/or eye drop fluid. Alternatively the stem loop RNA molecules may be provided in tablet form. Alternative delivery means include inhalers or nebulisers.

25

5

10

15

According to a yet further aspect of the invention there is provided a therapeutic composition comprising a stem loop RNA molecule according to the invention or a vector encoding a stem loop RNA according to the invention.

30 Preferably said stem loop RNA molecule or vector is for use in the manufacture of a medicament for use in promoting the differentiation of stem cells to provide

differentiated cells/tissues to treat diseases where cell/tissues are destroyed by said disease.

Typically this includes pernicious anemia; stroke, neurodegenerative diseases such as

Parkinson's disease, Alzhiemer's disease; coronary heart disease; cirrhosis;
diabetes. It will also be apparent that differentiated stem cells may be used to replace
nerves damaged as a consequence of (eg replacement of spinal cord tissue).

In a further preferred embodiment of the invention said therapeutic composition further comprises a diluent, carrier or excipient.

According to a further aspect of the invention there is provided a cell obtainable by the method according to the invention.

It will be apparent that a cell obtainable by the method according to the invention has useful applications. For example, a stably transfected cell under the control of a regulatable promoter (ie inducible, repressible, developmentally regulated, cell lineage regulated, cell-cycle regulated) offers the opportunity to modulate the expression of the stem-loop RNA in said cell thereby modulating the differentiation state, or not as the case maybe, in culture or in vivo.

According to a yet further aspect of the invention there is provided at least one organ comprising at least one cell obtainable by the method according to the invention.

- According to a yet further aspect of the invention there is provided a non-human transgenic animal comprising a RNA molecule according to the invention, or a nucleic acid molecule according to the invention, or a vector according to the invention.
- An embodiment of the invention will now be described by example only and with reference to the following figures and tables wherein:

Table 1 represents a selection of antibodies used to monitor stem cell differentiation;

Table 2 represents nucleic acid probes used to assess mRNA markers of stem differentiation;

Table 3 represents protein markers of stem cell differentiation;

Table 4 represents specific primers used to generate stem loop RNA for gene specific inhibition;

Table 5 represents vectors used for the expression of stem loop RNA in cells including the promoters used to drive transcription of stem loop RNA's.

15

20

Figure 1 illustrates stem cell differentiation is controlled by positive and negative regulators (A). The specific cell phenotypes that are derived are a direct result of positive and negative regulators which activate or suppress particular differentiation events. Stem loop RNA can be used to control both the initial differentiation of stem cells (A) and the ultimate fate of the differentiated cells D1 and D2 by repression of positive activators which would normally promote a particular cell fate;

Figure 2 represents the Oct 4 nucleic acid sequence from position 610-1032 of the sequence found in GenBank accession number NM_002701.

25

Fig 3A illustrates a transcription cassette comprising a promoter sequence operable linked to a nucleic acid encoding a stem loop RNA; Fig 3B illustrates a stem loop RNA synthesised from the cassette illustrated in Fig 1A;

Figure 4 is the nucleic acid sequence of murine notch ligand delta-like 1;

Figure 5 is the nucleic acid sequence of murine notch ligand jagged 1;

Figure 6 is the nucleic acid sequence of human notch ligand jagged 1 (alagille syndrome) (JAG1);

Figure 7 is the nucleic acid sequence of human notch ligand jagged 2 (JAG2)

5

Figure 8 is the nucleic acid sequence of murine notch ligand jagged 2;

Figure 9 is the nucleic acid sequence of human notch ligand delta-like 3 (DLL3);

10

Figure 10 is the nucleic acid sequence of human notch ligand delta-1 (DLL1);

Figure 11 is the nucleic acid sequence of human notch ligand delta-like 4 (DLL4);

Figure 12 is the nucleic acid sequence of murine notch ligand delta-like 4(DLL4);

15

Figure 13 represents the nucleic acid sequence of human Wnt 13;

Figure 14 represents the nucleic acid sequence of human dickkopf1;

20

Figure 15 represents the nucleic acid sequence of human dickkopf2;

Figure 16 represents the nucleic acid sequence of human dickkopf3; and

Figure 17 represents the nucleic acid sequence of human dickkopf4;

25

Figure 18 represents the nucleic acid sequence of WNT-1;

Figure 19 represents the nucleic acid sequence of WNT-2;

30

Figure 20 represents the nucleic acid sequence of WNT 2B;

| | Figure 21 represents the nucleic acid sequence of | WNT 3; |
|----|---|---------|
| | Figure 22 represents the nucleic acid sequence of | WNT 4; |
| 5 | Figure 23 represents the nucleic acid sequence of | WNT 5A |
| | Figure 24 represents the nucleic acid sequence of | WNT 6; |
| 10 | Figure 25 represents the nucleic acid sequence of | WNT 7A |
| | Figure 26 represents the nucleic acid sequence of | WNT 8B |
| | Figure 27 represents the nucleic acid sequence of | WNT 101 |
| 15 | Figure 28 represents the nucleic acid sequence of | WNT 11; |
| | Figure 29 represents the nucleic acid sequence of | WNT 14 |
| 20 | Figure 30 represents the nucleic acid sequence of | WNT 16; |
| | Figure 31 represents the nucleic acid sequence of | FZD 1; |
| | Figure 32 represents the nucleic acid sequence of | FZD 2; |

- 25 Figure 33 represents the nucleic acid sequence of FZE 3;
 - Figure 34 represents the nucleic acid sequence of FZD 4;
 - Figure 35 represents the nucleic acid sequence of FZD 5;

Figure 36 represents the nucleic acid sequence of FZD 6;

| | Figure 37 represents the nucleic acid sequence of FZD /; |
|----|--|
| | Figure 38 represents the nucleic acid sequence of FZD 8; |
| 5 | Figure 39 represents the nucleic acid sequence of FZD 9; |
| | Figure 40 represents the nucleic acid sequence of FZD 10 |
| 10 | Figure 41 represents the nucleic acid sequence of FRP; |
| | Figure 42 represents the nucleic acid sequence of SARP 1 |
| 15 | Figure 43 represents the nucleic acid sequence of SARP 2 |
| | Figure 44 represents the nucleic acid sequence of FRZB; |
| | Figure 45 represents the nucleic acid sequence of FRPHE; |
| 20 | Figure 46 represents the nucleic acid sequence of SARP 3 |
| ٠. | Figure 47 represents the nucleic acid sequence of CER 1; |
| | |

Figure 51 represents the nucleic acid sequence of DKK 4;

Figure 48 represents the nucleic acid sequence of DKK1;

Figure 49 represents the nucleic acid sequence of DKK 2;

Figure 50 represents the nucleic acid sequence of DKK 3;

Figure 52represents the nucleic acid sequence of WIF-1;

Figure 53 represents the nucleic acid sequence of SRFP 1;

5 Figure 54 represents the nucleic acid sequence of SRFP 4;

10

20

15 Materials and Methods

Cell Culture

NTERA2 and 2102Ep human EC cell lines were maintained at high cell density as previously described (Andrews et al 1982, 1984b), in DMEM (high glucose formulation) (DMEM)(GIBCO BRL), supplemented with 10% v/v bovine foetal calf serum (GIBCO BRL), under a humidified atmosphere with 10% CO₂ in air.

Stem Loop RNA Production

25 Primers were designed against specific target genes with T7 bacteriophage promoters at their 5' ends. The primers consist of typically 18-25 bp against the target gene, a linker sequence of variable length (indicated by N in primer sequence) followed by the reverse complement of the gene specific sequence. The primers were used in a standard RNA in vitro. transcription reaction using a MEGASCRIPT kit following manufacturers protocols (Ambion, USA). Longer slRNA templates were produced buy cloning head-to—tail the sense and anti-sense gene specific sequences to generate a palindromic template from which RNA could be synthesized.

The following primers were used

| Gene | Accession | Primer Sequence |
|------------|-----------|---|
| | Number | |
| Oct4 | Z11899 | TAA TAC GAC TCA CTA TAG Ggagcagcttggggctcgagaag(N)cttctcgagcccaagctgctc |
| HsNotch2 | | TAA TAC GAC TCA CTA TAGGt cgt gca aga gcc agt tac cc(N)gg gta act ggc tct tgcacg a |
| HsNotch1 | M73980 | TAA TAC GAC TCA CTA TAGGa atg gtc aat gcg agt ggc tgt cc(N)gg aca gcc act cgc gtt gac cat t |
| CIF | | TAA TAC GAC TCA CTA TAGGa gta gtg aga gtg aga gta aca(N)tgt tac tct cac tct cac tac t |
| RBPJ-kappa | : | TAA TAC GAC TCA CTA TAGGt cetgtg cetgtg gta gag a(N)t etc tac cac agg cac agg a |
| Dlk1 | NM_002226 | TAA TAC GAC TCA CTA TAGGcctc ttg ctc ctg ctg gct tt(N)aaagccagcaggagcaagagg |

Capital letters indicate the T7 polymerase promoter sequence.

In each case, a quantity of the PCR was electrophoresed through agarose to verify product size and abundance, whilst the remainder was purified by alkaline phenol/chloroform extraction. RNA was synthesized using the Megascript kit (Ambion Inc.) according to the manufacturer's protocol and acid phenol/chloroform extracted. The simultaneous synthesis of complementary strands of RNA in a single reaction circumvents the requirement for an annealing step. However, the quality and duplexing of the synthesized RNA was confirmed by agarose gel electrophoresis, with the desired products migrating as expected for double stranded DNA of the same length.

15 Stem Loop RNA introduction to Cell Lines

Human EC stem cells were seeded at 2 X10⁵ cells/well of a 6 well plate in 3 cm³ of Dulbecco's modified Eagles medium and allowed to settle for 3 hrs.

Appx. 9.5µg of DNA was incubated with an optimised amount of ExGEN 500 for each well of a 6-well plate. Previously cells were seeded 1 day before. This gives apprx. a 70% confluent culture. The DNA/ExGen mixture was added to the cells and the culture vessel spun at 280g for 5 mins.

Total RNA production

Growing cultures of cells were aspirated to remove the DME and foetal calf serum. Trace amounts of foetal calf serum was removed by washing in Phosphate-buffered saline. Fresh PBS was added to the cells and the cells were dislodged from the culture vessel using acid washed glass beads. The resulting cell suspension was centrifuged at 300xg. The pellets had the PBS aspirated from them. Tri reagent (Sigma, USA) was added at 1ml per 10⁷ cells and allowed to stand for 10 mins at room temperature. The lysate from this reaction was centrifuged at 12000 x g for 15 minutes at 4°C. The resulting aqueous phase was transferred to a fresh vessel and 0.5 ml of isopropanol / ml of trizol was added to precipitate the RNA. The RNA was pelleted by centrifugation at 12000 x g for 10 mins at 4°C. The supernatant was removed and the pellet washed in 70% ethanol. The washed RNA was dissolved in DEPC treated double-distilled water.

Analysis of the differentiation of EC stem cells induced by exposure to Stem Loop RNA

Following exposure to stem loop RNA corresponding to specific key regulatory genes, the subsequent differentiation of the EC cells was monitored in a variety of ways. One approach was to monitor the disapearance of typical markers of the stem cell phenotype; the other was to monitor the appearance of markers pertinent to the specific lineages induced. The relevant markers included surface antigens, mRNA species and specific proteins.

25 Analysis of Transfectants by Antibody Staining and FACS

Cells were treated with trypsin (0.25% v/v) for 5 mins to disaggregate the cells; they were washed and re-suspended to $2x10^5$ cells/ml. This cell suspension was incubated with 50µl of primary antibody in a 96 well plate on a rotary shaker for 1 hour at 4°C. Supernatant from a myeloma cell line P3X63Ag8, was used as a negative control. The 96 well plate was centrifuged at 100rpm for 3 minutes. The plate was washed 3 times with PBS containing 5% foetal calf serum to remove unbound antibody. Cell

30 ·

5

10

were then incubated with 50 μl of an appropriate FITC-conjugated secondary antibody at 4°C for 1 hour. Cells were washed 3 times in PBS + 5% foetal calf serum and analysed using an EPICS elite ESP flow cytometer (Coulter eletronics, U.K).(Andrews et. al., 1982)

5

15

20

25

30

Northern blot Analysis of RNA

RNA separation relies on the generally the same principles as standard DNA but with some concessions to the tendancy of RNA to hybridise with itself or other RNA molecules. Formaldehyde is used in the gel matrix to react with the amine groups of the RNA and form Schiff bases. Purified RNA is run out using standard agarose gel electrophresis. For most RNA a 1% agarose gel is sufficient. The agarose is made in 1X MOPS buffer and supplemented with 0.66M formaldehyde. Dryed down RNA samples are reconstituted and denatured in RNA loading buffer and loaded into the gel. Gels are run out for apprx. 3 hrs (until the dye front is 3/4 of the way down the gel).

The major problem with obtaining clean blotting using RNA is the presence of formaldehyde. The run out gel was soaked in distilled water for 20 mins with 4 changes, to remove the formaldehyde from the matrix. The transfer assembly was assembled in exactly the same fashion as for DNA (Southern) blotting. The transfer buffer used however was 10X SSPE. Gels were transfered overnight. The membrane was soaked in 2X SSPE to remove any agarose from the transfer assembly and the RNA was fixed to the memebrane. Fixation was acheived using short-wave (254 nM) UV light. The fixed membrane was baked for 1-2 hrs to drive off any residual formaldehyde.

Hybridisation was acheived in aqueous phase with formamide to lower the hybridisation temperatures for a given probe. RNA blots were prehybridised for 2-4 hrs in northern prehybridisation soloution. Labelled DNA probes were denatured at 95°C for 5 mins and added to the blots. All hybridisation steps were carried out in rolling bottles in incubation ovens. Probes were hybridised overnight for at least 16

hrs in the prehybridisation soloution. A standard set of wash soloutions were used. Stringency of washing was acheived by the use of lower salt containing wash buffers. The following wash procedure is outlined as follows

| | 2X SSPE | 15 mins | room temp |
|---|-------------------|---------|-----------|
| 5 | 2X SSPE | 15 mins | room temp |
| | 2X SSPE/ 0.1% SDS | 45 mins | .65°C |
| | 2X SSPE/ 0.1% SDS | 45 mins | 65°C |
| | 0.1X SSPE | 15 mins | room temp |

10 Preparation of radiolabelled DNA probes

The method of Feinberg and Vogelstein (Feinberg and Vogelstein, 1983) was used to radioactively label DNA. Briefly, the protocol uses random sequence hexanucleotides to prime DNA synthesis at numerous sites on a denatured DNA template using the Klenow DNA polymerase I fragment. Pre-formed kits were used to aid consistency. 5-100ng DNA fragment (obtained from gel purification of PCR or restriction digests) was made up in water, denatured for 5 mins at 95°C with the random hexamers. The mixture was quench cooled on ice and the following were added,

 $5 \mu l [\alpha$ -32P] dATP 3000 Ci/mmol

20 1 μl of Klenow DNA polymerase (4U)

The reaction was then incubated at 37°C for 1 hr. Unincorporated nucleotide were removed with spin columns (Nucleon Biosciences).

Production of cDNA

25

The enzymatic conversion of RNA into single stranded cDNA was achieved using the 3' to 5' polymerase activity of recombinant Moloney-Murine Leukemia Virus (M-MLV) reverse transcriptase primed with oligo (dT) and (dN) primers. For Reverse Transcription-Polymerase Chain Reaction, single stranded cDNA was used.

- 30 cDNA was synthesised from 1µg poly (A)+ RNA or total RNA was incubated with the following
 - 1.0μM oligo(dT) primer for total RNA or random hexcamers for mRNA

0.5mM 10mM dNTP mix

1U/μi RNAse inhibitor (Promega)

1.0U/µl M-MLV reverse transcriptase in manufacturers supplied buffer

(Promega)

5 The reaction was incubated for 2-3 hours at 42°C

Fluorescent Automated Sequencing

To check the specificity of the PCR primers used to generate the template used in stem loop RNA production automatic sequencing was carried out using the prism fluorescently labelled chain terminator sequencing kit (Perkin-Elmer) (Prober et al 1987). A suitable amount of template (200ng plasmid, 100ng PCR product), 10 µM sequencing primer (typically a 20mer with 50% G-C content) were added to 8 µl of prism pre-mix and the total reaction volume made up to 20 µl. 24 cycles of PCR (94°C for 10 seconds, 50°C for 10 seconds, 60°C for 4 minutes). Following thermal cycling, products were precipitated by the addition of 2µl of 3M sodium acetate and 50 µl of 100 % ethanol. DNA was pelleted in an Eppendorf microcentrifuge at 13000 rpm, washed once in 70% ethanol and vacuum dried. Samples were analysed by the in-house sequencing Service (Krebs Institute). Dried down samples were resuspended in 4 µl of formamide loading buffer, denatured and loaded onto a ABI 373 automatic sequencer. Raw sequence was collected and analysed using the ABI prism software and the results were supplied in the form of analysed histogram traces.

Detection of specific protein targets by SDS-PAGE and Western Blotting

25

30

20

10

15

To obtain cell lysates monolayers of cells were rinsed 3 times with ice-cold PBS supplemented with 2 mM CaCl₂. Cells were incubated with 1 ml/75 cm² flask lysis buffer (1% v/v NP40, 1% v/v DOC, 0.1 mM PMSF in PBS) for 15 min at 4°C. Cell lysates were transferred to eppendorf tubes and passed through a 21 gauge needle to shear the DNA. This was followed by freeze thawing and subsequent centrifugation (30 min, 4°C, 15000g) to remove insoluble material. Protein concentrations of the

supernatants were determined using a commercial protein assay (Biorad). Samples were prepared for SDS-PAGE by adding 6 times Laemmli electrophoresis sample buffer and boiling for 5 min. After electrophoresis with 16 µg of protein on a 10% polyacrylamide gel (Laemmli, 1970) the proteins were transferred to PVDF membrane. The blots were washed with PBS and 0.05% Tween (PBS-T). Blocking of the blots occurred in 5% milk powder in PBS-T (60 min, at RT). Blots were incubated with the appropriate primary antibody. Horseradish peroxidase labelled secondary antibody was used to visualise antibody binding by ECL (Amersham, Bucks., UK). Materials used for SDS-PAGE and western blotting were obtained from Biorad (California, USA) unless stated otherwise.

Table 1: Antibodies used to detect stem cell differentiation

| Antibody | Class | Species | Cell phenotype detected | Changes on Differentiation | Reference |
|---------------|-------|----------|-------------------------------|----------------------------|--|
| TRA-1- 60 | IgM | Mouse | Human EC, ES cells. | ↓ differentiation | Andrews et.al., 1984a |
| TRA-1- 81 | IgM | Mouse | Human EC, ES cells. | ↓ differentiation | Andrews et. al.,1984a |
| SSEA3 | IgM | Rat | Human EC, ES cells. | ↓ differentiation | Shevinsky et al 1982, Fenderson et al 1987 |
| SSEA4 | IgG | Mouse | Human EC, ES cells. | ↓ differentiation | Kannagi et al 1983 Fenderson et al 1987 |
| A2B5 | IgM | Mouse | | ↑ differentiation | Fenderson et al 1987 |
| ME311 | IgG | Mouse | | ↑ differentiation | Fenderson et al 1987 |
| VIN-IS- 56 | IgM | Mouse | | ↑ differentiation | Andrews et al 1990 |
| VIN-IS- 53 | IgG | Mouse | | ↑ differentiation | Andrews et al 1990 |
| | | <u> </u> | | · | |

15

5

Table 2: Probes used to assess mRNA markers of differentiation

| Gene | Cell Type | |
|---------------------|-----------------|--|
| Synaptophysin | Neuron | |
| NeuroD1 | Neuron | |
| MyoD1 | Muscle | |
| Collagens | Cartlidge | |
| Alpha-actin | Skeletal muscle | |
| Smooth-muscle actin | Smooth muscle | |

5

10

Table 3: Protein markers of differentiation, detected by Western Blot and/or immunofluorescence.

15 The following antibodies were detected by the appropriate commercially available antibodies

| Cell Type | Antigen | |
|-------------------------|------------------------|--|
| Neurons | Neurofilaments | |
| Glial cells | GFAP | |
| Epithelial cells | Cytokeratins | |
| Mesenchymal cells | Vimentin | |
| Muscle | Desmin | |
| Muscle | Tissue specific actins | |
| Connective tissue cells | Collagens | |

Table 4: Specific Primers used to generate Stem Loop RNA for gene specific inhibition

5 All sequences written 5' to 3'

| | Gene Name | Accession | PCR primer Sequences | Position |
|---------------------|---------------------------------------|-----------|--------------------------|-----------|
| | | number | | |
| Notch Pathway | ? | | | -du |
| Ligands: | | | | |
| | D11-1 | AF003522 | | |
| | D113 | NM_016941 | | |
| | D114 | NM_019454 | | |
| | Dlk-1 | NM_003836 | | |
| | Jagged1 | U73936 | | |
| | Jagged2 | NM_002226 | | |
| Receptors: | · · · · · · · · · · · · · · · · · · · | | | |
| | Notch1 | M73980 | gcggccgcctttgtggttctgttc | 5224-5726 |
| | | | gccggcgcgtcctcctcttcc | |
| | Notch2 | In-house | gccagaatgatgctacctgt | |
| $C_{N_{p_{n_{1}}}}$ | | sequence | tagagcagcaccaatggaac | r |
| | Notch3 | U97669 | Aagttaccccaagaggcaagtgtt | 7013-7348 |
| ž | | | Aaggaaatgagaggccagaagga | |
| | | | ga | |
| | Notch4 | U95299 | ggctgccctcccactctcg | 3727-4132 |
| | | | cagcccgggccccaggatag | |
| Downstream: | · | | | |
| <u></u> | TLE-1 | NM_005077 | | |
| | TLE-2 | M99436 | | |
| | TLE-3 | M99438 | | |
| | TLE-4 | M99439 | | |

| | FZD2 | NM_001466 | tacccagagcggcctatcattttt | 955-1439 |
|---------------|---------|---------------------|--------------------------|----------------|
| | | | | 055 1:50 |
| | LCDI | 14141_002202 | | |
| Receptors | FZD1 | NM_003505 | | |
| | Wnt16 | AF169963 | | |
| | Wnt15 | AF028703 | | |
| | Wnt14 | AF028702 | | |
| | Wnt11 | NM_004626 | | |
| | Wnt10B | NM_003394 | | |
| | Wnt8B | NM_003393 | | |
| | Wnt7A | NM_004625 | | |
| | Wnt6 | AF079522 | | |
| | Wnt5A | L20861 | | |
| · | | | actcacactgggtaacacgg | · |
| | Wnt2B | NM_004185 | tgagtggttcctgtactctg | 1159-1503 |
| | Wnt2 | NM_003391 | | |
| | Wnt1 | NM_005430 | | |
| Ligands | | | | |
| Wingless Path | way | | | |
| | LNX | NM_010727 | | |
| | Numb | NM_003744 | | |
| | Se11 | AF157516 | | |
| | rFringe | AF108139 | | |
| · | lfringe | U94354 | | <u> </u> |
| | mfringe | NM_002405 | | |
| | TCF1 | NM_000545 | | |
| | TCF19 | NM_007109 | · | |
| | TCF3 | M31523 | | • |
| | TCF7 | NM_003202 Y11306 | | , - |

| | | | | |
|-----------------|------------|-------------|--------------------------|----------|
| | | | acgaagccggccaggaggaagga | |
| | | | C | |
| | FZD3 | NM_017412 | | |
| | FZD4 | NM_012193 | | |
| | FZD5 | NM_003468 | <u> </u> | |
| | FZD6 | NM_003506 | Tggcctgaggagcttgaatgtgac | 607-1026 |
| | | | Ategeceageaaaaateeaatgaa | |
| | FZD7 | NM_003507 | | |
| <u></u> | FZD8 | AA481448 | | |
| | FZD9 | NM_003508 | | |
| | FZD10 | NM_007197 | | · |
| | FRZB | NM_001463 | | · |
| Extracellular | | | | |
| Effectors | | | | <u> </u> |
| | SFRP1 | NM_003012 | | |
| | SFRP2 | AF017986 | | |
| | SFRP4 | AF026692 | agaggagtggctgcaatgaggtc | 877-1178 |
| | | | gegeeggetgttttett | |
| | SFRP5 | NM_003015 | | |
| | SK | AB020315 | 4: | <u> </u> |
| | CER1 | NM_005454 | | 1 |
| | WIF-1 | NM_007191 | | |
| | DVL1 | U46461 | | <u> </u> |
| | DVL2 | NM_004422 | | |
| | DVL3 | NM_004423 | | |
| Transcription] | Factors | | | |
| | Oct4 | Z11899 | | |
| | | | | |
| | Brachyury | NM_003181 | | |
| • | Diadityary | | | |

| | NeuroD1 | NM_002500 | |
|----------|---------|-----------|--|
| | NeuroD2 | NM_006160 | |
| | NeuroD3 | U63842 | |
| | MyoD | NM_002478 | |
| | MDFI | NM_005586 | |
| | REST | NM_005612 | |
| <u> </u> | | | |
| | | | |

Table 5

5 Listed are examples of vector systems that are to be used in cells to direct the production of stem loop RNA.

| Expression System | Vectors | Accession numbers | Promoters |
|--------------------------|------------|-------------------|------------|
| Tet-on/Tet-off | pTet-on | U89930 | CMV |
| | pTet-off | U899 29 | MyoD1 |
| Clontech, USA | pTRE2-Hyg | | NeuroD1 |
| · | | | Oct4 |
| | | • | GATA1 |
| | | | Beta-actin |
| | | | PGK |
| IRES | pIRES-EGFP | | CMV |
| * : | | | MyoD1 |
| Invitrogen, | | | NeuroD1 |
| Nethelands) | | | Oct4 |
| · | | | GATA1 |
| | | | Beta-actin |
| | | | PGK |
| Ecdysone | pIND | | CMV |
| • | pVgRXR | | MyoD1 |
| Invitrogen, | | | NeuroD1 |
| Netherlands | | | Oct4 |
| | | | GATA1 |
| | | | Beta-actin |
| | | · | PGK |

References

5

10

15

20

25

Andrews P.W., Goodfellow P.N., Shevinsky L., Bronson D. L. and Knowles B.B. 1982. Cell surface antigens of a clonal human embryonal carcinoma cell line: Morphological and antigenic differentiation in culture. *Int. J. Cancer.* 29: 523-531.

Andrews P.W., Banting G.S., Damjanov I., Arnaud D. and Avner P. 1984a. Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. *Hybridoma*. 3: 347-361.

Andrews P.W., Damjanov I., Simon D., Banting G., Carlin C., Dracopoli N.C. and Fogh J. 1984b. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2: Differentiation in vivo and in vitro. Lab. Invest. 50: 147-162.

Andrews P.W., Nudelman E., Hakomori S. -i. and Fenderson B.A. 1990. Different patterns of glycolipid antigens are expressed following differentiation of TERA-2 human embryonal carcinoma cells induced by retinoic acid, hexamethylene bisacetamide (HMBA) or bromodeoxyuridine (BUdR). Differentiation. 43: 131-138.

Fenderson B.A., Andrews P.W., Nudelman E., Clausen H. and Hakomori S.-i. 1987. Glycolipid core structure switching from globo- to lacto- and ganglio-series during retinoic acid-induced differentiation of TERA-2-derived human embryonal carcinoma cells. *Dev. Biol.* 122: 21-34.

Kannagi, R., Levery, S.B., Ishigami, F., Hakomori, S., Shevinsky, L.H., Knowles, B.B. and Solter, D. (1983) New globoseries glycosphingolipids in human teratocarcinoma reactive with the monoclonal antibody directed to a developmentally regulated antigen, stage-specific embryonic antigen 3. *J. Biol. Chem.* 258, 8934-8942.

Shevinsky, L.H., Knowles, B.B., Damjanov, I. and Solter, D. (1982) Monoclonal antibody to murine embryos defines a stage-specific embryonic antigen expressed on mouse embryos and human teratocarcinoma cells. *Cell* 30, 697-705.

Solter, D. and Knowles, B.B. (1978) Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). *Proc. natl. Acad. Sci. USA* 75, 5565-5569.

Recent progress in identifying genes regulating hematopoietic stem cell function and fate Craig T Jordan, Gary Van Zant Current Opinion in Cell Biology 1998, 10:716-720.

10

Singer MJ, Selker EU. Genetic and epigenetic inactivation of repetitive sequences in Neurospora crassa: RIP, DNA methylation, and quelling. Curr Top Microbiol Immunol. 1995;197:165-77.

Matzke MA, Matzke AJ. Gene silencing in plants: relevance for genome evolution and the acquisition of genomic methylation patterns. Novartis Found Symp. 1998;214:168-80; discussion 181-6. Review.

Stam M, de Bruin R, van Blokland R, van der Hoorn RA, Mol JN, Kooter JM. Distinct features of post-transcriptional gene silencing by antisense transgenes in single copy and inverted T-DNA repeat loci. Plant J. 2000 Jan;21(1):27-42.

Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15502-7.

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

25 Nature. 1998 Feb 19;391(6669):806-11

Kennerdell JR, Carthew RW. Heritable gene silencing in Drosophila using double-stranded RNA. Nat Biotechnol. 2000 Aug;18(8):896-898.

Shi H, Djikeng A, Mark T, Wirtz E, Tschudi C, Ullu E. Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA. RNA. 2000 Jul;6(7):1069-76.

Wianny F, Zernicka-Goetz M. Specific interference with gene function by doublestranded RNA in early mouse development. Nat Cell Biol. 2000 Feb;2(2):70-5

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, JonesJM. Embryonic stem cell lines derived from human blastocysts. Science. 1998 Nov 6;282(5391):1145-7.

Thomson JA, Kalishman J, Golos TG, Durning M, Harris CP, Becker RA, Hearn JP. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7844-8.

15

10

Prober JM, Trainor GL, Dam RJ, Hobbs FW, Robertson CW, Zagursky RJ, Cocuzza AJ, Jensen MA, Baumeister K. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science. 1987 Oct 16;238(4825):336-41.

20

Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6-13.

25 Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerasecatalyzed chain reaction. Methods Enzymol. 1987;155:335-50.

Scholer HR, Hatzopoulos AK, Balling R, Suzuki N, Gruss P. A family of octamer-specific proteins present during mouse embryogenesis: evidence for germline-specific expression of an Oct factor. EMBO J. 1989 Sep;8(9):2543-50.

WO 03/012082 PCT/GB02/03409

Kraft HJ, Mosselman S, Smits HA, Hohenstein P, Piek E, Chen Q, Artzt K, van Zoelen EJ. Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells. J Biol Chem. 1996 May 31;271(22):12873-8.

Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000 Apr;18(4):399-404.

10

5

Shamblott MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, Blumenthal PD, Huggins GR, Gearhart JD. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13726-31.

15

Clarke DL, Johansson CB, Wilbertz J, Veress B, Nilsson E, Karlstrom H, Lendahl U, Frisen J. Generalized potential of adult neural stem cells. Science. 2000 Jun 2;288(5471):1660-3.

20

25

CLAIMS

5

- 1. A method to modulate the differentiation state of a stem cell comprising:
- A method to modulate the difference and an action and action as the contacting a stem cell with at least one nucleic acid molecule comprising a
- sequence of a gene which mediates at least one step in the differentiation of said cell sequence of a gene which mediates at least one step in the differentiation of said cell which nucleic acid molecule consists of a first part linked to a second part wherein said first and second parts are complementary over at least part of their length and further wherein said first and second parts form a double stranded region by complementary base pairing over at least part of their length;
- 10 (ii) providing conditions conducive to the growth and differentiation of the cell treated in (i) above; and optionally
 - (iii) maintaining and/or storing the cell in a differentiated state.
- A method according to Claim 1 wherein said first and second parts are linked
 by at least one nucleotide base.
 - A method according to Claim 1 or 2 wherein said nucleic acid molecule is a stem loop RNA molecule or a nucleic acid molecule or a vector encoding said stem loop RNA.
 - 4. A method according to any of Claims 1-3 wherein said conditions are in vitro cell culture conditions.
 - 5. A method according to any of Claims 1-4 wherein said stem cell is selected from the group consisting of: an embryonic stem cell; an embryonic germ cell; an embryonal carcinoma cell; a haemopoietic stem cell; a muscle stem cell; a nerve stem cell; a skin dermal sheath stem cell; a liver stem cell; a teratocarcinoma cell.
 - 6. A method according to any of Claims 1-5 wherein said stem cell is an embryonic stem cell or embryonic germ cell.

- 7. A method according to any of Claims 1-6 wherein said nucleic acid molecule is derived from at least one nucleic acid sequence as represented by Figures 4-54.
- 8. A RNA molecule derived from a coding sequence of at least one gene involved in stem cell differentiation comprising a first part linked to a second part wherein said first and second parts are complementary over at least part of their length and further wherein said first and second parts form a double stranded region by complementary base pairing over at least part of their length.
- 10 9. A RNA molecule according to Claim 8 wherein said first and second parts are linked by at least one nucleotide base (nb).
 - 10. A RNA molecule according to Claim 9 wherein said first and second parts are linked by 2, 3, 4, 5, 6, 7, 8, 9, or 10nb in length.
 - 11. A RNA molecule according to Claim 9 wherein said linker is at least 10nb in length.
- 12. A RNA molecule according to any of Claims 8-11 wherein the length of the
 20 RNA molecule is between 10nb -1000nb in length.
 - 13. A RNA molecule according to Claim 12 wherein the length of the RNA molecule is selected from 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb in length.
 - 14. A RNA molecule according to Claim 12 wherein said RNA molecule is 100nb; 200nb; 300nb; 400nb; 500nb; 600nb; 700nb; 800nb; 900nb; or 1000nb in length.
- 30 15. A RNA molecule according to Claim 8 wherein said RNA molecule is at least 1000nb in length.

40

15

16. A RNA molecule according to Claim 8 wherein said RNA molecule is 21nb in length.

- 5 17. A RNA molecule according to any of Claims 8 -16 wherein said RNA molecule comprises sequences identified in Figures 4-54.
 - 18. A RNA molecule according to any of Claims 8-17 wherein said RNA molecules comprise modified nucleotide bases.

19. A nucleic acid molecule which encodes an RNA molecule according to any of Claims 8-18 wherein said nucleic acid molecule is operably linked to at least one further nucleic acid molecule capable of promoting transcription of said nucleic acid linked thereto.

20. A nucleic acid molecule according to Claim 19 wherein said further nucleic acid molecule is a promoter capable of inducible transcription.

21. A vector including a nucleic acid molecule according to Claim 19 or 20.

- 22. A cell transfected with an RNA molecule according to any of Claims 8-18, nucleic acid molecule according to Claim 19 or 20 or a vector according to Claim 21.
- 25 23. A cell according to Claim 22 wherein said cell is an embryonic stem cell or embryonic germ cell.
 - 24. A cell according to Claim 22 wherein said cell is an embryonal carcinoma cell.
 - 25. A method to manufacture stem loop RNA molecules comprising:

30

10

15

WO 03/012082 PCT/GB02/03409

(i) providing a nucleic acid molecule according to Claim 19 or 20 or a vector according to Claim 21;

- 5 (ii) providing reagents and conditions which allow the synthesis of the RNA molecule comprising a RNA molecule according to any of Claims 8-18; and
 - (iii) providing conditions which allow the RNA molecule to base pair over at least part of its length, or at least that part corresponding to the nucleic acid sequence encoding said stem cell gene which mediates stem cell differentiation.
 - 26. An *in vivo* method to promote the differentiation of stem cells comprising administering to an animal an effective amount of an RNA molecule according to any of Claims 8-18, a nucleic acid molecule according to Claim 19 or 20 or a vector according to Claim 21, sufficient to effect differentiation of a target stem cell.
 - 27. A RNA molecule according to any of Claims 8-18, a nucleic acid molecule according to Claim 19 or 20 or a vector according to Claim 21 for use as a pharmaceutical.

20

10

15

- 28. A pharmaceutical composition comprising a RNA molecule according to any of Claims 8-18, a nucleic acid molecule according to Claim 19 or 20 or a vector according to Claim 21.
- 29. Use of a RNA molecule according to any of Claims 8-18, a nucleic acid molecule according to Claim 19 or 20 or a vector according to Claim 21 for the manufacture of a medicament for use in promoting the differentiation of stem cells to provide differentiated cells/tissues to treat diseases where cell/tissues are destroyed by said disease.

- 30 Use according to Claim 29 wherein said disease is selected from the group consisting of: pernicious anemia; stroke, neurodegenerative diseases such as Parkinson's disease, Alzhiemer's disease; coronary heart disease; cirrhosis; diabetes; nerves damaged as a consequence of trauma (e.g. replacement of spinal cord tissue).
- 31. A cell obtainable by the method according to any of Claims 1-7.
- 32. An organ comprising at least one cell according to Claim 31.

10

5


33. A non-human transgenic animal comprising a RNA molecule according to any of Claims 8-18, or a nucleic acid molecule according to Claim 19 or 20, or a vector according to Claim 21.

15

20

25


Figure 1



SUBSTITUTE SHEET (RULE 26)

Figure 2

SUBSTITUTE SHEET (RULE 26)



B
5'-cgagggtgcccgagaatggat-(N),
3'-(N),-gctcccacgggctcttacctaa-(N),

Figure 3

SUBSTITUTE SHEET (RULE 26)

Figure 3

GTCCAGCGGTACCATGGGCCGTCGGAGCGCGCTAGCCCTTGCCGTGGTCTCTGCCCTGCTGTGC CAGGTCTGGAGCTCCGGCGTATTTGAGCTGAAGCTGCAGGAGTTCGTCAACAAGAAGGGGCTG CTGGGGAACCGCAACTGCTGCCGCGGGGGCTCTGGCCCGCCTTGCGCCTGCAGGACCTTCTTTC GCGTATGCCTCAAGCACTACCAGGCCAGCGTGTCACCGGAGCCACCCTGCACCTACGGCAGTG CTTCAGCAACCCCATCCGATTCCCCTTCGGCTTCACCTGGCCAGGTACCTTCTCTCTGATCATTG AAGCCCTCCATACAGACTCTCCCGATGACCTCGCAACAGAAAACCCAGAAAGACTCATCAGCC GCCTGACCACAGAGGCACCTCACTGTGGGAGAAGAATGGTCTCAGGACCTTCACAGTAGCG GCCGCACAGACCTCCGGTACTCTTACCGGTTTGTGTGTGACGAGCACTACTACGGAGAAGGTTG CTCTGTGTTCTGCCGACCTCGGGATGACGCCTTTGGCCACTTCACCTGCGGGGACAGAGGGGAG CGCTACTGCGATGAGTGCATCCGATACCCAGGTTGTCTCCATGGCACCTGCCAGCAACCCTGGC AGTGTAACTGCCAGGAAGGCTGGGGGGGCCTTTTCTGCAACCAAGACCTGAACTACTGTACTCA CCATAAGCCGTGCAGGAATGGAGCCACCTGCACCAACACGGGCCAGGGGAGCTACACATGTTC CTGCCGACCTGGGTATACAGGTGCCAACTGTGAGCTGGAAGTAGATGAGTGTGCTCCTAGCCCC TGCAAGAACGGAGCGAGCTGCACGGACCTTGAGGACAGCTTCTCTTGCACCTGCCCTCCCGGCT TCTATGGCAAGGTCTGTGAGCTGAGCGCCATGACCTGTGCAGATGGCCCTTGCTTCAATGGAGG ACGATGTTCAGATAACCCTGACGGAGGCTACACCTGCCATTGCCCCTTGGGCTTCTCTGGCTTC AACTGTGAGAAGAAGATGGATCTCTGCGGCTCTTCCCCTTGTTCTAACGGTGCCAAGTGTGTGG ACCTCGGCAACTCTTACCTGTGCCGGTGCCAGGCTGGCTTCTCCGGGAGGTACTGCGAGGACAA TGTGGATGACTGTGCCTCCCCGTGTGCAAATGGGGGCACCTGCCGGGACAGTGTGAACGAC TTCTCCTGTACCTGCCCACCTGGCTACACGGGCAAGAACTGCAGCGCCCCTGTCAGCAGGTGTG AGCATGCACCCTGCCATAATGGGGCCACCTGCCACCAGAGGGGCCAGCGCTACATGTGTGAGT GCGCCCAGGGCTATGGCGGCCCCAACTGCCAGTTTCTGCTCCCTGAGCCACCACCAGGGCCCAT GGCTGAAGCTACAGAAACACCAGCCTCCACCTGAACCCTGTGGGGGAGAGACAGAAACCATGA ACAACCTAGCCAATTGCCAGCGCGAGAAGGACGTTTCTGTTAGCATCATTGGGGCTACCCAGAT CAAGAACACCAACAAGAAGGCGGACTTTCACGGGGACCATGGAGCCAAGAAGAGCAGCTTTA AGGTCCGATACCCCACTGTGGACTATAACCTCGTTCGAGACCTCAAGGGAGATGAAGCCACGG TCAGGGATACACACAGCAAACGTGACACCAAGTGCCAGTCACAGAGCTCTGCAGGAGAAGAG TTATAGCGACTGAGGTGTAAGATGGAAGCGATGTGGCAAAATTCCCCATTTCTCTCAAATAAAAT TCCAAGGATATAGCCCCGATGAATGCTGCTGAGAGAGGAAGGGAAGGGAAACCCAGGGACTG CTGCTGAGAACCAGGTTCAGGCGAAGCTGGTTCTCTCAGAGTTAGCAGAGGCGCCCGACACTG CCAGCCTAGGCTTTGGCTGCCGCTGGACTGCCTGCTGGTTGTTCCCATTGCACTATGGACAGTTG CACGTCTATCTTGGATTACTATGAGCCAGTCTTTCCTTGAACTAGAAACACAACTGCCTTTATTG TCCTTTTTGATACTGAGATGTGTTTTTTTTTTTCCTAGACGGGAAAAAGAAAACGTGTGTTATTT TTTTGGGATTTGTAAAAATATTTTTCATGATATCTGTAAAGCTTGAGTATTTTGTGACGTTCATT TTTTTATAATTTAAATTTTGGTAAATATGTACAAAGGCACTTCGGGTCTATGTGACTATATTTTT TTGTATATAAATGTATTTATGGAATATTGTGCAAATGTTATTTGAGTTTTTTACTGTTTTAAT GAAGAAATTCATTTTAAAAATATTTTTCCAAAATAAATATAATGAACTACA

Figure 4

CTGCTCGCCCTGCTGCCCTGCGAGCCAAGGTGTGCGGGGCCTCGGGTCAGTTTGAGCTGG AGATCCTGTCCATGCAGAACGTGAATGGAGAGCTACAGAATGGGAACTGTTGTGGTGGAGTCC GGAACCCTGGCGACGCAAGTGCACCCGCGACGAGTGTGATACGTACTTCAAAGTGTGCCTCA AGGAGTATCAGTCCCGCGTCACTGCCGGGGGACCCTGCAGCTTCGGCTCAGGGTCTACGCCTGT CATCGGGGGTAACACCTTCAATCTCAAGGCCAGCCGTGGCAACGACCGTAATCGCATCGTACTG CCTTTCAGTTTCGCCTGGCCGAGGTCCTACACTTTGCTGGTGGAGGCCTGGGATTCCAGTAATG GCAATGGCAGACACTGAAACAAAACACAGGGATTGCCCACTTCGAGTATCAGATCCGAGTGAC CTGTGATGACCACTACTATGGCTTTGGCTGCAATAAGTTCTGTCGTCCCAGAGATGACTTCTTTG GACATTATGCCTGTGACCAGAACGGCAACAAAACTTGCATGGAAGGCTGGATGGGTCCTGATT GCAACAAAGCTATCTGCCGACAGGGCTGCAGTCCCAAGCATGGGTCTTGTAAACTTCCAGGTG ACTGCAGGTGCCAGTACGGTTGGCAGGGCCTGTACTGCGACAAGTGCATCCCGCACCCAGGAT GTGTCCACGGCACCTGCAATGAACCCTGGCAGTGCCTCTGTGAGACCAACTGGGGTGGACAGC TCTGTGACAAGATCTGAATTACTGTGGGACTCATCAGCCCTGTCTCAACCGGGGAACATGTAG CAACACTGGGCCTGACAAATACCAGTGCTCCTGCCCAGAGGGCTACTCGGGCCCCAACTGTGA AATTGCTGAGCATGCTTGTCTCTCTGACCCCTGCCATAACCGAGGCAGCTGCAAGGAGACCTCC TCAGGCTTTGAGTGTGAGTGTTCTCCAGGCTGGACTGGCCCCACGTGTTCCACAAACATCGATG ACTGTTCTCCAAATAACTGTTCCCATGGGGGCACCTGCCAGGATCTGGTGAATGGATTCAAGTG TGTGTGCCCGCCCAGTGGACTGGCAAGACTTGTCAGTTAGATGCAAATGAGTGCGAGGCCAA ACCTTGTGTAAATGCCAGATCCTGTAAGAATCTGATTGCCAGCTACTACTGTGATTGCCTTCCTG GCTGGATGGGTCAGAACTGTGACATAAATATCAATGACTGCCTTGGCCAGTGTCAGAATGACG CCTCCTGTCGGGATTTGGTTAATGGTTATCGCTGTATCTGTCCACCTGGCTATGCAGGCGATCAC TGTGAGAGAGACATCGATGAGTGTGCTAGCAACCCCTGCTTGAATGGGGGTCACTGTCAGAAT GAAATCAACAGATTCCAGTGTCTCTGTCCCACTGGTTTCTCTGGAAACCTCTGTCAGCTGGACA TCGATTACTGCGAGCCCAACCCTTGCCAGAATGGCGCCCAGTGCTACAATCGTGCCAGTGACTA TTTCTGCAAGTGCCCCGAGGACTATGAGGGCAAGAACTGCTCACACCTGAAAGACCACTGCCG TACCACCACCTGCGAAGTGATTGACAGCTGCACTGTGGCCATGGCCTCCAACGACACGCCTGAA GGGGTGCGGTATATCTCTTCTAACGTCTGTGGTCCCCATGGGAAGTGCAAGAGCCAGTCGGGAG GCAAATTCACCTGTGACTGTAACAAAGGCTTCACCGGCACCTACTGCCATGAAAATATCAACGA CTGCGAGAGCAACCCCTGTAAAAACGGTGGCACCTGCATCGATGGCGTTAACTCCTACAAGTGT ATCTGTAGTGACGGCTGGGAGGGAGCGCACTGTGAGAACAACATAAATGACTGTAGCCAGAAC CCTTGTCACTACGGGGGTACATGTCGAGACCTGGTCAATGACTTTTACTGTGACTGCAAAAATG GCTGGAAAGGAAAGACTTGCCATTCCCGTGACAGCCAGTGTGACGAAGCCACGTGTAATAATG CAACTTGTAATATAGCTAGAAACAGTAGCTGCCTGCCGAACCCCTGTCATAATGGAGGTACCTG CGTGGTCAATGGAGACTCCTTCACCTGTGTCTGCAAAGAAGGCTGGGAGGGGCCTATTTGTACT CAAAATACCAACGACTGCAGTCCCCATCCTTGTTACAATAGCGGGACCTGTGTGGACGGAGAC AACTGGTATCGGTGCGAATGTGCCCCGGGTTTTGCTGGGCCAGACTGCAGGATAAACATCAATG AGTGCCAGTCTTCCCCTTGTGCCTTTGGGGCCACCTGTGTGGATGAGATCAATGGCTACCAGTG TATCTGCCCTCCAGGACATAGTGGTGCCAAGTGCCATGAAGTTTCAGGGCGATCTTGCATCACC ATGGGGAGAGTGATACTTGATGGGGCCAAGTGGGATGATGACTGTAACACCTGCCAGTGCCTG AATGGACGGGTGGCCTGCTCCAAGGTCTGGTGTGGCCCGAGACCTTGCAGGCTCCACAAAAGC CACAATGAGTGCCCCAGTGGGCAGAGCTGCATCCCGGTCCTGGATGACCAGTGTTTCGTGCGCC TGACTCCTATTACCAGGATAACTGTGCAAACATCACTTTCACCTTTAACAAAGAGATGATGTCT CCAGGTCTTACCACCGAACACATTTGCAGCGAATTGAGGAATTTGAATATCCTGAAGAATGTTT CTGCTGAATATTCGATCTACATAGCCTGTGAGCCTTCCCTGTCAGCAAACAATGAAATACACGT GGCCATCTCTGCAGAAGACATCCGGGATGATGGGAACCCTGTCAAGGAAATTACCGATAAAAT AATAGATCTCGTTAGTAAACGGGATGGAAACAGCTCACTTATTGCTGCGGTTGCAGAAGTCAG AGTTCAGAGGCGTCCTCTGAAAAACAGAACAGATTTCCTGGTTCCTCTGCTGAGCTCTGTCTTA ACAGTGGCTTGGGTGTGTGTGACAGCCTTCTACTGGTGTACGGAAGCGGCGGAAGC ACCAAATCAAAAACCCCATCGAGAAACACGGAGCCAACACGGTCCCCATTAAGGATTACGAGA ACAAAAACTCCAAAATGTCAAAAATCAGGACACACAACTCGGAAGTGGAGGAGGATGACATG GATAAACACCAGCAGAAAGTCCGCTTTGCCAAACAGCCAGTGTATACGCTGGTAGACAGAGAG GAGAAGGCCCCCAGCGGCACGCCGACAAAACACCCCGAACTGGACAAATAAACAGGACAACAG

AGACTTGGAAAGTGCCCAGAGCTTGAACCGGATGGAATACATCGTATAGCAGACAGTGGGCTGCCGCCATAGGTAGAGTTTGAGGGCACCGCGGGCCG

Figure 5

CAAGGTGTGTGGGGCCTCGGGTCAGTTCGAGTTGGAGATCCTGTCCATGCAGAACGTGAACGGGGAGCTG CAGAACGGGAACTGCTGCGGCGCCCCGGAACCCGGGAGACCGCAAGTGCACCCGCGACGAGTGTGAA CATACTTCAAAGTGTGCCTCAAGGAGTATCAGTCCCGCGTCACGGCCGGGGGGCCCTGCAGCTTCGGCTC AGGGTCCACGCCTGTCATCGGGGGCAACACCTTCAACCTCAAGGCCAGCCGCGCAACGACCGCAACCC ATCGTGCTGCCTTTCAGTTTCGCCTGGCCGAGGTCCTATACGTTGCTTGTGGAGGCGTGGGATTCCAGTA ATGACACCGTTCAACCTGACAGTATTATTGAAAAGGCTTCTCACTCGGGCATGATCAACCCCAGCCGGCA

GTGGCAGACGCTGAAGCAGAACACGGGCGTTGCCCACTTTGAGTATCAGATCCGCGTGACCTGTGATGAC TACTACTATGGCTTTGGCTGCAATAAGTTCTGCCGCCCCAGAGATGACTTCTTTGGACACTATGCCTGTG ACCAGAATGGCAACAAACTTGCATGGAAGGCTGGATGGCCCCGAATGTAACAGAGCTATTTGCCGAA CTGTACTGTGATAAGTGCATCCCACACCCGGGATGCGTCCACGGCATCTGTAATGAGCCCTGGCAGTGCC TCTGTGAGACCAACTGGGGCGGCCAGCTCTGTGACAAAGATCTCAATTACTGTGGGACTCATCAGCCGTG TCTCAACGGGGAACTTGTAGCAACACAGGCCCTGACAAATATCAGTGTTCCTGCCCTGAGGGGTATTCA GGACCCAACTGTGAAATTGCTGAGCACGCCTGCCTCTCTGATCCCTGTCACAACAGAGGCAGCTGTAAGG AGACCTCCCTGGGCTTTGAGTGTGAGTGTTCCCCAGGCTGGACCGGCCCCACATGCTCTACAAACATTGA TGACTGTTCTCCTAATAACTGTTCCCACGGGGCACCTGCCAGGACCTGGTTAACGGATTTAAGTGTGTG ACGCCAAATCCTGTAAGAATCTCATTGCCAGCTACTACTGCGACTGTCTTCCCGGCTGGATGGGTCAGAA TTGTGACATAAATATTAATGACTGCCTTGGCCAGTGTCAGAATGACGCCTCCTGTCGGGATTTGGTTAAT GCAACCCCTGTTTGAATGGGGGTCACTGTCAGAATGAAATCAACAGATTCCAGTGTCTGTGTCCCACTGG TTTCTCTGGAAACCTCTGTCAGCTGGACATCGATTATTGTGAGCCTAATCCCTGCCAGAACGGTGCCCAG TGCTACAACCGTGCCAGTGACTATTTCTGCAAGTGCCCCGAGGACTATGAGGGCAAGAACTGCTCACACC TGAAAGACCACTGCCGCACGACCCCCTGTGAAGTGATTGACAGCTGCACAGTGGCCATGGCTTCCAACGA GGAGGCAAATTCACCTGTGACTGTAACAAAGGCTTCACGGGAACATACTGCCATGAAAATATTAATGACT GTGAGAGCAACCCTTGTAGAAACGGTGGCACTTGCATCGATGGTGTCAACTCCTACAAGTGCATCTGTAG TGACGGCTGGGAGGGGCCTACTGTGAAACCAATATTAATGACTGCAGCCAGAACCCCTGCCACAATGG GGCACGTGTCGCGACCTGGTCAATGACTTCTACTGTGACTGTAAAAATGGGTGGAAAGGAAAGACCTGCC ACTCACGTGACAGTCAGTGTGATGAGGCCACGTGCAACAACGGTGGCACCTGCTATGATGAGGGGGATC TTTTAAGTGCATGTCCTGGCGGCTGGGAAGGAACAACCTGTAACATAGCCCGAAACAGTAGCTGCCTG CCCAACCCCTGCCATAATGGGGGCACATGTGTGGTCAACGGCGAGTCCTTTACGTGCGTCTGCAAGGAAG GCTGGGAGGGCCCATCTGTGCTCAGAATACCAATGACTGCAGCCCTCATCCCTGTTACAACAGCGGCAC CTGTGTGGATGGAGACAACTGGTACCGGTGCGAATGTGCCCCGGGTTTTGCTGGGCCCGACTGCAGAATA AACATCAATGAATGCCAGTCTTCACCTTGTGCCTTTGGAGCGACCTGTGTGGATGAGATCAATGGCTACC GGTGTGTCTGCCCTCCAGGGCACAGTGGTGCCAAGTGCCAGGAAGTTTCAGGGAGACCTTGCATCACCAT GGGGAGTGTGATACCAGATGGGGCCAAATGGGATGATGACTGTAATACCTGCCAGTGCCTGAATGGACG ATCGCCTGCTCAAAGGTCTGGTGTGGCCCTCGACCTTGCCTGCTCCACAAAGGGCACAGCGAGTGCCCCA GCGGGCAGAGCTGCATCCCCATCCTGGACGACCAGTGCTTCGTCCACCCCTGCACTGGTGTGGGCGAGTG TCGGTCTTCCAGTCTCCAGCCGGTGAAGACAAAGTGCACCTCTGACTCCTATTACCAGGATAACTGTGCG AACATCACATTTACCTTTAACAAGGAGATGATGTCACCAGGTCTTACTACGGAGCACATTTGCAGTGAAT TGAGGAATTTGAATATTTTGAAGAATGTTTCCGCTGAATATTCAATCTACATCGCTTGCGAGCCTTCCCC TTCAGCGAACAATGAAATACATGTGGCCATTTCTGCTGAAGATATACGGGATGATGGGAACCCGATCAAG GAAATCACTGACAAAATAATCGATCTTGTTAGTAAACGTGATGGAAACAGCTCGCTGATTGCTGCCGTTG CAGAAGTAAGAGTTCAGAGGCGGCCTCTGAAGAACAGAACAGATTTCCTTGTTCCCTTGCTGAGCTCTGT CTTAACTGTGGCTTGGATCTGTTGCTTGGTGACGGCCTTCTACTGGTGCCTGCGGAAGCGGCAAGCCG GGCAGCCACACACTCAGCCTCTGAGGACAACACCCACCAACAACGTGCGGGAGCAGCTGAACCAGATA

AAAACCCCATTGAGAAACATGGGGCCAACACGGTCCCCATCAAGGATTACGAGAACAAGAACTCCAAAT GTCTAAAATAAGGACACACAATTCTGAAGTAGAAGAGGACGACATGGACAAACACCAGCAGAAAAGCCCG GTTTGCCAAGCAGCCGCGTATACGCTGGTAGACAGAGAAGAGAAGCCCCCCAACGGCACGCCGACAAC ACCCAAACTGGACAAACAAACAGGACAACAGAGACTTGGAAAGTGCCCAGAGCTTAAACCGAATGGAGA CATCGTATAGCAGACCGCGGGCACTGCCGCCGCTAGGTAGAGTCTGAGGGCTTGTAGTTCTTTAAACTGT CGTGTCATACTCGAGTCTGAGGCCGTTGCTGACTTAGAATCCCTGTGTTAATTTAAGTTTTGACAAGCTG GCTTACACTGGCAATGGTAGTTTCTGTGGTTGGCTGGGAAATCGAGTGCCGCATCTCACAGCTATGCAAA AAGCTAGTCAACAGTACCCTGGTTGTGTCCCCTTGCAGCCGACACGGTCTCGGATCAGGCTCCCAGGA GCCTGCCCAGCCCCCTGGTCTTTGAGCTCCCACTTCTGCCAGATGTCCTAATGGTGATGCAGTCTTAGAT CATAGTTTTATTTATTTATTGACTCTTGAGTTGTTTTTGTATATTGGTTTTATGATGACGTACAAGTA GTTCTGTATTTGAAAGTGCCTTTGCAGCTCAGAACCACAGCAACGATCACAAATGACTTTATTATT TTTTTAATTGTATTTTTGTTGTTGGGGGGGGGGGGGGTTGCTGATGTCAGCAGTTGCTGGTAAAATGAAGAA TTTAAAGAAAAAATGTCAAAAGTAGAACTTTGTATAGTTATGTAAATAATTCTTTTTTATTAATCACTG GTTTAGAATTGAAGGTTTTTGATAGCATTGTAAGCGTATGGCTTTATTTTTTTGAACTCTTCTCATTACT TGTTGCCTATAAGCCAAAATTAAGGTGTTTGAAAATAGTTTATTTTAAAACAATAGGATGGGCTTCTGTG CCCAGAATACTGATGGAATTTTTTTTTTGTACGACGTCAGATGTTTAAAACACCTTCTATAGCATCACTTAA TTTGTTTTTCTGCTTTAGACTTGAAAAGAGACAGGCAGGTGATCTGCTGCAGAGCAGTAAGGGAACAAGT AACTTGGAAGCACACCAATCTGACTTTGTAAATTCTGATTTCTTTTCACCATTCGTACATAATACTGAAC CACTTGTAGATTTGATTTTTTTTTTAATCTACTGCATTTAGGGAGTATTCTAATAAGCTAGTTGAATACT GAAATCAAAGTGCTATTACGAAGTTCAAGATCAAAAAGGCTTATAAAACAGAGTAATCTTGTTGGTTCAC CATTGAGACCGTGAAGATACTTTGTATTGTCCTATTAGTGTTATATGAACATACAAATGCATCTTTGATG GTGGCTCTTCTGAGCTTACGTAGTTCTACCGGCTTTGCCGTGTGCTTCTGCCACCCTGCTGAGTCTGTTC TGGTAATCGGGGTATAATAGGCTCTGCCTGACAGAGGGATGGAGGAAGAACTGAAAGGCTTTTCAACCC AAAACTCATCTGGAGTTCTCAAAGACCTGGGGCTGCTGTGAAGCTGGAACTGCGGGAGCCCCATCTAGGG GAGCCTTGATTCCCTTGTTATTCAACAGCAAGTGTGAATACTGCTTGAATAAACACCACTGGATTAATGG AAAAAAAAAAAA

Figure 6

GGAGCGGCGCGCGGCGGGGCCGGGCGGGCGGGCGGGCGAATGCGGGCGCAGGCCCG GGGCCTTCCCCCGGCGCTGCTGCTGCTGCTGCGCGCTCTGGGTGCAGGCGGCGCGCCCATGGGCTATTT CGAGCTGCAGCTGAGCGCGCTGCGGAACGTGAACGGGGGGGCTGCTGAGCGCGCCTGCTGTGACGGCGCCCCC AGTACCAGGCCAAGGTGACGCCCACGGGGCCCTGCAGCTACGGCCACGGCGCCACGCCCGTGCTGGGCG GACCAGGACCCGGGCTTCGTCGTCATCCCCTTCCAGTTCGCCTGGCCGCGCTCCTTTACCCTCATCGTGG CATGATCAACCCGGAGGACCGCTGGAAGAGCCTGCACTTCAGCGGCCACGTGGCGCACCTGGAGCTGCG ATCCGCGTGCGCTGCGACGAGAACTACTACAGCGCCACTTGCAACAAGTTCTGCCGGCCCCGCAACGACT TTTTCGGCCACTACACCTGCGACCAGTACGGCAACAAGGCCTGCATGGACGGCTGGATGGGCAAGGAGTG CAAGGAAGCTGTGTAAACAAGGGTGTAATTTGCTCCACGGGGGATGCACCGTGCCTGGGGAGTGCAG TGCAGCTACGGCTGGCAAGGGAGGTTCTGCGATGAGTGTCCCCTACCCCGGCTGCGTGCATGGCAGTT GTGTGGAGCCCTGGCAGTGCAACTGTGAGACCAACTGGGGCGGCCTGCTCTGTGACAAAGACCTGAACTA CTGTGGCAGCCACCCCTGCACCAACGGAGGCACGTGCATCAACGCCGAGCCTGACCAGTACCGCTGC ACCTGCCCTGACGGCTACTCGGGCAGGAACTGTGAGAAGGCTGAGCACGCCTGCACCTCCAACCCGTGTG CCAACGGGGCTCTTGCCATGAGGTGCCGTCCGGCTTCGAATGCCACTGCCCATCGGGCTGGAGCGGGCC CACCTGTGCCCTTGACATCGATGAGTGTGCTTCGAACCCGTGTGCGGCCGGTGGCACCTGTGTGGACCAG GTGAAGGGAAGCCATGCCTTAACGCTTTTTCTTGCAAAAACCTGATTGGCGGCTATTACTGTGATTGCAT CCCGGGCTGGAAGGCATCAACTGCCATATCAACGTCAACGACTGTCGCGGGCAGTGTCAGCATGGGGC ACCTGCAAGGACCTGGTGAACGGGTACCAGTGTGTGCCCACGGGGCTTCGGAGGCCGGCATTGCGAGC TGGAACGAGACAAGTGTGCCAGCAGCCCTGCCACAGCGGCGGCCTCTGCGAGGACCTGGCCGACGGCT CCACTGCCACTGCCCCAGGGCTTCTCCGGGCCTCTCTGTGAGGTGGATGTCGACCTTTGTGAGCCAAGC CCCTGCCGGAACGCCCTCGCTGCTATAACCTGGAGGGTGACTATTACTGCGCCTGCCCTGATGACTTTG GTGGCAAGAACTGCTCCGTGCCCGCGAGCCGTGCCCTGGCGGGGCCTGCAGAGTGATCGATGGCTGCGG

GTCAGACGCGGGGCCTGGGATGCCTGGCACAGCAGCCTCCGGCGTGTGTGGCCCCCATGGACGCTGCGTC AGCCAGCCAGGGGGCAACTTTTCCTGCATCTGTGACAGTGGCTTTACTGGCACCTACTGCCATGAGAACA TTGACGACTGCCTGGGCCAGCCCTGCCGCAATGGGGGCACATGCATCGATGAGGTGGACGCCTTCCGCTG CTTCTGCCCCAGCGGCTGGGAGGGCGAGCTCTGCGACACCAATCCCAACGACTGCCTTCCCGATCCCTGC AGACCTGCCACTCACGCGAGTTCCAGTGCGATGCCTACACCTGCAGCAACGGTGGCACCTGCTACGACAG CGGCGACACCTTCCGCTGCGCCTGCCCCCCGGCTGGAAGGGCAGCACCTGCGCCGTCGCCAAGAACAGC AGCTGCCTGCCCAACCCCTGTGTGAATGGTGGCACCTGCGTGGGCAGCGGGGCCTCCTTCTCCTGCATCT GCCGGGACGGCTGGGAGGGTCGTACTTGCACTCACAATACCAACGACTGCAACCCTCTGCCTTGCTACAA TGGTGGCATCTGTGTTGACGGCGTCAACTGGTTCCGCTGCGAGTGTGCACCTGGCTTCGCGGGGCCTGAC TGCCGCATCAACATCGACGAGTGCCAGTCCTCGCCCTGTGCCTACGGGGCCACGTGTGTGGATGAGATCA ACGGGTATCGCTGTAGCTGCCCACCCGGCCGAGCCGGCCCCCGGTGCCAGGAAGTGATCGGGTTCGGGAG ATCCTGCTGGTCCCGGGGCACTCCGTTCCCACACGGAAGCTCCTGGGTGGAAGACTGCAACAGCTGCCGC CCGAGGCCCTGAGCGCCCAGTGCCCACTGGGGCAAAGGTGCCTGGAGAAGGCCCCAGGCCAGTGTCTGG GGCCACCTGGACAATAACTGTGCCCGCCTCACCTTGCATTTCAACCGTGACCACGTGCCCCAGGGCACCA GGTGTTGCTTTGCGACCGGGCGTCCTCGGGGGCCAGTGCCGTGGAGGTGGCCGTGTCCTTCAGCCCTGCC AGGGACCTGCCTGACAGCAGCCTGATCCAGGGCGCGCCCACGCCATCGTGGCCGCCATCACCCAGCGG GGAACAGCTCACTGCTCCTGGCTGTCACCGAGGTCAAGGTGGAGACGGTTGTTACGGGCGGCTCTTCCAC TGGTGGACACGCAAGCGCAGGAAAGAGCGGGAGAGGAGCCGGCTGCCGCGGGAGGAGAGCGCCAACAC AGTGGGCCCCGCTCAACCCCATCCGCAACCCCATCGAGCGGCCGGGGGGCCACAAGGACGTGCTCTACCA GTCAGGGAGGATGAGGAGGACGAGGATCTGGGCCGCGGTGAGGAGGACTCCCTGGAGGCGGAGAAGTTC AGTGGACAACCGCGCGGTCAGGAGCATCAATGAGGCCCGCTACGCCGGCAAGGAGTAGGGGCGGCTGCG CTGGGCCGGGACCCAGGGCCCTCGGTGGGAGCCATGCCGTCTGCCGGACCCGGAGCCGAGGCATGTGCT AGTTTCTTTATTTTGTGTAAAAAAACCACCAAAAACCAAAACCAAATGTTTATTTTCTACGTTTCTTTAA CCTTGTATAAATTATTCAGTAACTGTCAGGCTGAAAACAATGGAGTATTCTCGGATAGTTGCTATTTTTG TAAAGTTTCCGTGCGTGGCACTCGCTGTATGAAAGGAGAGAGCAAAGGGTGTCTGCGTCGTCACCAAATC GTAGCGTTTGTTACCAGAGGTTGTGCACTGTTTACAGAATCTTCCTTTTATTCCTCACTCGGGTTTCTCT GTGGCTCCAGGCCAAAGTGCCGGTGAGACCCATGGCTGTTGTTGGTGGCCCATGGCTGTTGGTGGGACC CGTGGCTGATGGTGTGGCTGTGGCTGTGGGTGGGACTCGTGGCTGTCAATGGGACCTGTGGCTGTCGGT GGGACCTACGGTGGTCGGTGGGACCCTGGTTATTGATGTGGCCCTGGCTGCCGGCACGGCCCGTGGCTGT TGACGCACCTGTGGTTGTTAGTGGGGCCTGAGGTCATCGGCGTGCCCAAGGCCGGCAGGTCAACCTCGCG CTTGCTGGCCAGTCCACCCTGCCGTCTGTGCTTCCTCCTGCCCAGAACGCCCGCTCCAGCGATCTC TCCACTGTGCTTTCAGAAGTGCCCTTCCTGCTGCGCAGTTCTCCCATCCTGGGACGGCGGCAGTATTGAA GCTCGTGACAAGTGCCTTCACACAGACCCCTCGCAACTGTCCACGCGTGCCGTGGCACCAGGCGCTGCCC

Figure 7

GTTCTGTGACGAGTGTCCCCTACCCTGGCTGCGTGCATGGCAGCTGTGTGGAGCCCTGGCAC TGTGACTGTGAGACCAACTGGGGTGGCCTGCTCTGCGACAAAGACCTGAACTACTGTGGCAGC CACCACCCTGTGTCAACGGGGGTACCTGCATCAATGCTGAGCCTGACCAATACCTCTGCGCCT GCCCAGATGGCTACTTGGGCAAGAACTGTGAGCGGGCTGAGCACGCCTGTGCCTCCAACCCGT GTGCCAATGGGGGCTCTTGCCACGAAGTGCCATCTGGCTTTGAATGCCACTGTCCGTCAGGATG GAGCGGACCCACCTGTGCGCTCGACATTGATGAGTGTGCCTCTAACCCATGTGCAGCGGGTGGT TGCCAGCTGGACGCCAATGAGTGTGAAGGGAAGCCGTGCCTTAATGCTTTTTCTTGCAAAAACC TGATTGGCGGCTATTACTGTGATTGCCTCCCGGGCTGGAAGGGCATCAACTGCCAAATCAACAT CAACGATTGTCATGGGCAGTGTCAGCATGGGGGCACCTGCAAGGACCTGGTCAATGGGTACCA GTGTGTGTGCCCGCGGGGCTTTGGAGGTCGCCATTGCGAACTAGAGTACGACAAGTGTGCCAG CAGCCCTGCCGCGGGGTGGCATCTGCGAGGACCTGGTGGATGGCTTCCGCTGCCACTGCCCA CGGGGCCTCTCTGGGCTGCACTGTGAGGTGGACATGGATCTCTGTGAACCAAGCCCCTGCCTCA ACGGTGCTCGCTGCAACCTTGAGGGTGACTACTACTGCGCCTGCCCAGAAGACTTTGGTGG CAAGAACTGCTCAGTGCCCAGGGACACATGCCCTGGCGGGGCATGTAGAGTGATCGATGGCTG CGGGTTCGAGGCAGGGTCCAGGGCACGCGTGTCGCACCCTCTGGTATATGTGGCCCTCACGG GCACTGCGTTAGCCTGCGTGGGGAAACTTCTCCTGCATCTGTGACAGCGGCTTCACAGGCACC TACTGCCATGAAAACATTGACGACTGCATGGGCCAGCCCTGCCGCAACGGGGGCACGTGCATT ATCCCAACGACTGCCTCCCGACCCCTGCCACAGCCGCGGCCGCTGCTATGACCTGGTCAATGA CTTCTACTGTGCCTGTGACGATGGCTGGAAGGGCAAGACCTGCCACTCACGCGAGTTCCAGTGT GACGCCTACACCTGCAGCAACGGTGGCACATGCTATGACAGCGGCGACACCTTCCGCTGCGCG TGCCCTCCGGGCTGGAAGGGCAGCACCTGCACCATCGCCAAGAACAGCAGCTGTGTGCCCAAT CCCTGTGTGAATGGAGGCACCTGCGTGGGTAGCGGAGACTCTTTCTCCTGCATCTGCCGGGATG GCTGGGAGGGCCGCACCTGCACACATAACACCAATGACTGCAACCCTCTGCCCTGCTATAACG GAGGCATCTGTGTTGATGGCGTCAACTGGTTCCGCTGCGAGTGTGCGCCTGGCTTTGCGGGTCC TGACTGCCGTATCAACATTGATGAGTGCCAGTCCTCGCCCTGTGCCTACGGAGCCACGTGTGTG GATGAGATCAACGGGTACCGCTGCAGCTGCCCACCAGGTCGTTCTGGCCCCAGGTGCCAGGAA GTGGTCATATTCACGAGGCCCTGCTGGTCCCGGGGAATGTCCTTCCCGCATGGGAGTTCCTGGA TGGAAGACTGCAACAGCTGCCGCTGCCTGGATGGCCACCGGGATTGTAGCAAGGTATGGTGCG GATGGAAGCCTTGCCTCTCTGGTCAGCCCAGCGATCCGAGTGCCCAGTGCCCCCAGGGCA GCAATGTCAGGAGAAGGCCGTGGGTCAGTGCTTGCAGCCACCCTGTGAGAACTGGGGGAGTG TACAGCGGAGGAGCCTCTGCCACCCAGCACCCCTGTCAGCCACGGAGCAGTCATTTGGACAA CAACTGTGCCCGACTCACACTGCGCTTCAACCGTGATCAAGTGCCTCAGGGCACCACCGTGGGC GCTATCTGCTCTGGAATCCGAGCCTTGCCTGCCACGAGGGCGGCGCACACGACCGCCTCCTCC TGCTGCTTTGTGATCGAGCATCCTCGGGGGCCAGTGCTGTGGAGGTGGCTATGTCTTTCAGCCC TGCAAGGGACCTGCCTGACAGCAGCCTGATCCAGAGCACAGCCCACGCCATCGTGGCTGCTAT CACTCAGAGAGAAATAGCTCACTGCTGCTGTCACCGAGGTCAAGGTGGAAACAGTTGT TATGGGTGGCTCTTCCACAGGTCTGTTGGTGCCCGTGCTGTGCAGCGTGTTCAGTGTGCTGTGGC TCGCCTGTGTGGTTATCTGCGTATGGTGGACACGAAAGCGCAGGAAAGAACGTGAGAGGAGCC GGCTACCACGGGATGAGAGCACCAACAACCAGTGGGCCCCGCTCAATCCCATCCGCAACCCCA TTGAGCGGCCAGGCGGCAGCGGTCTGGGAACTGGGGGCCACAAGGACATACTCTACCAGTGCA AAAACTTCACACCGCCGCCCCGCAGGGCAGGCGAGGCACTGCCCGGGCCAGCTGGCCATGGGG CTGGTGGGGAGGACGAGGAGGATGAAGAGCTGAGCCGTGGAGATGGGGACTCCCCAGAGGCA GAGAAGTTCATCTCACACAAGTTCACCAAAGACCCCAGCTGCTCCCTCGGAAGGCCAGCCTGCT GGGCTCCAGGGCCCAAAGTGGACAACCGCGCCGTCAGAAGTACCAAGGACGTGCGCCGTGCTG CAAAAAACAAATGTTTATTTTTACGTTTCTTTAACCTTGTATAAATTATTCAACGGCTGTCAGG

Figure 8

GAAGGCCATGGTCTCCCCACGGATGTCCGGGCTCCTCTCCCAGACTGTGATCCTAGCGCTCATTTTCCTCCCCAGACACGCCCGCGCTGGCGTCTTCGAGCTGCAGATCCACTCTTTCGGGCCGGGTCCAGGCCCTGGGGCCCCGCGGGTCCCCCTGCAGCCCCTGCCGCCTCTTCTTCAGAGTCTGCCTGAAGCCTGGGCT

GAGCAGCCCGGAGCCCCGCCCTGATCTCCCACTGCCCGACGGGCTCTTGCAGGTGCCCTTCCGGGACG CCTGGCCTGGCACCTTCTCTTTCATCATCGAAACCTGGAGAGAGGAGTTAGGAGACCAGATTGGAGGGCC CGCCTGGAGCCTGCCGCGCGTGGCTGGCAGGCGGCGCTTGGCAGCCGGAGGCCCGTGGCCCGGGC CCGCGTGCACGCGCCTCTGCCGTCCGCGCAGCGCCCCCTCGCGGTGCGGTCCGGGACTGCGCCCCTGCGC ACCGCTCGAGGACGAATGTGAGGCGCCGCTGGTGTGCCGAGCAGGCTGCAGCCCTGAGCATGGCTTCTGT GAACAGCCCGGTGAATGCCGATGCCTAGAGGGCTGGACTGGACCCCTCTGCACGGTCCCTGTCTCCACCA GCAGCTGCCTCAGCCCCAGGGGCCCGTCCTCTGCTACCACCGGATGCCTTGTCCCTGGGCCTGGGCCCTG TGACGGGAACCCGTGTGCCAATGGAGGCAGCTGTAGTGAGACACCCAGGTCCTTTGAATGCACCTGCCCG CGTGGGTTCTACGGGCTGCGGTGTGAGGTGAGCGGGGTGACATGTGCAGATGGACCCTGCTTCAACGGCG GCTTGTGTGTCGGGGGTGCAGACCCTGACTCTGCCTACATCTGCCACTGCCCACCTGGTTTCCAAGGCTC CAACTGTGAGAAGAGGGTGGACCGGTGCAGCCTGCAGCCATGCCGCAATGGCGGACTCTGCCTGGACCG GGCCACGCCTGCGCTGCCGCGCCGCCGGCTTCGCGGGTCCTCGCTGCGAGCACGACCTGGACGACT GGCCGCTGCTACGCCCACTTCTCCGGCCTCGTCTGCGCTTGCGCTCCCGGCTACATGGGAGCGCGGTGTG AGTTCCCAGTGCACCCCGACGGCGAAGCGCCTTGCCCGCGGGCCCCGGGGCCTCAGGCCCGGGGACCC CGTCAGTCCACGCACTCCCGGATGCACTCAACAACCTAAGGACGCAGGAGGGTTCCGGGGATGGTCCGG CTCGTCCGTAGATTGGAATCGCCCTGAAGATGTAGACCCTCAAGGGATTTATGTCATATCTGCTCCTTCC ATCTACGCTCGGGAGGTAGCGACGCCCCTTTTCCCCCCGCTACACACTGGGCGCGCTGGGCAGAGGCAGC ACCTGCTTTTTCCCTACCCTTCCTCGATTCTGTCCGTGAAATGAATTGGGTAGAGTCTCTGGAAGGTTTT AAGCCCATTTTCAGTTCTAACTTACTTTCATCCTATTTTGCATCCCTCTTATCGTTTTGAGCTACCTGCC ATCTTCTCTTT

Figure 9

AAACCGGAACGGGCCCAACTTCTGGGGCCTGGAGAAGGGAAACGAAGTCCCCCCGGTTTCCCGAGGT GCCTTTCCTCGGGCATCCTTGGTTTCGGCGGGACTTCGCAGGGCGGATATAAAGAACGGCGCCTTTGGGA AGAGGCGGAGACCGGCTTTAAAGAAAGAAGTCTTGGTCCTGCGGCTTGGGCGAGGCAAGGGCGAGGCAG GGCGCTTTCTGCCGACGCTCCCCGTGGCCCTACGATCCCCCGCGCGTCCGCCGCTGTTCTAAGGAGAGAA GTGGGGGCCCCCAGGCTCGCGCGTGGAGCGAAGCAGCATGGGCAGTCGGTGCGCGCTGGCCTGGCGT GCTCTCGGCCTTGCTGTCAGGTCTGGAGCTCTGGGGTGTTCGAACTGAAGCTGCAGGAGTTCGTCAAC AAGAAGGGCTGCTGGGAACCGCAACTGCTGCCGGGGGGCGCGGGGCCACCGCCGTGCCCGA CCTTCTTCCGCGTGTGCCTCAAGCACTACCAGGCCAGCGTGTCCCCCGAGCCGCCCTGCACCTACGGCAG AGCAACCCCATCCGCTTCCCCTTCGGCTTCACCTGGCCGGCACCTTCTCTCTGATTATTGAAGCTCTCC ACACAGATTCTCCTGATGACCTCGCAACAGAAAACCCAGAAAGACTCATCAGCCGCCTGGCCACCCAGAG GCACCTGACGGTGGGCGAGGAGTGGTCCCAGGACCTGCACAGCAGCGGCCGCACGGACCTCAAGTACTC TACCGCTTCGTGTGTGACGAACACTACTACGGAGAGGGCTGCTCCGTTTTCTGCCGTCCCCGGGACGATG CACAGAGCCGATCTGCCTGCCTGGATGTGATGAGCAGCATGGATTTTGTGACAAACCAGGGGAATGCAAG TGCAGAGTGGGCTGGCAGGGCCGGTACTGTGACGAGTGTATCCGCTATCCAGGCTGTCTCCATGGCACCT GCCAGCAGCCCTGGCAGTGCAACTGCCAGGAAGGCTGGGGGGGCCTTTTCTGCAACCAGGACCTGAACTA CTGCACACACCATAAGCCCTGCAAGAATGGAGCCACCTGCACCAACACGGGCCAGGGGAGCTACACTTC TCTTGCCGGCCTGGGTACACAGGTGCCACCTGCGAGCTGGGGATTGACGAGTGTGACCCCAGCCCTTGTA AGAACGGAGGGAGCTGCACGGATCTCGAGAACAGCTACTCCTGTACCTGCCCACCCGGCTTCTACGGCAA AATCTGTGAATTGAGTGCCATGACCTGTGCGGACGGCCCTTGCTTTAACGGGGGTCGGTGCTCAGACAGC CCCGATGGAGGGTACAGCTGCCCCGTGGGCTACTCCGGCTTCAACTGTGAGAAGAAAATTGACT ACTGCAGCTCTTCACCCTGTTCTAATGGTGCCAAGTGTGTGGACCTCGGTGATGCCTACCTGTGCCGCTG CCAGGCCGGCTTCTCGGGGAGGCACTGTGACGACAACGTGGACGACTGCGCCTCCTCCCCGTGCGCCAAC GGGGGCACCTGCCGGGATGGCGTGAACGACTTCTCCTGCACCTGCCCGCCTGGCTACACGGGCAGGAACT GCAGTGCCCCGTCAGCAGGTGCGAGCACGCACCCTGCCACAATGGGGCCACCTGCCACCAGAGGGGCCA CGGCTATGTGTGCGAATGTGCCCGAAGCTACGGGGGTCCCAACTGCCAGTTCCTGCTCCCCGAGCTGCCC TGTGCGCCGGGGTCATCCTTGTCCTCATGCTGCTGCTGGGCTGTGCCGCTGTGGTGGTCTGCGTCCGGCT GAGGCTGCAGAAGCACCGGCCCCCAGCCGACCCCTGCCGGGGGGAGACGGAGACCATGAACAACCTGGC AACTGCCAGCGTGAGAAGGACATCTCAGTCAGCATCATCGGGGCCACGCAGATCAAGAACACCAACAAA AGGCGGACTTCCACGGGGACCACAGCGCCGACAAGAATGGCTTCAAGGCCCGCTACCCAGCGGTGGACA TAACCTCGTGCAGGACCTCAAGGGTGACGACACCGCCGTCAGGGACGCGCACAGCAAGCGTGACACCAG

Figure 10

ATGGCGGCAGCGTCCCGGAGCGCCTCTGGCTGGCGCGCTACTGCTGGTGGCACTTTGGCAGCAGCGCG CGGCCGGCTCCCAGCTGCAGCTGCAGGAGTTCATCAACGAGCGCGCGTACTGGCCAGTGG GCGGCCTTGCGAGCCCGGCTGCCGGACTTTCTTCCGCGTCTGCCTTAAGCACTTCCAGGCGGTCGTCTCG CCCGGACCCTGCACCTTCGGGACCGTCTCCACGCCGGTATTGGGCACCAACTCCTTCGCTGTCCGGGACG ACAGTAGCGGCGGGGGGCGCAACCCTCTCCAACTGCCCTTCAATTTCACCTGGCCGGGTACCTTCTCGCT CATCATCGAAGCTTGGCACGCCCAGGAGACGACCTGCGGCCAGAGGCCTTGCCACCAGATGCACTCATC AGCAAGATCGCCATCCAGGGCTCCCTAGCTGTGGGTCAGAACTGGTTATTGGATGAGCAAACCAGCACCC TCACAAGGCTGCGCTACTCTTACCGGGTCATCTGCAGTGACAACTACTATGGAGACAACTGCTCCCGCCT GGTTGGACTGGGGAATATTGCCAACAGCCTATCTGTCTTTCGGGCTGTCATGAACAGAATGGCTACTGCA GCAAGCCAGCAGAGTGCCTCTGCCGCCCAGGCTGGCAGGGCCGGCTGTGTAACGAATGCATCCCCCACAA TGGCTGTCGCCACGGCACCTGCAGCACTCCCTGGCAATGTACTTGTGATGAGGGCTGGGGAGGCCTGTTT TGTGACCAAGATCTCAACTACTGCACCCACCACTCCCCATGCAAGAATGGGGCAACGTGCTCCAACAGTG GGCAGCGAAGCTACACCTGCACCTGTCGCCCAGGCTACACTGGTGTGGACTGTGAGCTGGAGCTCAGCGA GTGTGACAGCAACCCCTGTCGCAATGGAGGCAGCTGTAAGGACCAGGAGGATGGCTACCACTGCCTGTGT CCTCCGGGCTACTATGGCCTGCATTGTGAACACAGCACCTTGAGCTGCGCCGACTCCCCCTGCTTCAATG GGGGCTCCTGCCGGGAGCGCAACCAGGGGGCCAACTATGCTTGTGAATGTCCCCCCAACTTCACCGGCTC CAACTGCGAGAAGAAGTGGACAGGTGCACCAGCAACCCCTGTGCCAACGGGGGACAGTGCCTGAACCA GGTCCAAGCCGCATGTGCCGCTGCCGTCCTGGATTCACGGGCACCTACTGTGAACTCCACGTCAGCGACT GTGCCCGTAACCCTTGCGCCCACGGTGGCACTTGCCATGACCTGGAGAATGGGCTCATGTGCACCTGCCC AACAGGGCCACCTGCTACACCGACCTCTCCACAGACACCTTTGTGTGCAACTGCCCTTATGGCTTTGTGG GCAGCCGCTGCGAGTTCCCCGTGGGCTTGCCGCCCAGCTTCCCCTGGGTGGCCGTCTCGCTGGGTGTGGG GCTGGCAGTGCTGGTACTGCTGGGCATGGTGGCAGTGCGGCAGCTGCGGCTTCGACGGCCG GACGACGCAGCAGGGAAGCCATGAACAACTTGTCGGACTTCCAGAAGGACAACCTGATTCCTGCCGCC AGCTTAAAAACACAAACCAGAAGAAGGAGCTGGAAGTGGACTGTGGCCTGGACAAGTCCAACTGTGGCA ACAGCAAAACCACACTTGGACTATAATCTGGCCCCAGGGCCCCTGGGGCGGGGGGACCATGCCAGGAAG TTTCCCCACAGTGACAAGAGCTTAGGAGAGAGGCGCCACTGCGGTTACACAGTGAAAAGCCAGAGTGC GGATATCAGCGATATGCTCCCCCAGGGACTCCATGTACCAGTCTGTGTGTTTTGATATCAGAGGAGAGGAA TGAATGTGTCATTGCCACGGAGGTATAA

Figure 11

CTCGCAGGCTAGGAACCCGAGGCCAAGAGCTGCAGCCAAAGTCACTTGGGTGCAGTGTACTCCCTCACTA
GCCCGCTCGAGACCCTAGGATTTGCTCCAGGACACGTACTTAGAGCAGCACCGCCCAGTCGCCCTCACC
TGGATTACCTACCGAGGCATCGAGCAGCGGAGTTTTTGAGAAGGCGACAAGGGAGCAGCGTCCCGAGGG
AATCAGCTTTTCAGGAACTCGGCTGGCAGACGGGACTTGCGGGAGAGCGACATCCCTAACAAGCAGATTC
GGAGTCCCGGAGTGGAGAGGACACCCCAAGGGATGACGCCTGCGTCCCGGAGCGCCTGTCGCTGGCGT
ACTGCTGCTGGCGGTACTGTGGCCGAGCAGCGCGCTGCGGGCTCCGGCATCTTCCAGCTGCGGCTGCAG
GAGTTCGTCAACCAGCGCGGTATGCTGGCCAATGGGCAGTCCTGCGAACCGGGCTGCCGGACTTTCTTCC
GCATTTGCCTTAAGCACTTCCAGGCAACCTTCTCCGAGGGACCCTGCACCTTTGGCAATGTCTCCACGCC
GGTATTGGGCACCAACTCCTTCGTCGTCAGGGACAAGAATAGCGGCAGTGGTCGCAACCCTCTGCAGTTG
CCCTTCAATTTCACCTGGCCGGGAACCTTCTCACTCAACATCCAAGCTTGGCACACCCTCTGCGG
TGCGGCCAGAGACTTCGCCAGGAAACTCTCTCATCAGCCAAATCATCCAAGGCTCTCTTGCTGTGGG

TAAGATTTGGCGAACAGACGAGCAAAATGACACCCTCACCAGACTGAGCTACTCTTACCGGGTCATCTGC AGTGACAACTACTATGGAGAGAGCTGTTCTCGCCTATGCAAGAAGCGCGATGACCACTTCGGACATTATG AGTGCCAGCCAGATGGCAGCCTGTCCTGCCTGCCGGGCTGGACTGGGAAGTACTGTGACCAGCCTATATG TCTTTCTGGCTGTCATGAGCAGAATGGTTACTGCAGCAAGCCAGATGAGTGCATCTGCCGTCCAGGTTGG CAGGGTCGCCTGTGCAATGAATGTATCCCCCACAATGGCTGTCGTCATGGCACCTGCAGCATCCCCTGGC AGTGTGCCTGCGATGAGGGATGGGGAGGTCTGTTTTGTGACCAAGATCTCAACTACTGTACTCACCACTC TCCGTGCAAGAATGGATCAACGTGTTCCAACAGTGGGCCAAAGGGTTATACCTGCACCTGTCTCCCAGGC TACACTGGTGAGCACTGTGAGCTGGGACTCAGCAAGTGTGCCAGCAACCCCTGTCGAAATGGTGGCAGCT GTAAGGACCAGGAGAATAGCTACCACTGCCTGTGTCCCCCAGGCTACTATGGCCAGCACTGTGAGCATAG TACCTTGACCTGTGCGGACTCACCCTGCTTCAATGGGGGCTCTTGCCGGGAGCGCAACCAGGGGTCCAGT TATGCCTGCGAATGCCCCCCAACTTTACCGGCTCTAACTGTGAGAAGAAAGTAGACAGGTGTACCAGCA ACCCGTGTGCCAATGGAGGCCAGTGCCTGAACAGAGGTCCAAGCCGAACCTGCCGCTGCCGGCCTGGATT CACAGGCACCCACTGTGAACTGCACATCAGCGATTGTGCCCGAAGTCCCTGTGCCCACGGGGGCACTTGC CACGATCTGGAGAATGGGCCTGTGTGCACCTGCCCCGCTGGCTTCTCTGGCAGGCGCTGCGAGGTGCGGA TAACCCACGATGCCTGTGCCTCCGGACCCTGCTTCAATGGGGCCACCTGCTACACTGGCCTCTCCCCAAA CAACTTCGTCTGCAACTGTCCTTATGGCTTTGTGGGCAGCCGCTGCGAGTTTCCCGTGGGCTTGCCACCC AGCTTCCCCTGGGTAGCTGTCTCGCTGGGCGTGGGGCTAGTGGTACTGCTGGTGCTGCTGGTCATGGTGG TAGTGGCTGTGCGCAGCTGCGGCTTCGGAGGCCCGATGACGAGGCAGGGAAGCCATGAACAATCTGC AGACTTCCAGAAGGACAACCTAATCCCTGCCGCCCAGCTCAAAAACACAAACCAGAAGAAGGAGCTGGA GTGGACTGTGGTCTGGACAAGTCCAATTGTGGCAAACTGCAGAACCACACATTGGACTACAATCTAGCCC CGGGACTCCTAGGACGGGCAGCATGCCTGGGAAGTATCCTCACAGTGACAAGAGCTTAGGAGAGAAGT GCCACTTCGGTTACACAGTGAGAAGCCAGAGTGTCGAATATCAGCCATTTGCTCTCCCAGGGACTCTATG TACCAATCAGTGTGTTTGATATCAGAAGAGAGGAACGAGTGTGTGATTGCCACAGAGGTATAAGGCAGA ATGGGACATCTTTAGTATGCACAGTGCTGCTGCGGAGGAGGAGGGAATGGCATGAACTGAACAGACG TGAACCCGCCAAGAGTTGCACCGGCTCTGCACACCTCCAGGAGTCTGCCTGGCTTCAGATGGGCAGCCCC GCCAAGGGAACAGAGTTGAGGAGTTAGAGGAGCATCAGTTGAGCTGATATCTAAGGTGCCTCTCGAACTT GGACTTGCTCTGCCAACAGTGGTCATCATGGAGCTCTTGACTGTTCTCCAGAGAGTGGCAGTGGCCCTAG TGGGTCTTGGCGCTGTAGCTCCTGTGGGCATCTGTATTTCCAAAGTGCCTTTGCCCAGACTCCATCC CCTTGGAGTTTGGCATTAAGCAGGAGCTACTCTGCAGGTGAGGAAAGCCCGAGGAGGGGACACGTGTGC TCCTGCCTCCAACCCCAGCAGGTGGGGTGCCACCTGCAGCCTCTAGGCAAGAGTTGGTCCTTCCCCTGGT CCTCACTGGGGAGCTCAGGGCCTTCATGCTAAACTCCCAATAAGGGAGATGGGGGGAAGGGGGCTGTGC CTAGGCCCTTCCCTCCCCCACACCCATTTTTGGGCCCTTGAGCCTGGGCTCCACCAGTGCCCACTGTTGC CCCGAGACCAACCTTGAAGCCGATTTTCAAAAATCAATAATATGAGGTTTTGTTTTGTAGTTTATTTTGG AATCTAGTATTTTGATAATTTAAGAATCAGAAGCACTGGCCTTTCTACATTTTATAACATTATTTTGTAT

Figure 12

AAACCCACTCCACCTTACTACCAGACAACCTTAGCCAAACCATTTACCCAAATAAAGTATAGGC GATAGAAATTGAAACCTGGCGCAATAGATATAGTACCGCAAGGGAAAGATGAAAAATTATAAC CAAGCATAATATAGCAAGGACTAACCCCTATACCTTCTGCATAATGAATTAACTAGAAATAACT TTGCAAGGAGAGTCAAAGCTAAGGCCCCCGAAACCAGGCGAGCTACCTAAGAACAGCTAAAA GAGCACACCCGTCTATGTAGCAAAATAGTGGGAAGATTTATAGGTAGAGGCGACAAACCTACC GAGCCTGGTGATAGCTGGTTGTCCAAGATAGAATCTTAGTTCAACTTTAAATTTGCCCACAGAA CCCTCTAAATCCCCTTGTAAATTTAACTGTTAGTCCAAAGAGGAACAGCTCTTTGGACACTAGG AAAAAACCTTGTAGAGAGAGTGTCAGCCCAATTCCACACTTTTCCACATGTTGGATGGCCTTGG AGTGGTAGCCATAAGCATTTTTGGAATTCAACTAAAAACTGAAGGATCCTTGAGGACGGCAGT ACCTGGCATACCTACACAGTCAGCGTTCAACAAGTGTTTGCAAAGGTACATTGGGGCACTGGG GGCACGAGTGATCTGTGACAATATCCCTGGTTTGGTGAGCCGGCAGCGGCAGCTGTGCCAGCGT TACCCAGACATCATGCGTTCAGTGGGCGAGGGTGCCCGAGAATGGATCCGAGAGTGTCAGCAC CAATTCCGCCACCACCGCTGGAACTGTACCACCCTGGACCGGGACCACACCGTCTTTGGCCGTG TCATGCTCAGAAGTAGCCGAGAGGCAGCTTTTGTATATGCCATCTCATCAGCAGGGGTGATCCA CGCTATTACTCGCGCCTGTAGCCAGGGTGAACTGAGTGTGTGCAGCTGTGACCCCTACACCCGT GGCCGACACCATGACCAGCGTGGGACTTTTGACTGGGGTGGCTGCAGTGACAACATCCACTAC GGTGTCCGTTTTGCCAAGGCCTTCGTGGATGCCAAGGAGAAGAGGCTTAAGGATGCCCGGGCC CTCATGAACTTACATAATAACCGCTGTGGTCGCACGGCTGTGCGGCGGTTTGTCAAGCTGGAGT

GTAAGTGCCATGGCGTGAGTGGTTCCTGTACTCTGCGCACCTGCTGGCGTGCACTCTCAGATTT CCGCCGCACAGGTGATTACCTGCGGCGACGCTATGATGGGGCTGTGCAGGTGATGGCCACCCA AGATGGTGCCAACTTCACCGCAGCCCGCCAAGGCTATCGCCGTGCCACCCGGAGTGATCTTGTC TACTTTGACAACTCTCCAGATTACTGTGTCTTGGACAAGGCTGCAGGTTCCCTAGGCACTGCAG GCCGTGTCTGCAGCAAGACATCAAAAGGAACAGACGGTTGTGAAATCATGTGCTGTGGCCGAG GGTACGACACACTCGAGTCACCCGTGTTACCCAGTGTGAGTGCAAATTCCACTGGTGCTGTGC TGTACGGTGCAAGGAATGCAGAAATACTGTGGACGTCCATACTTGCAAAGCCCCCAAGAAGGC AGAGTGGCTGGACCAGACCACACACAGATACCTCACTCATCCCTCCAATTCAAGCCTCTCA ACTCAAAAGCACAAGATCCTTGCATGCACACCTTCCTCCACCCTCCACCCTGGGCTGCTACCGC TGGGAAGGAGTTGTCAGGGGATATAAGAAACTGTGCAAGCTCCCTGATTTCCCGCTCTGGAGAT TTGAAGGGAGAGTAGAGAGATAGGGGGTCTTTAGAGTGAAATGAGTTGCACTAAAGTACGTA GTTGAGGCTCCTTTTTCTTTCCTTTGCACCAGCTTCCCGACACTTCTTGGTGTGCAAGAGGAAG GGTACCTGTAGAGAGCTTCTTTTTGTTTCTACCTGGCCAAAGTTAGATGGGACAAAGATGAATG GCTACCACATTCTATTATTGAGAGCCTGAGATGTTAGCCATAGTGGACAAGGTTCCATTCACAT GCTCATATGTTTATAAACTGTGTTTTGTAGAAGAAAAAGAATCATAACAATACAAACACACATT CATTCTCTCTTTTCTCTCTACCATTCTCAACCTGTATTGGACAGCACTGCCTCTTTTGCTTACTT GCTGCCTGTTCAAACTGAGGTGGAATGCAGTGGTTCCCATGCTTAACAGATCATTAAAACACCC TAGAACACTCCTAGGATAGATTAATGT

Figure 13

ACCGCAGGGGCTCCCGGACCCTGACTCTGCAGCCGAACCGGCACGGTTTCGTGGGGACCCAG GCTTGCAAAGTGACGGTCATTTTCTCTTTCTTCTCCCTCTTGAGTCCTTCTGAGATGATGGCTCT GGGCGCAGCGGAGCTACCCGGGTCTTTGTCGCGATGGTAGCGGCGGCTCTCGGCGGCCACCC TCTGCTGGGAGTGAGCGCCACCTTGAACTCGGTTCTCAATTCCAACGCTATCAAGAACCTGCCC CCACCGCTGGGCGCGCTGCGGGCACCCAGGCTCTGCAGTCAGCGCCGCGCGGGAATCCTG TACCCGGGCGGAATAAGTACCAGACCATTGACAACTACCAGCCGTACCCGTGCGCAGAGGAC GAGGAGTGCGCACTGATGAGTACTGCGCTAGTCCCACCCGCGGAGGGGACGCAGGCGTGCAA ATCTGTCTCGCCTGCAGGAAGCGCCGAAAACGCTGCATGCGTCACGCTATGTGCCCCCGGGA ATTACTGCAAAAATGGAATATGTGTGTCTTCTGATCAAAATCATTTCCGAGGAGAAATTGAGGA AACCATCACTGAAAGCTTTGGTAATGATCATAGCACCTTGGATGGGTATTCCAGAAGAACCACC TTGTCTCAAAAATGTATCACACCAAAGGACAAGAAGGTTCTGTTTGTCTCCGGTCATCAGACT GTGCCTCAGGATTGTGTTGTGCTAGACACTTCTGGTCCAAGATCTGTAAACCTGTCCTGAAAGA AGGTCAAGTGTGTACCAAGCATAGGAGAAAAGGCTCTCATGGACTAGAAATATTCCAGCGTTG TTACTGTGGAGAAGGTCTGTCTTGCCGGATACAGAAAGATCACCATCAAGCCAGTAATTCTTCT AGGCTTCACACTTGTCAGAGACACTAAACCAGCTATCCAAATGCAGTGAACTCCTTTTATATAA TAGATGCTATGAAAACCTTTTATGACCTTCATCAACTCAATCCTAAGGATATACAAGTTCTGTG GTTTCAGTTAAGCATTCCAATAACACCTTCCAAAAACCTGGAGTGTAAGAGCTTTGTTTCTTTAT GGAACTCCCCTGTGATTGCAGTAAATTACTGTATTGTAAATTCTCAGTGTGGCACTTACCTGTAA ATGCAATGAAACTTTTAATTATTTTTCTAAAGGTGCTGCACTGCCTATTTTTCCTCTTGTTATGTA AATTTTTGTACACATTGATTGTTATCTTGACTGACAAATATTCTATATTGAACTGAAGTAAATCA TTTCAGCTTATAGTTCTTAAAAGCATAACCCTTTACCCCATTTAATTCTAGAGTCTAGAACGCAA GGATCTCTTGGAATGACAAATGATAGGTACCTAAAATGTAACATGAAAATACTAGCTTATTTTC TGAAATGTACTATCTTAATGCTTAAATTATATTTCCCTTTAGGCTGTGATAGTTTTTGAAATAAA ATTTAACATTTAATATCATGAAATGTTATAA

Figure 14

AGAAAGCGGGAGCCCGCGGCGAGCGTAGCGCAAGTCCGCTCCCTAGGCATCGCTGCGCAGCGATTCGCTGTCTCTTGTGAGTCAGGGGACAACGCTTCGGGGCAACTGTGAGTGCGCGTGTGGGGGACCTCGATTCTCTTCAGATCTCGAGGATTCGGTCCGGGGACGTCTCCTGATCCCCTACTAA

AGCGCCTGCTAACTTTGAAAAGGAGCACTGTGTCCTGCAAAGTTTGACACATAAAGGATAGGA AAAGAGAGGAGAAAAAGCAACTGAGTTGAAGGAGAAGGAGCTGATGCGGGCCTCCTGATCA ATTAAGAGGAGAGTTAAACCGCCGAGATCCCGGCGGGACCAAGGAGGTGCGGGGCAAGAAGG AACGGAAGCGGTGCGATCCACAGGGCTGGGTTTTCTTGCACCTTGGGTCACGCCTCCTTGGCGA GAAAGCGCCTCGCATTTGATTGCTTCCAGTTATTGCAGAACTTCCTGTCCTGGTGGAGAAGCGG GTCTCGCTTGGGTTCCGCTAATTTCTGTCCTGAGGCGTGAGACTGAGTTCATAGGGTCCTGGGTC CCCGAACCAGGAAGGGTTGAGGGAACACAATCTGCAAGCCCCCGCGACCCAAGTGAGGGGCCC CGTGTTGGGGTCCTCCCTTTGCATTCCCACCCCTCCGGGCTTTGCGTCTTCCTGGGGACCC CCTCGCCGGGAGATGGCCGCGTTGATGCGGAGCAAGGATTCGTCCTGCTGCTGCTCCTACTGG CCGCGGTGCTGATGGTGGAGAGCTCACAGATCGGCAGTTCGCGGGCCAAACTCAACTCCATCA AGTCCTCTCTGGGCGGGAGACGCCTGGTCAGGCCGCCAATCGATCTGCGGGCATGTACCAAG GACTGGCATTCGGCGGCAGTAAGAAGGGCAAAAACCTGGGGCAGGCCTACCCTTGTAGCAGTG ATAAGGAGTGTGAAGTTGGGAGGTATTGCCACAGTCCCCACCAAGGATCATCGGCCTGCATGG TGTGTCGGAGAAAAAAGAAGCGCTGCCACCGAGATGGCATGTGCCCCCAGTACCCGCTGCA ATAATGGCATCTGTATCCCAGTTACTGAAAGCATCTTAACCCCTCACATCCCGGCTCTGGATGG TACTCGGCACAGAGATCGAAACCACGGTCATTACTCAAACCATGACTTGGGATGGCAGAATCT AGGAAGACCACACTAAGATGTCACATATAAAAGGGCATGAAGGAGACCCCTGCCTACGATC ATCAGACTGCATTGAAGGGTTTTGCTGTGCTCGTCATTTCTGGACCAAAATCTGCAAACCAGTG CTCCATCAGGGGGAAGTCTGTACCAAACAACGCAAGAAGGGTTCTCATGGGCTGGAAATTTTC CAGCGTTGCGACTGTGCGAAGGGCCTGTCTTGCAAAGTATGGAAAGATGCCACCTACTCCTCCA AAGCCAGACTCCATGTGTGTCAGAAAATTTGATCACCATTGAGGAACATCATCAATTGCAGACT GTGAAGTTGTGTATTTAATGCATTATAGCATGGTGGAAAATAAGGTTCAGATGCAGAAGAATG GCTAAAATAAGAAACGTGATAAGAATATAGATGATCACAAAAAGGGAGAAAAGAAAACATGAA CTGAATAGATTAGAATGGGTGACAAATGCAGTGCAGCCAGTGTTTCCATTATGCAACTTGTCTA TGTAAATAATGTACACATTTGTGGAAAATGCTATTATTAAGAGAACAAGCACACAGTGGAAAT TACTGATGAGTAGCATGTGACTTTCCAAGAGTTTAGGTTGTGCTGGAGGAGAGGTTTCCTTCAG ATTGCTGATTGCTTATACAAATAACCTACATGCCAGATTTCTATTCAACGTTAGAGTTTAACAA AATACTCCTAGAATAACTTGTTATACAATAGGTTCTAAAAATAAAATTGCTAAACAAGAAATGA AAACATGGAGCATTGTTAATTTACAACAGAAAATTACCTTTTGATTTGTAACACTACTTCTGCTG TTCAATCAAGAGTCTTGGTAGATAAGAAAAAAATCAGTCAATATTTCCAAATAATTGCAAAAAA ACTITITITCAAAATTTTAGTTTTACCTGTAATTAATAAGAACTGATACAAGACAAAAACAGTT CCTTCAGATTCTACGGAATGACAGTATATCTCTCTTTATCCTATGTGATTCCTGCTCTGAATGCA TTATATTTTCCAAACTATACCCATAAATTGTGACTAGTAAAATACTTACACAGAGCAGAATTTT CACAGATGGCAAAAAATTTAAAGATGTCCAATATATGTGGGAAAAGAGCTAACAGAGAGATC ATTATTTCTTAAAGATTGGCCATAACCTGTATTTTGATAGAATTAGATTGGTAAATACATGTATT CATACATACTCTGTGGTAATAGAGACTTGAGCTGGATCTGTACTGCACTGGAGTAAGCAAGAA AATTGGGAAAACTTTTTCGTTTGTTCAGGTTTTGGCAACACATAGATCATATGTCTGAGGCACA AGTTGGCTGTTCATCTTTGAAACCAGGGGATGCACAGTCTAAATGAATATCTGCATGGGATTTG CTATCATAATATTTACTATGCAGATGAATTCAGTGTGAGGTCCTGTGTCCGTACTATCCTCAAAT TATTTATTTTATAGTGCTGAGATCCTCAAATAATCTCAATTTCAGGAGGTTTCACAAAATGGACT CCTGAAGTAGACAGAGTAGTGAGGTTTCATTGCCCTCTATAAGCTTCTGACTAGCCAATGGCAT CATCCAATTTTCTTCCCAAACCTCTGCAGCATCTGCTTTATTGCCAAAGGGCTAGTTTCGGTTTT CTGCAGCCATTGCGGTTAAAAAATATAAGTAGGATAACTTGTAAAACCTGCATATTGCTAATCT ATAGACACCACAGTTTCTAAATTCTTTGAAACCACTTTACTACTTTTTTTAAACTTAACTCAGTT CTAAATACTTTGTCTGGAGCACAAAACAATAAAAGGTTATCTTATAGTCGTGACTTTAAACTTT TGTAGACCACAATTCACTTTTAGTTTTCTTTTACTTAAATCCCATCTGCAGTCTCAAATTTAAGT TCTCCCAGTAGAGATTGAGTTTGAGCCTGTATATCTATTAAAAATTTCAACTTCCCACATATATT TACTAAGATGATTAAGACTTACATTTTCTGCACAGGTCTGCAAAAACAAAAATTATAAACTAGT CCATCCAAGAACCAAAGTTTGTATAAACAGGTTGCTATAAGCTTGGTGAAAATGAAAATGGAAC ATTTCAATCAAACATTTCCTATATAACAATTATATATTTACAATTTGGTTTCTGCAATATTTTTC TATTTTCTTATAGAGATATTTCTTACAGAAAGCTTTGTAGCAGAATATATTTGCAGCTATTGACT TTGTAATTTAGGAAAAATGTATAATAAGATAAAATCTATTAAATTTTTCTCCTCTAAAAACTGA ATTCAAAGC

Figure 15

CCTGCTGCTGGCGGCGGCGCCCACGGCCCCGCGCCCGACGGCGACCTCGGCTCCA GTCAAGCCCGGCCCGGCTCTCAGCTACCCGCAGGAGGAGGCCACCCTCAATGAGATGTTCCGC GAGGTTGAGGAACTGATGGAGGACACGCAGCACAAATTGCGCAGCGCGGTGGAAGAGATGGA GGCAGAAGAAGCTGCTAAAGCATCATCAGAAGTGAACCTGGCAAACTTACCTCCCAGCTA TCACAAGATAACCAACAACCAGACTGGACAAATGGTCTTTTCAGAGACAGTTATCACATCTGTG GGAGACGAAGAAGGCAGAGCCACGAGTGCATCATCGACGAGGACTGTGGGCCCAGCAT ACCCGGGACAGTGAGTGCTGTGGAGACCAGCTGTGTGTCTGGGGTCACTGCACCAAAATGGCC ACCAGGGGCAGCAATGGGACCATCTGTGACAACCAGAGGGACTGCCAGCCGGGGCTGTGCTGT GCCTTCCAGAGAGGCCTGCTGTTCCCTGTGTGCACACCCCTGCCCGTGGAGGGCGAGCTTTGCC ATGACCCCGCCAGCCGGCTTCTGGACCTCATCACCTGGGAGCTAGAGCCTGATGGAGCCTTGGA CCGATGCCCTTGTGCCAGTGGCCTCCTCTGCCAGCCCACAGCCACAGCCTGGTGTATGTGTGC AAGCCGACCTTCGTGGGGAGCCGTGACCAAGATGGGGAGATCCTGCTGCCCAGAGAGGTCCCC GATGAGTATGAAGTTGGCAGCTTCATGGAGGAGGTGCGCCAGGAGCTGGAGGACCTGGAGAGA AGCCTGACTGAAGAGATGGCGCTGGGGGAGCCTGCGGCTGCCGCCGCTGCACTGCTGGGAGGG CCAGGTGTGTGCTTTAGGCGTGGGCTGACCAGGCTTCTTCCTACATCTTCTTCCCAGTAAGTTTC CCCTCTGGCTTGACAGCATGAGGTGTTGTGCATTTGTTCAGCTCCCCCAGGCTGTTCTCCAGGCT TCACAGTCTGGTGCTTGGGAGAGTCAGGCAGGGTTAAACTGCAGGAGCAGTTTGCCACCCCTGT CCAGATTATTGGCTGCTTTGCCTCTACCAGTTGGCAGACAGCCGTTTGTTCTACATGGCTTTGAT AATTGTTTGAGGGGAGATGGAAACAATGTGGAGTCTCCCTCTGATTGGTTTTGGGGAAATG TGGAGAAGAGTGCCCTGCTTTGCAAACATCAACCTGGCAAAAATGCAACAAATGAATTTTCCA CGCAGTTCTTTCCATGGGCATAGGTAAGCTGTGCCTTCAGCTGTTGCAGATGAAATGTTCTGTTC ACCCTGCATTACATGTGTTTATTCATCCAGCAGTGTTGCTCAGCTCCTACCTCTGTGCCAGGGCA GCATTTCATATCCAAGATCAATTCCCTCTCTCAGCACAGCCTGGGGAGGGGGTCATTGTTCTCC TCGTCCATCAGGGATCTCAGAGGCTCAGAGACTGCAAGCTGCTTGCCCAAGTCACACAGCTAGT GAAGACCAGAGCAGTTTCATCTGGTTGTGACTCTAAGCTCAGTGCTCTCTCCACTACCCCACAC TGCACATCTGGAATTAAGGTCAAACTAATTCTCACATCCCTCTAAAAGTAAACTACTGTTAGGA ACAGCAGTGTTCTCACAGTGTGGGGCAGCCGTCCTTCTAATGAAGACAATGATATTGACACTGT CCCTCTTTGGCAGTTGCATTAGTAACTTTGAAAGGTATATGACTGAGCGTAGCATACAGGTTAA CCTGCAGAAACAGTACTTAGGTAATTGTAGGGCGAGGATTATAAATGAAATTTGCAAAATCAC TTAGCAGCAACTGAAGACAATTATCAACCACGTGGAGAAAATCAAACCGAGCAGGGCTGTGTG AAACATGGTTGTAATATGCGACTGCGAACACTGAACTCTACGCCACTCCACAAATGATGTTTTC AGGTGTCATGGACTGTTGCCACCATGTATTCATCCAGAGTTCTTAAAGTTTAAAGTTGCACATG ATTGTATAAGCATGCTTTCTTTGAGTTTTAAATTATGTATAAACATAAGTTGCATTTAGAAATCA AGCATAAATCACTTCAACTGCTCTTCT

Figure 16

GACAAACAGACGACGTGCTGAGCTGCCAGCTTAGTGGAAGCTCTGCTCTGGGTGGAGAGCAGC CTCGCTTTGGTGACGCACAGTGCTGGGACCCTCCAGGAGCCCCGGGATTGAAGGATGGTGGCG GCCGTCCTGCTGGGGCTGAGCTGGCTCTGCTCTCCCCTGGGAGCTCTGGTCCTGGACTTCAACA ACATCAGGAGCTCTGCTGACCTGCATGGGGCCCCGGAAGGGCTCACAGTGCCTGTCTGACACGG ACTGCAATACCAGAAAGTTCTGCCTCCAGCCCCGCGATGAGAAGCCGTTCTGTGCTACATGTCG TGGGTTGCGGAGGGGGCCAGCGAGATGCCATGTGCTGCCCTGGGACACTCTGTGTGAACGA TGTTTGTACTACGATGGAAGATGCAACCCCAATATTAGAAAGGCAGCTTGATGAGCAAGATGG GTATTAAGAAATCACAAGGCAGGAAGGGACAAGAGGGAGAAAGTTGTCTGAGAACTTTTGACT GTGGCCCTGGACTTTGCTGTGCTCGTCATTTTTGGACGAAAATTTGTAAGCCAGTCCTTTTGGAG GGACAGGTCTGCTCCAGAAGAGGGCATAAAGACACTGCTCAAGCTCCAGAAATCTTCCAGCGT

TGCGACTGTGGCCCTGGACTACTGTCGAAGCCAATTGACCAGCAATCGGCAGCATGCTCGAT
TAAGAGTATGCCAAAAAATAGAAAAGCTATAAATATTTCAAAATAAAGAAGAATCCACATTGC
ATTTGAG

Figure 17

ATGGGGCTCTGGCCGCTGGCTGGCTTCTGCTACGCTGCTGCTGCCGCCTCT GCCCGCAGCCCTGGCTGCCAACAGCAGTGGCCGATGGTGGGGTATTGTGAACGTAGCCTCCTCC ACGAACCTGCTTACAGACTCCAAGAGTCTGCAACTGGTACTCGAGCCCAGTCTGCAGCTGTTGA GCCGCAAACAGCGGCGCCTGATACGCCAAAATCCGGGGATCCTGCACAGCGTGAGTGGGGGGC TGCAGAGTGCCGTGCGGGGTGCAAGTGGCAGTTCCGGAATCGCCGCTGGAACTGTCCCACTG CTCCAGGGCCCCACCTCTTCGGCAAGATCGTCAACCGAGGCTGTCGAGAAACGGCGTTTATCTT CGCTATCACCTCCGCCGGGGTCACCCATTCGGTGGCGCGCTCCTGCTCAGAAGGTTCCATCGAA TCCTGCACGTGTGACTACCGGCGGCGCGCCCGGGGGGCCCCGACTGGCACTGGGGGGGCTGC AGCGACAACATTGACTTCGGCCGCCTCTTCGGCCGGGAGTTCGTGGACTCCGGGGAGAAGGGG AGATGCGCCAGGAGTGCAAGTGCCACGGGATGTCCGGCTCATGCACGGTGCGCACGTGCTGGA TGCGGCTGCCCACGCTGCGCGCGTGGGCGATGTGCTGCGCGACCGCTTCGACGGCGCCTCGCG CGTCCTGTACGGCAACCGCGCAGCAACCGCGCTTCGCGAGCGGAGCTGCTGCGCCTGGAGCC GGAAGACCCGGCCCACAAACCGCCCTCCCCCACGACCTCGTCTACTTCGAGAAATCGCCCAAC TTCTGCACGTACAGCGGACGCCTGGGCACAGCAGGCACGGCAGGGCGCCCTGTAACAGCTCG CGCGTCACCGAGCGCTGCAACTGCACCTTCCACTGGTGCTGCCACGTCAGCTGCCGCAACTGCA CGCACACGCGCGTACTGCACGAGTGTCTGTGA

Figure 18

GCGGCGCCGTGACGAGCGCTCCCGGAGCTGAGCGCTTCTGCTCTGGGCACGCATGGCGCCC GCACACGGAGTCTGACCTGATGCAGACGCAAGGGGGTTAATATGAACGCCCCTCTCGGTGGAA TCTGGCTCTGGCTCTCTTGACCTGGCTCACCCCGAGGTCAACTCTTCATGGTGGTAC ATGAGAGCTACAGGTGGCTCCTCCAGGGTGATGTGCGATAATGTGCCAGGCCTGGTGAGCAGC CAGCGGCAGCTGTCACCGACATCCAGATGTGATGCGTGCCATTAGCCAGGGCGTGGCCGAG TGGACAGCAGAATGCCAGCACCAGTTCCGCCAGCACCGCTGGAATTGCAACACCCTGGACAGG GATCACAGCCTTTTTGGCAGGGTCCTACTCCGAAGTAGTCGGGAATCTGCCTTTGTTTATGCCAT CTCCTCAGCTGGAGTTGTATTTGCCATCACCAGGGCCTGTAGCCAAGGAGAAGTAAAATCCTGT TCCTGTGATCCAAAGAAGATGGGAAGCGCCAAGGACAGCAAAGGCATTTTTGATTGGGGTGGC TGCAGTGATAACATTGACTATGGGATCAAATTTGCCCGCGCATTTGTGGATGCAAAGGAAAGG AAAGGAAAGGATGCCAGAGCCCTGATGAATCTTCACAACAACAGAGCTGGCAGGAAGGCTGTA AAGCGGTTCTTGAAACAAGAGTGCAAGTGCCACGGGGTGAGCGGCTCATGTACTCTCAGGACA TGCTGGCTGGCCATGGCCGACTTCAGGAAAACGGGCGATTATCTCTGGAGGAAGTACAATGGG GCCATCCAGGTGGTCATGAACCAGGATGGCACAGGTTTCACTGTGGCTAACGAGAGGTTTAAG AAGCCAACGAAAAATGACCTCGTGTATTTTGAGAATTCTCCAGACTACTGTATCAGGGACCGAG AGGCAGGCTCCCTGGGTACAGCAGGCCGTGTGTGCAACCTGACTTCCCGGGGCATGGACAGCT GTGAAGTCATGTGCTGTGGGAGAGGCTACGACACCTCCCATGTCACCCGGATGACCAAGTGTG GGTGTAAGTTCCACTGGTGCTGCGCCGTGCGCTGTCAGGACTGCCTGGAAGCTCTGGATGTGCA CACATGCAAGGCCCCCAAGAACGCTGACTGGACAACCGCTACATGACCCCAGCAGGCGTCACC ATCCACCTTCCCTTCTACAAGGACTCCATTGGATCTGCAAGAACACTGGACCTTTGGGTTCTTTC TGGGGGGATATTTCCTAAGGCATGTGGCCTTTATCTCAACGGAAGCCCCCTCTTCCTCCCTGGG GGCCCCAGGATGGGGGGCCACACGCTGCACCTAAAGCCTACCCTATTCTATCCATCTCCTGGTG TTCTGCAGTCATCTCCCCTCCTGGCGAGTTCTCTTTGGAAATAGCATGACAGGCTGTTCAGCCGG

Figure 19

CGGGAGTCTTCGGGGAGCTATGCTGAGACCGGGTGGTGCGGAGGAAGCTGCGCAGCTCCCGCT TCGGCGCCCCGGTCCCTGTGCCGTCGCCCGGGCCCCCGACGGCTCCCGGGCTTCG GCCCGCCTAGGTCTTGCCTCCTGCTCCTGCTGCTGACGCTGCCGGCCCGCGTAGACAC GTCCTGGTGGTACATTGGGGCACTGGGGCACGAGTGATCTGTGACAATATCCCTGGTTTGGTG AGCCGGCAGCGCAGCTGTGCCAGCGTTACCCAGACATCATGCGTTCAGTGGGCGAGGGTGCC CGAGAATGGATCCGAGAGTGTCAGCACCAATTCCGCCACCACCGCTGGAACTGTACCACCCTG GACCGGGACCACACCGTCTTTGGCCGTGTCATGCTCAGAAGTAGCCGAGAGGCAGCTTTTGTAT ATGCCATCTCATCAGCAGGGTAGTCCACGCTATTACTCGCGCCTGTAGCCAGGGTGAACTGAG TGTGTGCAGCTGTGACCCCTACACCCGTGGCCGACACCATGACCAGCGTGGGGACTTTGACTGG GGTGGCTGCAGTGACAACATCCACTACGGTGTCCGTTTTGCCAAGGCCTTCGTGGATGCCAAGG AGAAGAGGCTTAAGGATGCCCGGGCCCTCATGAACTTACATAATAACCGCTGTGGTCGCACGG CTGTGCGGCGGTTTCTGAAGCTGGAGTGTAAGTGCCATGGCGTGAGTGGTTCCTGTACTCTGCG CACCTGCTGCGTGCACTCTCAGATTTCCGCCGCACAGGTGATTACCTGCGGCGACGCTATGAT GGGGCTGTGCAGGTGATGGCCACCCAAGATGGTGCCAACTTCACCGCAGCCCGCCAAGGCTAT CGCCGTGCCACCCGGACTGATCTTGTCTACTTTGACAACTCTCCAGATTACTGTGTCTTGGACAA GGCTGCAGGTTCCCTAGGCACTGCAGGCCGTGTCTGCAGCAAGACATCAAAAGGAACAGACGG TTGTGAAATCATGTGCCGAGGGTACGACACACACTCGAGTCACCCGTGTTACCCAGTGT GAGTGCAAATTCCACTGGTGCTGTGCTGTACGGTGCAAGGAATGCAGAAATACTGTGGACGTC CATACTTGCAAAGCCCCCAAGAAGGCAGAGTGGCTGGACCAGACCTGAACACACAGATACCTC CCACCCTCCACCCTGGGCTGCTACCGCTTCTATTTAAGGATGTAGAGAGTAATCCATAGGGACC ATGGTGTCCTGGCTGCTTAGCCCTGGGAAGGAGTTGTCAGGGGATATAAGAAACTGTGCA CGACACTTCTTGGTGTGCAAGAGGAAGGGTACCTGTAGAGAGCTTCTTTTTGTTTCTACCTGGC CAAAGTTAGATGGGACAAAGATGAATGGCATGTCCCTTCTCTGAAGTCCGTTTGAGCAGAACTA CCTGGTACCCCGAAAGAAAATCTTAGGCTACCACATTCTATTATTGAGAGCCTGAGATGTTAG CCATAGTGGACAAGGTTCCATTCACATGCTCATATGTTTATAAACTGTGTTTTGTAGAAGAAAA AGAATCATAACAATACAAACACACATTCATTCTCTCTTTTTCTCTCTACCATTCTCAACCTGTAT TGGACAGCACTGCCTCTTTTGCTTACTTGCTGCCTGTTCAAACTGAGGTGGAATGCAGTGGTTCC CATGCTTAACAGATCATTAAAACACCCTAGAACACTCCTAGGATAGATTAATGT

Figure 20

GCGCTTCTGACAAGCCCGAAAGTCATTTCCAATCTCAAGTGGACTTTGTTCCAACTATTGGGGGCTCGCCCCCTCYTCATGGTCGCGGGCAAACTTCCTCCTCGGCGCCTCTTCTAATGGAGCCCCACTGCTCGGGCTGCTCCTCGGCCTCCTGCTCGGTGGCACCAGGGTCCTCGCTGGCTACCCAATTTGGTGGTCCCTGGCCCTGGGCCAGCAGTACACATCTCTGGGCTCACAGCCCCTGCTCTGCGGCTCCATCCCAGGCCTGGTCCCCAAGCAACTGCGCTTCTGCCGCAATTACATCGAGATCATGCCCG

CGTGGCCGAGGGCGTGAAGCTGGGCATCCAGGAGTGCCAGCACCAGTTCCGGGGCCGCCCT

GGAACTGCACCACATAGATGACAGCCTGGCCATCTTTGGGCCCGTCCTCGACAAAGCCACCCG
CGAGTCGGCCTTCGTTCACGCCATCGCCTCGGCCGGCGTGGCCTTCGCCGTCACCCGCTCCTGC
GCCGAGGGCACCTCCACCATTTGCGGCTGTGACTCGCATCATAAGGGGCCGCCTGGCGAAGGC
TGGAAGTGGGGCGGCTGCAGCGAGGACGCTGACTTCGGCGTGTTAGTGTCCAGGGAGTTCGCG
GATGCGCGCGAGAACAGGCCGGACGCGCGCTCGGCCATGAACAAGCACAACAACAACGAGGCGGG
CCGCACGACTATCCTGGACCACATGCACCTCAAATGCAAGTGCCACGGGCTGTCGGCCAGCTGT
GAGGTGAAGACCTGCTGGTGGGCGCAGCCTGACTTCCGTGCCATCGGTGACTTCCTCAAGGACA
AGTATGACAGCGCCTCGGAGATGGTAGTAGAGAAGCACCGTGAGTCCCGAGGCTGGGTGGAGA
CCCTCCGGGCCAAGTACTCGCTCTTCAAGCCACCCACGGAGAGGGACCTGGTCTACTACGAGA
ACTCCCCCAACTTTTGTGAGCCCAACCCAGAGACGGTTCCTTTGGCACAAGGGACCGGACTTG
CAATGTCACCTCCCACGGCATCGATGGCTGCGATCTCTCTGCTGTGGCCGGGCCACAACACG
AGGACGGAGAAGCGGAAGGAAAAAATGCCACTGCATCTTCCACTGGTGCTGCTACGTCAGCTGC
CAGGAGTGTATTCGCATCTACGACGTGCACCCTGCAAGTAGGGCACCAG

Figure 21

GAGCAACTGGCTGTACCTGGCCAAGCTGTCGTCGGTGGGGAGCATCTCAGAGGAGGAGACGTG CGAGAAACTCAAGGGCCTGATCCAGAGGCAGGTGCAGATGTGCAAGCGGAACCTGGAAGTCAT GGACTCGGTGCCCGGGTGCCCAGCTGGCCATTGAGGAGTGCCAGTACCAGTTCCGGAACCG GCGCTGGAACTGCTCCACACTCGACTCCTTGCCCGTCTTCGGCAAGGTGGTGACGCAAGGGATT CGGGAGGCGCCTTGGTGTACGCCATCTCTTCGGCAGGTGTGGCCTTTGCAGTGACGCGGGCGT GCAGCAGTGGGGAGCTGGAGAAGTGCGGCTGTGACAGGACAGTGCATGGGGTCAGCCCACAG GGCTTCCAGTGGTCAGGATGCTCTGACAACATCGCCTACGGTGTGGCCTTCTCACAGTCGTTTG TGGATGTGCGGGAGAAGCAAGGGGGCCTCGTCCAGCAGAGCCCTCATGAACCTCCACAACA ATGAGGCCGGCAGGAAGGCCATCCTGACACACATGCGGGTGGAATGCAAGTGCCACGGGGTGT CAGGCTCCTGTGAGGTAAAGACGTGCTGGCGAGCCGTGCCGCCCTTCCGCCAGGTGGGTCACG CACTGAAGGAGAAGTTTGATGGTGCCACTGAGGTGGAGCCACGCCGCGTGGGCTCCTCCAGGG CACTGGTGCCACGCAACGCACAGTTCAAGCCGCACACAGATGAGGACTTGGTGTACTTGGAGC CTAGCCCGACTTCTGTGAGCAGGACATGCGCAGCGGCGTGCTGGGCACGAGGGGCCGCACAT GCAACAAGACGTCCAAGGCCATCGACGGCTGTGAGCTGCTGTGCTGTGCCGCGCGCTTCCACA CGGCGCAGGTGGAGCTGCAACGCTGCAACTTCCACTGGTGCTGCTCCAAGTG CCGGCAGTGCCAGCGGCTCGTGGAGTTGCACACGTGCCGATGA

Figure 22

ATTAATTCTGGCTCCACTTGTTGCTCGGCCCAGGTTGGGGAGAGGACGAGGTGGCCGCAGC
GGGTTCCTGAGTGAATTACCCAGGAGGACTGAGCACACCAACTAGAGAGGGGTCAGGG
GTGCGGGACTCGAGCAGCAGGAAGGAAGGAGCACCCAGCCCCACCAGGCTTTGACTCAACAGA
ATTGAGACACGTTTGTAATCGCTGGCGTGCCCCGCGCACAGGATCCCAGCGAAAATCAGATTTC
CTGGTGAGGTTGCGTGGGTGGATTAATTTGGAAAAAGAAACTGCCTATATCTTGCCATCAAAA
ACTCACGGAGGAGAAGCGCAGTCAATCAACAGTAAACTTAAGAGACCCCCGATGCTCCCCTGG
TTTAACTTGTATGCTTGAAAATTATCTGAGAGGGAATAAACATCTTTTCCTTCTCCTCCCAG
AAGTCCATTGGAATATTAAGCCCAGGAGTTGCTTTGGGGATGGCTGGAAGTGCAATGTCTTCCA
AGTTCTTCCTAGTGGCTTTGGCCATATTTTTCTCTTCGCCCAGGTTGTAATTGAAGCCAATTCTT
GGTGGTCGCTAGGTATGAATAACCCTGTTCAGATGTCAGAAGTATATATTATAGGAGCACAGCC
TCTCTGCAGCCAACTGGCAGGACTTTCTCAAGGACAGAAGAAACTGTGCCACTTGTATCAGGAC
CACATGCAGTACATCGGAGAAGGCGCGAAGACAGCATCAAAGAATGCCAGTATCAATTCCGA
CATCGACGGTGGAACTGCAGCACTGTGGATAACACCTCTGTTTTTTGGCAGGGTGATCAATTCCGA
GCAGCCGCGAGACGGCCTTCACATACGCCGTGAGCGCAGCAGCGGGTGGTGAACGCCCATGAGCC
GGGCGTGCCGCGAGGGCGAGCTGTCCACCTGCGCTGCAGCCCCCCAAGGACC

TGCCGCGGGACTGGCTCTGGGGCGGCGGCGACAACATCGACTATGGCTACCGCTTTGCCAA GGAGTTCGTGGACGCCCGCGAGCGGAGCGCATCCACGCCAAGGGCTCCTACGAGAGTGCTCG CATCCTCATGAACCTGCACAACAACGAGGCCGGCCGCAGGACGGTGTACAACCTGGCTGATGT AGACTTCCGCAAGGTGGGTGATGCCCTGAAGGAGAAGTACGACAGCGCGGCGGCCATGCGGCT CAACAGCCGGGGCAAGTTGGTACAGGTCAACAGCCGCTTCAACTCGCCCACCACACAAGACCT GGTCTACATCGACCCCAGCCCTGACTACTGCGTGCGCAATGAGAGCACCGGCTCGCTGGGCAC CCGTGGGTACGACCAGTTCAAGACCGTGCAGACGGAGCGCTGCCACTGCAAGTTCCACTGGTG CTGCTACGTCAAGTGCAAGAAGTGCACGGAGATCGTGGACCAGTTTGTGTGCAAGTAGTGGGT TTTTGGTTTTTAGAAATATTTTTTTTTTCCCCAAGAATTGCAACCGGAACCATTTTTTTCCTG TTACCATCTAAGAACTCTGTGGTTTATTATTAATATTATAATTATTATTATTTGGCAATAATGGGGGT GGGAACCACGAAAAATATTTATTTTGTGGATCTTTGAAAAGGTAATACAAGACTTCTTTTGGAT AGTATAGAATGAAGGGGGAAATAACACATACCCTAACTTAGCTGTGTGGGACATGGTACACAT CCAGAAGGTAAAGAAATACATTTTCTTTTTCTCAAATATGCCATCATATGGGATGGGTAGGTTC CAGTTGAAAGAGGGTGGTAGAAATCTATTCACAATTCAGCTTCTATGACCAAAATGAGTTGTAA CCAGCAGGGCTGCTAGCTTGCTTTCTGCATTTTCAAAATGATAATTTACAATGGAAGGACAAGA ATGTCATATTCTCAAGGAAAAAAGGTATATCACATGTCTCATTCTCCTCAAATATTCCATTTGCA GACAGACCGTCATATTCTAATAGCTCATGAAATTTGGGCAGCAGGGAGGAAAGTCCCCAGAAA TTAAAAAATTTAAAACTCTTATGTCAAGATGTTGATTTGAAGCTGTTATAAGAATTGGGATTCC AACATAAATGAAATATCCTGTATTTTCTTAGGGATACTTGGTTAGTAAATTATAATAGTAGAAA TAATACATGAATCCCATTCACAGGTTTCTCAGCCCAAGCAACAAGGTAATTGCGTGCCATTCAG CACTGCACCAGAGCAGCAACCTATTTGAGGAAAAACAGTGAAATCCACCTTCCTCTTCACACT GAGCCCTCTCTGATTCCTCCGTGTTGTGATGTGATGCTGGCCACGTTTCCAAACGGCAGCTCCAC TGGGTCCCCTTTGGTTGTAGGACAGGAAATGAAACATTAGGAGCTCTGCTTGGAAAACAGTTCA CTACTTAGGGATTTTTGTTTCCTAAAACTTTTATTTTGAGGAGCAGTAGTTTTCTATGTTTTAATG ACAGAACTTGGCTAATGGAATTCACAGAGGTGTTGCAGCGTATCACTGTTATGATCCTGTGTTT AGATTATCCACTCATGCTTCTCCTATTGTACTGCAGGTGTACCTTAAAACTGTTCCCAGTGTACT TGAACAGTTGCATTTATAAGGGGGGAAATGTGGTTTAATGGTGCCTGATATCTCAAAGTCTTTT GTACATAACATATATATATATACATATATAAATATAAATATAAATATATATCTCATTGCAGC CAGTGATTTAGATTTACAGCTTACTCTGGGGTTATCTCTCTGTCTAGAGCATTGTTGTCCTTCAC TGCAGTCCAGTTGGGATTATTCCAAAAGTTTTTTGAGTCTTGAGCTTGGGCTGTGGCCCCGCTGT GATCATACCCTGAGCACGACGAAGCAACCTCGTTTCTGAGGAAGAAGCTTGAGTTCTGACTCAC CATTTCTGTTCACTTTGTGGAGAGGGCATTACTTGTTCGTTATAGACATGGACGTTAAGAGATAT TCAAAACTCAGAAGCATCAGCAATGTTTCTCTTTTCTTAGTTCATTCTGCAGAATGGAAACCCAT GCCTATTAGAAATGACAGTACTTATTAATTGAGTCCCTAAGGAATATTCAGCCCACTACATAGA TAGCTTTTTTTTTTTTTTTTTTTTAATAAGGACACCTCTTTCCAAACAGGCCATCAAATATGT TCTTATCTCAGACTTACGTTGTTTTAAAAGTTTGGAAAGATACACATCTTTTCATACCCCCCTT AGGAGGTTGGGCTTTCATATCACCTCAGCCAACTGTGGCTCTTAATTTATTGCATAATGATATCC ACATCAGCCAACTGTGGCTCTTTAATTTATTGCATAATGATATTCACATCCCCTCAGTTGCAGTG AATTGTGAGCAAAAGATCTTGAAAGCAAAAAGCACTAATTAGTTTAAAATGTCACTTTTTTGGT TTTTATTATACAAAAACCATGAAGTACTTTTTTTATTTGCTAAATCAGATTGTTCCTTTTTAGTGA CTCATGTTTATGAAGAGAGTTGAGTTTAACAATCCTAGCTTTTAAAAGAAACTATTTAATGTAA AATATTCTACATGTCATTCAGATATTATGTATATCTTCTAGCCTTTATTCTGTACTTTAATGTAC **CCAAATGGAAG**

Figure 23

TAGGGCGGTCACG ATGCTGCCGCCCTTACCCTCCCGCCTCGGGCTGCTGCTGCTGCTCCTGTGCCCG ${\tt GCGCACGTCGGCGGACTGTGGGCCGCCTGGCCCCTTGGTTATGGACCCTACCAGCATCTGCAGGA}$ $\tt CACAGCAAGGCCTTTGGACGCATCCTGCAACAGGACATTCGGGAGACGGCCTTCGTGTTCGCCATCACTG$ GCCCGCGGGCGGCCCTCCCGGCCTCCGGCCTGCCCGGCACCCCGGACCCCTGGCCCGCGGGC ${\tt TCCCCGGAAGGCAGCGCCGCCTGGGAGTGGGGAGGCTGCGGCGACGACGTGGACTTCGGGGACGAGAAGT}$ GCTTCCACGGCGCCTCACGCGTCATGGGCACCAACGACGGCAAGGCCCTGCTGCCCGCCGCCGCCACGCT CAAGCCGCCGGGCCGACCTCCTCTACGCCGCCGATTCGCCCGACTTTTGCGCCCCCAACCGACGC ACCGGCTCCCCGGCACGCGCGGTCGCGCCTGCAATAGCAGCGCCCCGGACCTCAGCGGCTGCGACCTGC GTGCTGCGTAGTACAGTGCCACCGTTGCCGTGTGCGCAAGGAGCTCAGCCTCTGCCTGTGACCCGCCGCC GGGGCTTGAGAGGAACGCCCACCCACGAAGGCCCAGGGCGCCAGACGGCCCCGAAAAGGCGCTCGGGGAG

Figure 24

CACGCGTCCGGGCCAATCGGGACTATGAACCGGAAAGCGCTGCGCTGCCTGGGCCACCTCTTTC TCAGCCTGGGCATGGTCTGCCTCCGGATCGGTGGCTTCTCCTCAGTGGTAGCTCTGGGCGCAAC GATCATCTGTAACAAGATCCCAGGCCTGGCTCCCAGACAGCGGGCGATCTGCCAGAGCCGGCC CGACGCCATCATCGTCATAGGAGAAGGCTCACAAATGGGCCTGGACGAGTGTCAGTTTCAGTTC CGCAATGGCCGCTGGAACTGCTCTGCACTGGGAGAGCGCACCGTCTTCGGGAAGGAGCTCAAA GTGGGGACCGGGCGTCCCTACCCATCATTGCCGCCGCGTGGCCCACGCCATC ACAGCTGCCTGTACCCATGGCAACCTGÄGCGACTGTGGCTGCGACAAAGAGAAGCAAGGCCAG TACCACCGGGACGAGGGCTGGAAGTGGGGTGGCTGCTCTGCCGACATCCGCTACGGCATCGGC TTCGCCAAGGTCTTTGTGGATGCCCGGAGATCAAGCAGAATGCCCGGACTCTCATGAACTTGC ACAACAACGAGGCAGGCCGAAAGATCCTGGAGGAGAACATGAAGCTGGAATGTAAGTGCCAC GGCGTGTCAGGCTCGTGCACCACCAGACGTGCTGGACCACACTGCCACAGTTTCGGGAGCTG AACAAGCGGCCCACCTTCCTGAAGATCAAGAAGCCACTGTCGTACCGCAAGCCCATGGACACG GACCTGGTGTACATCGAGAAGTCGCCCAACTACTGCGAGGAGGACCCGGTGACCGGCAGTGTG GGCACCCAGGCCGCCTGCAACAAGACGGCTCCCCAGGCCAGCGGCTGTGACCTCATGTGC TGTGGGCGTGCTACAACACCCACCAGTACGCCCGCGTGTGGCAGTGCAACTGTAAGTTCCACT GGTGCTGCTATGTCAAGTGCAACACGTGCAGCGAGCGCACGGAGATGTACACGTGCAAGTGAG CCCCGTGTGCACACCACCCTCCCGCTGCAAGTCAGATTGCTGGGAGGACTGGACCGTTTCCAAG CTGCGGGCTCCCTGGCAGGATGCTGAGCTTGTCTTTTCTGCTGAGGAAGGTACTTTTCCTGGGTT TCCTGCAGGCATCCGTGGGGGAAAAAAAATCTCTCAGAACCCTCAACTATTCTGTTCCACACCC AATGCTGCTCCACCCTCCCCAGACACAGCCCAAGTCCCTCCGCGGCTGGAGCGAAGCCTTCTG CAGCAGGAACTCTGGACCCCTGGGCCTCATCACAGCAATATTTAACAATTTATTCTGATAAAAA AAAAGGGGGG

Figure 25

TCCGCTTACACACCAAGGAAAGTTGGGCTTTGAAGAATTCCATCCCCATGGCCACTGGAGGAA GAATATTTCNCCCGTCTTGCTTACCCATCTCCCCAGTTTTTTGGAATTTTCTCTAGCTGTTACTCC AGAGGATTATGTTTCTTCAAAGCCTTCTGTGTACATCTGTCTTTTCACCTGTGTCCTCCAACTC AGCCACAGCTGGTCGGTGAACAATTTCCTGATGACTGGTCCAAAGGCTTACCTGATTTACTCCA GCAGTGTGGCAGCTGGTGCCCAGAGTGGTATTGAAGAATGCAAGTATCAGTTTGCCTGGGACC GCTGGAACTGCCCTGAGAGAGCCCTGCAGCTGTCCAGCCATGGTGGGCTTCGCAGTGCCAATCG GGAGACAGCATTTGTGCATGCCATCAGTTCTGCTGGAGTCATGTACACCCTGACTAGAAACTGC AGCCTTGGAGATTTTGATAACTGTGGCTGTGATGACTCCCGCAACGGGCAACTGGGGGGACAA GGCTGGCTGTGGGGAGGCTGCAGTGACAATGTGGGCTTCGGAGAGGCGATTTCCAAGCAGTTT GTCGATGCCCTGGAAACAGGACAGGATGCACGGGCAGCCATGAACCTGCACAACAACGAGGCT GGCCGCAAGGCGTGAAGGGCACCATGAAACGCACGTGTAAGTGCCATGGCGTGTCTGGCAGC TGCACCACGCAGACCTGTTGGCTGCAGCTGCCCGAGTTCCGCGAGGTGGGCGCGCACCTGAAG GAGAAGTACCACGCAGCACTCAAGGTGGACCTGCTGCAGGGTGCTGGCAACAGCGCGCCCCCC CGCGGCGCCATCGCCGACACCTTTCGCTCCATCTCTACCCGGGAGCTGGTGCACCTGGAGGACT CCCCGGACTACTGCCTGGAGAACAAAACGCTAGGGCTGCTGGGCACCGAAGGCCGAGAGTGCC TAAGGCGCGGGCCCTGGGTCGCTGGGAACTCCGCAGCTGCCGCCGGCTCTGCGGGGACT GCGGGCTGGCGTGGAGGAGCGCCGAGACCGTGTCCAGCTGCAACTGCAAGTTCCACT GGTGCTGTGCAGTCCGCTGCGAGCAGTGCCGCCGGAGGGTCACCAAGTACTTCTGTAGCCGCGC AGAGCGGCCGCGGGGGGCGCTGCGCACAAACCCGGGAGAAAACCCTAAGGGTTTCCTCTGCC CCCTCCTTTTCCCACTGGTTCTTGGCTTCCTTTAGAGACCCCGGTAATTGTGGAACCTAGGGAAT GGGGAACCCGCTCTCCCAGACCTAGGGATCCTGAAAGGGAAAAACTGCAATTTCTCCAAAGCT AGCCACACCTAGGTCTGAAAACTCAGGCTTTGAGTTACTGATCTTCCTTGGATTAGGAAAACAG GTGTTCCTCCCCCTCTCCTATCAGCCCTAATCTCTGACCTAGCCTATCAACCCTTAGGCGCTG GAAAAACCTTCTCATACACGCAGGACCCAGGTTAACTCAAAGCTTTGCCCTTTTGCCCACTGTC TGCTACCAGGGGCTCACCCTCTGCTGCACCTCTCTTCTGCACAGCTCCTCCCCTGCTACTGCTGA GAAGAGGGAGCTCTGGAGTGCTAACTTGAACACCAAGGGTGCTACTCATCCCTATGGTATCATA TCATGAATGGACTTTACTAGTGGGGCAATGACTTTCCTAGACAATAACCCGAGGGACTCCAGAT ACATACCCCGAAGGTCTAGGAAATACGTTAAGGGCAGATTACAGTCATTTCCTACCCTTTAAAG GTAACTTCTCCCTGACCTACTTCCTCCTAGCAACCAACTTTACCTCTTCTTCTCCAAAGG ATCTTTGTTCCTCTGAGCCAAGACTGAGGTAAATAAAGCCACTTTCCTCTTCAGATCCTGGTCTG CACCTCTAGA

Figure 26

GCGGCCGCGTCGACGGAGGGGCTGCAGCTCCGTCAGCCCGGCAGAGCCACCCTGAGCTCGGTG CGGCCCTGGAAGAATGCGGCTCTGACAAGGGGACAGAACCCAGCGCAGTCTCCCCACGGTTTA AGCAGCACTAGTGAAGCCCAGGCAACCCAACCGTGCCTGTCTCGGACCCCGCACCCAAACCAC TGGAGGTCCTGATCGATCTGCCCACCGGAGCCTCCGGGCTTCGACATGCTGGAGGAGCCCCGGC CGCGGCCTCCGCGCCTCGCGGGTCTCCTGTTCCTGGCGTTGTGCAGTCGGGCTCTAAG CAATGAGATTCTGGGCCTGAAGTTGCCTGGCGAGCCGCCGCTGACGGCCAACACCCGTGTGCTTG ACGCTGTCCGGCCTGAGCAAGCGGCAGCTAGACCTGTGCCTGCGCAACCCCGACGTGACGCG TCCGCGCTTCAGGGTCTGCACATCGCGGTCCACGAGTGTCAGCACCAGCTGCGCGACCAGCGCT GGAACTGCTCCGCGCTTGAGGGCGGCGGCCGCCTGCCGCACCACAGCGCCATCCTCAAGCGCG GTTTCCGAGAAAGTGCTTTTTCCTTCTCCATGCTGGCTGCTGGGGTCATGCACGCAGTAGCCAC GGCCTGCAGCCTGGGCAAGCTGGTGAGCTGTGGCTGGGCAGGGCAGTGGTGAGCAGGA TCGGCTGAGGGCCAAACTGCTGCAGCTGCAGGCACTGTCCCGAGGCAAGAGTTTCCCCCACTCT CTGCCCAGCCCTGGCCCTGGCTCAAGCCCCAGCCCTGGCCCCAGGACACATGGGAATGGGGT GGCTGTAACCATGACATGGACTTTGGAGAGAAGTTCTCTCGGGATTTCTTGGATTCCAGGGAAG CTCCCGGGACATCCAGGCACGAATGCGAATCCACAACAGGGTGGGGGGCGCCAGGTGGTAA CTGAAAACCTGAAGCGGAAATGCAAGTGTCATGGCACATCAGGCAGCTGCCAGTTCAAGACAT

GCTGGAGGCCGCCCAGAGTTCCGGGCAGTGGGGGGCGCGTTGAGGGAGCGGCTGGGCCGG GCCATCTTCATTGATACCCACAACCGCAATTCTGGAGCCTTCCAGCCCCGTCTGCGTCCCCGTCG CCTCTCAGGAGAGCTGGTCTACTTTGAGAAGTCTCCTGACTTCTGTGAGCGAGACCCCACTATG GGCTCCCCAGGGACAAGGGCCGGGCCTGCAACAAGACCAGCCGCCTGTTGGATGGCTGTGGC AGCCTGTGCTGTGGCCGTGGGCACAACGTGCTCCGGCAGACACGAGTTGAGCGCTGCCATTGCC GCTTCCACTGGTGCTGTGTGTGTGTGATGAGTGCAAGGTTACAGAGTGGGTGAATGTGTG TAAGTGAGGGTCAGCCTTACCTTGGGGGCTGGGGAAGAGGACTGTGTGAGAGGGGCGCCTTTTC AGCCCTTTGCTCTGATTTCCTTCCAAGGTCACTCTTGGTCCCTGGAAGCTTAAAGTATCTACCTG GAAACAGCTTTAGGGGTGGGGGTCAGGTGGACTCTGGGATGTGTAGCCTTCTCCCCAACA ATTGGAGGGTCTTGAGGGGAAGCTGCCACCCCTCTTCTGCTCCTTAGACACCTGAATGGACTAA GATGAAATGCACTGTATTGCTCCTCCCACTTCTCAACTCCAGAGCCCCTTTAACCCTGATTCATA CTCCTTTTGGCTGGGGAGTCCCTATAGTTTCACCACTCCTCTCCCTTGAGGGATAACCCCAGGCA CTGTTTGGAGCCATAAGATCTGTATCTAGAAAGAGATCACCCACTCCTATGTACTATCCCCAAA CTCCTTTACTGCAGCCTGGGCTCCCTCTTGTGGGATAATGGGAGACAGTGGTAGAGAGGTTTTT TTCCCATGACTCTTGGAGCCTCTTTTTCCTTCTTCAGCAGGAAGGGTGGGAAGGGATAATTTATC AAAAAAAA

Figure 27

TAACCCGCCGCCTCCCCCGGCTGCAGGCGGCGTGCAGGACCAGCGGCGGCCGTGCAG GCGGAGGACTTCGGCGCGCCCCCCCGGGTGTGACCCCGGGCGCGCCGCCGCGACGATG AGGGCGCGCCGCAGGTCTGCGAGGCGCTGCTCTTCGCCCTGGCGCTCCAGACCGGCGTGTGCT ATGGCATCAAGTGGCTGGCGCTGTCCAAGACACCATCGGCCCTGGCACTGAACCAGACGCAAC ACTGCAAGCAGCTGGAGGGTCTGGTGTCTGCACAGGTGCAGCTGTGCCGCAGCAACCTGGAGC TCATGCACACGGTGGTGCACGCCGCCGCGAGGTCATGAAGGCCTGTCGCCGGGCCTTTGCCGA CATGCGCTGGAACTGCTCCTCCATTGAGCTCGCCCCCAACTATTTGCTTGACCTGGAGAGAGGG ACCCGGGAGTCGGCCTTCGTGTATGCGCTGTCGGCCGCCACCATCAGCCACGCCATCGCCCGGG CCTGCACCTCCGGCGACCTGCCCGGCTGCTCCTGCGGCCCCGTCCCAGGTGAGCCACCCGGGCC CGGGAACCGCTGGGGAAGATGTGCGGACAACCTCAGCTACGGGCTCCTCATGGGGGCCAAGTT TTCCGATGCTCCTATGAAGGTGAAAAAAACAGGATCCCAAGCCAATAAACTGATGCGTCTACA CAACAGTGAAGTGGGGAGACAGGCTCTGGCGCCCTCTCTGGAAATGAAGTGTAAGTGCCATGG GGTGTCTGGCTCCTCCATCCGCACCTGCTGGAAGGGGCTGCAGGAGCTGCAGGATGTGGCT GCTGACCTCAAGACCCGATACCTGTCGGCCACCAAGGTAGTGCACCGACCCATGGGCACCCGC AAGCACCTGGTGCCCAAGGACCTGGATATCCGGCCTGTGAAGGACTGGGAACTTGTTTATTTGC AGAGCTCACCTGACTTTTGCATGAAGAATGAGAAGGTGGGCTCCCACGGGACACAAGACAGGC AGTGCAACAAGACTTCCAACGGAAGCGACAGCTGCGACCTTATGTGCTGCGGGCGTGGCTACA ACCCCTACACAGACCGCGTGGTCGAGCGGTGCCACTGTAAGTACCACTGGTGTTGCTACGTCAC CTGCCGCAGGTGTGAGCGTACCGTGGAGCGCTATGTCTGCAAGTGAGGCCCTGCCCTCCGCCCC ACGCAGGAGCGAGGACTTTGCTCAAGGACCCTCAGCAACTGGGGCCCGGGGCCTGGAGACACT CCATGGAGCTCTGCTTGTGAATTCCAGATGCCAGGCATGGGAGGCGGCTTGTGCTTTGCCTTCA CTTGGAAGCCACCAGGAACAGAAGGTCTGGCCACCCTGGAAGGAGNGCAGGACATCAAAGGA AACCGACAAGATTAAAAATAACTTGGCAGCCTGAGNTCTGGAGTGCCCACAGNNTGGTGTAAG GAGCGGGGCTTGGGATCGGTGAGACTGATACAGACTTGACCTTTCAGGGCCACAGAGACCAGC CTCCGGGAAGGGGTCTGCCCGCCTTCTTCAGAATGTTCTGCGGGACCCCCTGGCCCACCCTGGG GTCTGAGCCTGCTGGGCCACCACATGGAATCACTAGCTTCGGGTTGTAAATGTTTTCTTTTGTTT NTTGCTTTTCTTCCTTTGGGATGTTGGAAGCTACAGAAATATTTATAAAACATAGCTTTTTCTT GCCCGCCCTGCAGTTCCCGGCCTCGTCAAGTGAACTCGGCAGACCCTGGGGGCTGGCAGAGGG AGCTCTCCAGTTTCCGGGCA

Figure 28

23/41

CGCTGCTGCCCGCGCTGCGCCCTTCGGCCGCCTACTTCGGGCTGACGGGCAGCGAGCCCCT GACCATCCTCCCGCTGACCCTGGAGCCAGAGGCGGCCCCCAGGCGCACTACAAGGCCTGCGA CCGGCTGAAGCTGGAGCGGAAGCAGCGGCGCGCATGTGCCGCCGGGACCCGGGCGTGGCAGAGA CGCTGGTGGAGCCGTGAGCATGAGTGCGCTCGAGTGCCAGTTCCAGTTCCGCTTTGAGCGCTG GAACTGCACGCTGGAGGGCCGCTACCGGGCCAGCCTGCTCAAGCGAGGCTTCAAGGAGACTGC CGCATGGAGCGCTGTACCTGCGATGAGGCACCCGACCTGGAGAACCGTGAGGCCTGGCAGTGG GGGGGCTGCGGAGACAACCTTAAGTACAGCAGCAAGTTCGTCAAGGAATTCCTGGGCAGACGG TCAAGCAAGGATCTGCGAGCCCGTGTGGACTTCCACAACAACCTCGTGGGTGTGAAGGTGATC AAGGCTGGGGTGGAGACCACCTGCAAGTGCCACGGCGTGTCAGGCTCATGCACGGTGCGGACC TGCTGGCGGCAGTTGGCGCCTTTCCATGAGGTGGGCAAGCATCTGAAGCACAAGTATGAGACG GCACTCAAGGTGGGCAGCACCACCAATGAAGCTGCCGGCGAGGCAGGTGCCATCTCCCCACCA CGGGGCCGTGCCTCGGGGGCAGGTGCCAGCGCACCCGCACTCCAGAGCTGGTGCAC CTGGATGACTCGCCTAGCTTCTGCCTGGCCGCCTTCTCCCCGGGCACCGCTGGCCGTAGGT GCCACCGTGAGAAGAACTGCGAGAGCATCTGCTGTGGCCGCGGCCATAACACACAGAGCCGGG CGCAGCGTGAGGGGCTCACACCTGCAAGGGCTGAGTTCCCAGGCCCTGCCAGCCCTGCTGCA CAGGGTGCAGGCATTGCACACGGTGTGAAGGGTCTACACCTGCACAGGCTGAGTTCCTGGGCT CGACCAGCCCAGCTGCGTGGGGTACAGGCATTGCACACAGTGTGAATGGGTCTACACCTGCAT GGGCTGAGTCCCTGGGCTCAGACCTAGCAGCGTGGGGTAGTCCCTGGGCTCAGTCCTAGCTGCA TGGGGTGCAGGCATTGCACAGAGCATGAATGGGCCTACACCTGCCAAGGCTGAATCCCTGGGC CCAGCCAGCCTGCTGCACATGGCACAGGCATTGCACACGGTGTGAGGAGTGTACACCTGCAA GGGCTGAGGCCCTGGGCCCAGTCAGCCCTGCTCAGAGTGCAGGCATTGCACATGGTGTGA GAAGGTCTACACCTGCAAGGGACGAGTCCCCGGGCCTGGCCAACCCTGCTGCAGGGTGAGG GCCATGCATGCTAGTATGAGGGGTCTACACCTGCAAGGACTGAGAGGCTTTT

Figure 29

ACCACTTGCCTCAGGGAGACCCTCTTCACAGGGGCTTCTCAAAAGACCTCCCTATGGTGGTTGG GCATTGCCTCCTTCGGGGTTCCAGAGAAGCTGGGCTGCGCCAATTTGCCGCTGAACAGCCGCCA GAAGGAGCTGTGCAAGAGGAAACCGTACCTGCTGCCGAGCATCCGAGAGGGCGCCCGGCTGGG CATTCAGGAGTGCAGGAGCCAGTTCAGACACGAGAGATGGAACTGCATGATCACCGCCGCCGC CACTACCGCCCGATGGGCGCCAGCCCCTCTTTGGCTACGAGCTGAGCAGCGGCACCAAAGA GACAGCATTTATTTATGCTGTGATGGCTGCAGGCCTGGTGCATTCTGTGACCAGGTCATGCAGT GCAGGCAACATGACAGAGTGTTCCTGTGACACCACCTTGCAGAACGGCGGCTCAGCAAGTGAA GGCTGGCACTGGGGGGGCTGCTCCGATGATGTCCAGTATGGCATGTTCGGTTCAGCAGAAAGTTCC TAGATTTCCCCATCGGAAACACCACGGGCAAAGAAAACAAAGTACTATTAGCAATGAACCTAC ATAACAATGAAGCTGGAAGGCAGGCTGTCGCCAAGTTGATGTCAGTAGACTGCCGCTGCCACG GAGTTTCCGGCTCCTGTGCTGAAAACATGCTGGAAAACCATGTCTTCTTTTGAAAAGATTGG CCATTTGTTGAAGGATAAATATGAAAACAGTATCCAGATATCAGACAAAATAAAGAGGAAAAAT GCGCAGGAGAAAAAGATCAGAGGAAAATACCAATCCATAAGGATGATCTGCTCTATGTTAA TAAGTCTCCCAACTACTGTGTAGAAGATAAGAAACTGGGAATCCCAGGGACACAAGGCAGAGA ATGCAACCGTACATCAGAGGGTGCAGATGGCTGCAACCTCCTCTGCTGTGGCCGAGGTTACAAC ACCCATGTGGTCAGGCACGTGGAGAGGTGTGAGTGTAAGTTCATCTGGTGCTGCTATGTCCGTT GCAAGATGCCTCAGCAATATACAATGGCATTGCAACCAGAGAGGTGCCCATCCCTGTGCAGCG CTAGTAAAGTTGACTCTTGCAGTGGAATCCC

Figure 30

AGTTGAGGGATTGACACAAATGGTCAGGCGGCGGCGGGGGGAGAAGGAGGCGGAGGCGCAGGG GGGAGCCGAGCCCGCTGGGCTGCGGAGAGTTGCGCTCTCTACGGGGCCGCGCCACTAGCGCG GCGCCGCCAGCCGGGAGCCAGCGAGCCGAGGGCCAGGAAGGCGGGACACGACCCCGGCGCGC CCTAGCCACCCGGGTTCTCCCCGCCGCCGCGCTTCATGAATCGCAAGTTTCCGCGGCGGCGC GGCTGCGGTACGCAGAACAGGAGCCGGGGGGGGGGGCCGAAAGCGGCTTGGGCTCGACGGAG CCCAGCGGAGCGCCCAAGAGAGGAGCCGAGAAAGTATGGCTGAGGAGGAGGCGCCTAAGA AGTCCCGGGCCGCCGGTGGCGCGAGCTGGGAACTTTGTGCCGGGGCGCTCTCGGCCCGGC TGGCGGAGGAGGCAGCGGGGACGCCGGTGGCCGCCGCCGCCAGTTGACCCCCGGCGAT TGGCGCGCCAGCTGCTGCTGCTTTGGCTGCTGGAGGCTCCGCTGCTGCTGGGGGTCCGGGC CTCAGCAGCACAGAGCGGCAGCAGTACAACGGCGAGCGGGCATCTCCGTCCCGGACCACG GCTATTGCCAGCCCATCTCCATCCCGCTGTGCACGGACATCGCGTACAACCAGACCATCATGCC CAACCTGCTGGGCCACACGAACCAGGAGGACGCGGGCCTGGAGGTGCACCAGTTCTACCCTCT AGTGAAAGTGCAGTGTTCCGCTGAGCTCAAGTTCTTCCTGTGCTCCATGTACGCGCCCGTGTGC GAGGCGCTCATGAACAAGTTCGGCTTCCAGTGGCCAGACACGCTCAAGTGTGAGAAGTTCCCG GTGCACGGCGCGGCGAGCTGTGCGTGGGCCAGAACACGTCCGACAAGGGCACCCCGACGCCC TCGCTGCTTCCAGAGTTCTGGACCAGCAACCCTCAGCACGGCGGCGGAGGGCACCGTGGCGGC CCCTCCTACCTCAACTACCACTTCCTGGGGGAGAAGGACTGCGGCGCACCTTGTGAGCCGACCA AGGTGTATGGGCTCATGTACTTCGGGCCCGAGGAGCTGCGCTTCTCGCGCACCTGGATTGGCAT TTGGTCAGTGCTGCTGCGCCTCCACGCTCTTCACGGTGCTTACGTACCTGGTGGACATGCGG CGCTTCAGCTACCCGGAGCGGCCCATCATCTTCTTGTCCGGCTGTTACACGGCCGTGGCCGTGG CCTACATCGCCGGCTTCCTCCTGGAAGACCGAGTGGTGTGTAATGACAAGTTCGCCGAGGACGG GGCACGCACTGTGGCGCAGGGCACCAAGAAGGAGGGCTGCACCATCCTCTTCATGATGCTCTA CTTCTTCAGCATGGCCAGCTCCATCTGGTGGGTGATCCTGTCGCTCACCTGGTTCCTGGCGGCTG GCATGAAGTGGGGCCACGAGGCCATCGAAGCCAACTCACAGTATTTTCACCTGGCCGCCTGGG CTGTGCCGGCCATCAAGACCATCACCATCCTGGCGCTGGGCCAGGTGGACGGCGATGTGCTGA GCGGAGTGTGCTTCGTGGGGCTTAACAACGTGGACGCGCTGCGTGGCTTCGTGCTGGCGCCCCT CTTCGTGTACCTGTTTATCGGCACGTCCTTTCTGCTGGCCGGCTTTGTGTCGCTCTTCCGCATCCG CACCATCATGAAGCACGATGGCACCAAGACCGAGAAGCTGGAGAAGCTCATGGTGCGCATTGG CGTCTTCAGCGTGCTGTACACTGTGCCAGCCACCATCGTCATCGCCTGCTACTTCTACGAGCAG GCCTTCCGGGACCAGTGGGAACGCAGCTGGGTGGCCCAGAGCTGCAAGAGCTACGCTATCCCC TGCCCTCACCTCCAGGCGGGGGGGGGCGCCCCGCCGCACCCGCCATGAGCCCGGACTTCACG GTCTTCATGATTAAGTACCTTATGACGCTGATCGTGGGCATCACGTCGGGCTTCTGGATCTGGTC CGGCAAGACCCTCAACTCCTGGAGGAAGTTCTACACGAGGCTCACCAACAGCAAACAAGGGGA GACTACAGTCTGAGACCCGGGGCTCAGCCCATGCCCAGGCCTCGGCCGGGGCGCAGCGATCCC CCAAAGCCAGCGCCGTGGAGTTCGTGCCAATCCTGACATCTCGAGGTTTCCTCACTAGACAACT CTCTTTCGCAGGCTCCTTTGAACAACTCAGCTCCTGCAAAAGCTTCCGTCCCTGAGGCAAAAGG ACACGAGGCCCGACTGCCAGAGGGAGGATGGACAGACCTCTTGCCCTCACACTCTGGTACCA GGACTGTTCGCTTTTATGATTGTAAATAGCCTGTGTAAGATTTTTGTAAGTATATTTGTATTAA ATGACGACCGATCACGCGTTTTTCTTTTTCAAAAGTTTTTAATTATTTAGGGCGGTTTAACCATT TGAGGCTTTTCCTTCTTGCCCTTTTCGGAGTATTGCAAAGGAGCTAAAACTGGTGTGCAACCGC ACAGCGCTCCTGGTCGTCCTCGCGCGCCTCTCCCTACCACGGGTGCTCGGGACGGCTGGGCGCC AGCTCCGGGGCGAGTTCAGCACTGCGGGGTGCGACTAGGGCTGCGCTGCCAGGGTCACTTCCC GCTCTTAAGGTACAGAACTCCACAAACCTTCCAAATCTGGAGGAGGGCCCCCATACATTACAAT TCCTCCCTTGCTCGGCGGTGGATTGCGAAGGCCCGTCCCTTCGACTTCCTGAAGCTGGATTTTTA ACTGTCCAGAACTTTCCTCCAACTTCATGGGGGCCCACGGGTGTGGGCGCTGGCAGTCTCAGCC TCCCTCCACGGTCACCTTCAACGCCCAGACACTCCCTTCTCCCACCTTAGTTGGTTACAGGGTGA GTGAGATAACCAATGCCAAACTTTTTGAAGTCTAATTTTTGAGGGGTGAGCTCATTTCATTCTCT AGTGTCTAAAACCTGGTATGGGTTTGGCCAGCGTCATGGAAAGATGTGGTTACTGAGATTTGGG AAGAAGCATGAAGCTTTGTGTGGGTTGGAAGAGACTGAAGATATGGGTTATAAAATGTTAATT CTAATTGCATACGGATGCCTGGCAACCTTGCCTTTGAGAATGAGACAGCCTGCGCTTAGATTTT ACCGGTCTGTAAAATGGAAATGTTGAGGTCACCTGGAAAGCTTTGTTAAGGAGTTGATGTTTGC

Figure 31

CGAGTAAAGTTTGCAAAGAGGCGCGGGAGGCGGCAGCCGCAGCGAGGAGGCGGGGGAAGA CGGCCAGCATGCGGCCCGCAGCGCCCTGCCCGCCTGCTGCTGCTGCTGCTGCCCGC CGCCGGGCCGGCCCAGTTCCACGGGGAGAAGGGCATCTCCATCCCGGACCACGGCTTCTGCCA GCCCATCTCCATCCCGCTGTGCACGGACATCGCCTACAACCAGACCATCATGCCCAACCTTCTG GGCCACACGAACCAGGAGGACGCAGGCCTAGAGGTGCACCAGTTCTATCCGCTGGTGAAGGTG CAGTGCTCGCCCGAACTGCGCTTCTTCCTGTGCTCCATGTACGCACCCGTGTGCACCGTGCTGG GAACAAGTTCGGTTTTCAGTGGCCCGAGCGCCTGCGCGAGCACTTCCCGCGCCACGGCGCC GAGCAGATCTGCGTCGGCCAGAACCACTCCGAGGACGGAGCTCCCGCGCTACTCACCACCGCG CCCCGCGCTACGCCACGCTGGAGCACCCCTTCCACTGCCCGCGCGTCCTCAAGGTGCCATCCT ATCTCAGCTACAAGTTTCTGGGCGAGCGTGATTGTGCTGCGCCCTGCGAACCTGCGCGCCCGA TGGTTCCATGTTCTCACAGGAGGAGACGCGTTTCGCGCGCCTCTGGATCCTCACCTGGTCG GTGCTGTGCTGCGCTTCCACCTTCTTCACTGTCACCACGTACTTGGTAGACATGCAGCGCTTCCG CTACCCAGAGCGCCTATCATTTTCTGTCGGGCTGCTACACCATGGTGTCGGTGGCCTACATC GCGGGCTTCGTGCTCCAGGAGCGCGTGTGCAACGAGCGCTTCTCCGAGGACGGTTACCGC ACGGTGGTGCAGGGCACCAAGAAGGAGGGCTGCACCATCCTCTTCATGATGCTCTACTTCTTCA GCATGGCCAGCTCCATCTGGTGGGTCATCCTGTCGCTCACCTGGTTCCTGGCAGCCGGCATGAA GTGGGCCACGAGGCCATCGAGGCCAACTCTCAGTACTTCCACCTGGCCGCCTGGGCCGTGCCG GCCGTCAAGACCATCACCATCCTGGCCATGGGCCAGATCGACGGCGACCTGCTGAGCGGCGTG TGCTTCGTAGGCCTCAACAGCCTGGACCCGCTGCGGGGCTTCGTGCTAGCGCCGCTCTTCGTGT ACCTGTTCATCGGCACGTCCTTCCTCCTGGCCGGCTTCGTGTCGCTCTTCCGCATCCGCACCATC ATGAAGCACGACGGCACCAAGACCGAAAAGCTGGAGCGGCTCATGGTGCGCATCGGCGTCTTC TCCGTGCTCTACACAGTGCCCGCCACCATCGTCATCGCTTGCTACTTCTACGAGCAGGCCTTCCG CGAGCACTGGGAGCGCTCGTGGGTGAGCCAGCACTGCAAGAGCCTGGCCATCCCGTGCCCGGC GCACTACACGCCGCGCATGTCGCCCGACTTCACGGTCTACATGATCAAATACCTCATGACGCTC ATCGTGGGCATCACGTCGGGCTTCTGGATCTGGTCGGGCAAGACGCTGCACTCGTGGAGGAAG TTCTACACTCGCCTCACCAACAGCCGACACGGTGAGACCACCGTGTGAGGGACGCCCCCAGGC CGGAACCGCGCGCGCTTTCCTCCGCCCGGGGTGGGGCCCCTACAGACTCCGTATTTTATTTTTT TAAATAAAAAACGATCGAAACCATTTCACTTTTAGGTTGCTTTTTAAAAGAGAACTCTCTGCCC AACACCCCC

Figure 32

GGAATGTGGTTGATCAACTTGATATGTTGGCCAAATGTGCCCCATGTAATAAAATGAAAAGAA GCTAACAAACCTCTGACGGTGCGAAGAGTATTTAACTGTTTGAAGAATTTAACAGTAAGATACA GAAGAAGTACCTTCGAGCTGAGACCTGCAGGTGTATAAATATCTAAAATACATATTGAATAGG CCTGATCATCTGAATCTCCTTCAGACCCAGGAAGGATGGCTATGACTTGGATTGTCTCTCTT CTTGAGGATGTGCCAAGATTTGCCTTATAATACTACCTTCATGCCTAATCTTCTGAATCATTATG ACCAACAGACAGCAGCTTTGGCAATGGAGCCATTCCACCCTATGGTGAATCTGGATTGTTCTCG GGATTTCCGGCCTTTTCTTTGTGCACTCTACGCTCCTATTTGTATGGAATATGGACGTGTCACAC TTCCCTGTCGTAGGCTGTCAGCGGGCTTACAGTGAGTGTTCGAAGCTCATGGAGATGTTTGG TGTTCCTTGGCCTGAAGATATGGAATGCAGTAGGTTCCCAGATTGTGATGAGCCATATCCTCGA CTTGTGGATCTGAATTTAGCTGGAGAACCAACTGAAGGAGCCCCAGTGGCAGTGCAGAGAGAC TATGGTTTTTGGTGTCCCCGAGAGTTAAAAATTGATCCTGATCTGGGTTATTCTTTTCTGCATGT GCGTGATTGTTCACCTCCTTGTCCAAATATGTACTTCAGAAGAAGAAGAACTGTCATTTGCTCGCT ATTTCATAGGATTGATTTCAATCATTTGCCTCTCGGCCACATTGTTTACTTTTTAACTTTTTTGA TTGATGTCACAAGATTCCGTTATCCTGAAAGGCCTATTATATTTTATGCAGTCTGCTACATGATG TGCACAATATAAGGCTTCCACAGTGACACAAGGATCTCATAATAAAGCCTGTACCATGCTTTTT ATGATACTCTATTTTTTACTATGGCTGGCAGTGTATGGTGGGTAATTCTTACCATCACATGGTT TTTAGCAGCTGTGCCAAAGTGGGGTAGTGAAGCTATTGAGAAGAAAGCATTGCTGTTTCACGCC AGTGCATGGGGCATCCCCGGAACTCTAACCATCATCCTTTTAGCGATGAATAAAATTGAAGGTG ACAATATTAGTGGCGTGTTTTTGTTGGCCTCTACGATGTTGATGCATTGAGATATTTTGTTCTT GCTCCCCTCTGCCTGTATGTGGTAGTTGGGGTTTCTCTCCTCTTAGCTGGCATTATATCCCTAAA CAGAGTTCGAATTGAGATTCCATTAGAAAAGGAGAACCAAGATAAATTAGTGAAGTTTATGAT CCGGATCGGTGTTTTCAGCATTCTTTATCTCGTACCACTCTTGGTTGTAATTGGATGCTACTTTTA TGAGCAAGCTTACCGGGGCATCTGGGAAACAACGTGGATACAAGAACGCTGCAGAGAATATCA CATTCCATGTCCATATCAGGTTACTCAAATGAGTCGTCCAGACTTGATTCTCTTTCTGATGAAAT ACCTGATGGCTCTCATAGTTGGCATTCCCTCTGTATTTTGGGTTGGAAGCAAAAAGACATGCTTT GAATGGGCCAGTTTTTTCATGGTCGTAGGAAAAAAGAGATAGTGAATGAGAGCCGACAGGTA CTCCAGGAACCTGATTTTGCTCAGTCTCTCCTGAGGGATCCAAATACTCCTATCATAAGAAAGT CAAGGGGAACTTCCACTCAAGGAACATCCACCCATGCTTCTTCAACTCAGCTGGCTATGGTGGA TGATCAAAGAAGCAAAGCAGGAAGCATCCACAGCAAAGTGAGCAGCTACCACGGCAGCCTCC ACAGATCACGTGATGGCAGGTACACGCCCTGCAGTTACAGAGGAATGGAGGAGAGACTACCTC ATGGCAGCATGTCACGACTAACAGATCACTCCAGGCATAGTAGTTCTCATCGGCTCAATGAACA GTCACGACATAGCAGCATCAGAGATCTCAGTAATAATCCCATGACTCATATCACACATGGCACC TCTTGTGCTGTTTAAAAAGCAGATTTTATTCTTTGCCTTTTGCATGACTGATAGCTGTACTCACA GTTAACATGCTTTCAGTCAAGTACAGATTGTGTCCACTGGAAAGGTAAATGATTGCTTTTTATA TTGCATCAAACTTGGAACATCAAGGCATCCAAAACACTAAGAATTCTATCATCACAAAAAATAAT TCGTCTTTCTAGGTTATGAAGAGATAATTATTTGTCTGGTAAGCATTTTTATAAACCCACTCATT TTATATTTAGAAAAATCCTAAATGTGTGGTGACTGCTTTGTAGTGAACTTTCATATACTATAAAC TAGTTGTGAGATAACATTCTGGTAGCTCAGTTAATAAAACAATTTCAGAATTAAAGAAATTTTC TATGCAAGGTTTACTTCTCAGATGAACAGTAGGACTTTGTAGTTTTATTTCCACTAAGTGAAAA AAGAACTGTGTTTTTAAACTGTAGGAGAATTTAATAAATCAGCAAGGGTATTTTAGCTAATAGA ATAAAAGTGCAACAGAAGAATTTGATTAGTCTATGAAAGGTTCTCTTAAAATTCTATCGAAATA ATCTTCATGCAGAGATATTCAGGGTTTGGATTAGCAGTGGAATAAAGAGATGGGCATTGTTTCC CCTATAATTGTGCTGTTTTTATAACTTTTGTAAATATTACTTTTTCTGGCTGTGTTTTTATAACTT ATCCATATGCATGATGGAAAAATTTTAATTTGTAGCCATCTTTTCCCATGTAATAGTATTGATTC ATAGAGAACTTAATGTTCAAAATTTGCTTTGTGGAGGCATGTAATAAGATAAACATCATACATT ATAAGGTAACCACAATTACAAAATGGCAAAACA

Figure 33

TCACACTCCCGTCCCGGGAGCTGGGAGCAGCGCGGGCAGCCGGCGCCCCCGTGCAAACTGGGG GTGTCTGCCAGAGCAGCCCCAGCCGCTGCCGCTGCTACCCCCGATGCTGGCCATGGCCTGCCGG GGCGCAGGGCCGAGCGTCCCGGGGGCGCCCGGGGGCGTCGGTCTCAGTCTGGGGTTGCTCCTG CAGTTGCTGCTGCTGCGGGCCCGGGGGGCTTCGGGGACGAGGAAGAGCGGCGCTGCGAC CCCATCCGCATCTCCATGTGCCAGAACCTCGGCTACAACGTGACCAAGATGCCCAACCTGGTTG GGCACGAGCTGCAGACGGCCGAGCTGCAGCTGACAACTTTCACACCGCTCATCCAGTACG GCTGCTCCAGCCAGCTGCAGTTCTTCCTTTGTTCTGTTTATGTGCCAATGTGCACAGAGAAGATC AACATCCCCATTGGCCCATGCGGCGCATGTGTCTTTCAGTCAAGAGACGCTGTGAACCCGTCC TGAAGGAATTTGGATTTGCCTGGCCAGAGAGTCTGAACTGCAGCAAATTCCCACCACAGAACG ACCACAACCACATGTGCATGGAAGGGCCAGGTGATGAAGAGGTGCCCTTACCTCACAAAACCC CCATCCAGCCTGGGGAAGAGTGTCACTCTGTGGGAACCAATTCTGATCAGTACATCTGGGTGAA AAGGAGCCTGAACTGTGCTCAAGTGTGGCTATGATGCTGGCTTATACAGCCGCTCAGCCAAG GAGTTCACTGATATCTGGATGGCTGTGTGGGCCAGCCTGTGTTTCATCTCCACTGCCTTCACAGT ACTGACCTTCCTGATCGATTCTTCTAGGTTTTCCTACCCTGAGCGCCCCATCATATTTCTCAGTA TGTGCTATAATATTTATAGCATTGCTTATATTGTCAGGCTGACTGTAGGCCGGGAAAGGATATC CTGTGATTTTGAAGAGGCAGCAGAACCTGTTCTCATCCAAGAAGGACTTAAGAACACAGGATG TGCAATAATTTCTTGCTGATGTACTTTTTTGGAATGGCCAGCTCCATTTGGTGGGTTATTCTGA CACTCACTTGGTTTTTGGCAGCAGGACTCAAATGGGGTCATGAAGCCATTGAAATGCACAGCTC TTATTTCCACATTGCAGCCTGGGCCATCCCCGCAGTGAAAACCATTGTCATCTTGATTATGAGA CTGGTGGATGCAGATGAACTGACTGGCTTGTGCTATGTTGGAAACCAAAATCTCGATGCCCTCA CCGGGTTCGTGGTGGCTCCCCTCTTTACTTATTTGGTCATTGGAACTTTGTTCATTGCTGCAGGT GAAAGACTGATGGTCAAGATTGGGGTGTTCTCAGTACTGTACACAGTTCCTGCAACGTGTGTGA TTGCCTGTTATTTTATGAAATCTCCAACTGGGCACTTTTTCGGTATTCTGCAGATGATTCCAAC ATGGCTGTTGAAATGTTGAAAACTTTTATGTCTTTGTTGGTGGGCATCACTTCAGGCATGTGGAT TTGGTCTGCCAAAAGTCTTCACACGTGGCAGAAGTGTTCCAACAGATTGGTGAATTCTGGAAAG GTAAAGAGAGAGAAGAGGAAATGGTTGGGTGAAGCCTGGAAAAGGCAGTGAGACTGTGGT ATAAGGCTAGTCAGCCTCCATGCTTTCTTCATTTTGAAGGGGGGAATGCCAGCATTTTGGAGGA AATTCTACTAAAAGTTTTATGCAGTGAATCTCAGTTTGAACAAACTAGCAACAATTAAGTGACC CCCGTCAACCCACTGCCTCCCACCCCGACCCCAGCATCAAAAAACCAATGATTTTGCTGCAGAC TTTGGAATGATCCAAAATGGAAAAGCCAGTTAGAGGCTTTCAAAGCTGTGAAAAATCAAAACG TTGATCACTTTAGCAGGTTGCAGCTTGGAGCGTGGAGGTCCTGCCTAGATTCCAGGAAGTCCAG GGCGATACTGTTTTCCCCTGCAGGGTGGGATTTGAGCTGTGAGTTGGTAACTAGCAGGGAGAAA TATTAACTTTTTAACCCTTTACCATTTTAAATACTAACTGGGTCTTTCAGATAGCAAAGCAATC TATAAACACTGGAAACGCTGGGTTCAGAAAAGTGTTACAAGAGTTTTATAGTTTGGCTGATGTA ACATAAACATCTTCTGTGGTGCGCTGTCTGCTGTTTAGAACTTTGTGGACTGCACTCCCAAGAA GTGGTGTTAGAATCTTTCAGTGCCTTTGTCATAAAACAGTTATTTGAACAAAAAAAGTACTGT ACTCACACACATAAGGTATCCAGTGGATTTTTCTTCTCTGTCTTCCTCTCTTAAATTTCAACATCT CTCTTCTTGGCTGCTGTTTTCTTCATTTTATGTTAATGACTCAAAAAAGGTATTTTATAGAA TAATTCAGAGGAAAATGAGATTTACTAAGTTGACTTACCTGACGGACCCCAGAGACCTATTGCA TTGAGCAGTGGGGACTTAATATTTTACTTGTGTGATTGCATCTATGCAGACGCCAGTCTGGA AGAGCTGAAATGTTAAGTTTCTTGGCAACTTTGCATTCACACAGATTAGCTGTGTAATTTTTGTG TGTCAATTACAATTAAAAGCACATTGTTGGACCATGACATAGTATACTCAACTGACTTTAAAAC TATGGTCAACTTCAACTTGCATTCTCAGAATGATAGTGCCTTTAAAATTTTTTTATTTTTAAAG CATAAGAATGTTATCAGAATCTGGTCTACTTAGGACAATGGAGACTTTTTCAGTTTTATAAAGG GAACTGAGGACAGCTAATCCAACTACTTGGTGCTGTAATTGTTTCCTAGTAATTGGCAAAGGCT CCTTGTAAGATTTCACTGGAGCAGTGTGGCCTGGAGTATTTATATGGTGCTTAATGAATCTCC AGAATGCCAGCCAGAAGCCTGATTGGTTAGTAGGGAATAAAGTGTAGACCATATGAAATGAAC TGCAAACTCTAATAGCCCAGGTCTTAATTGCCTTTAGCAGAGGTATCCAAAGCTTTTAAAATTT ATGCATACGTTCTTCACAAGGGGGTACCCCCAGCAGCCTCTCGAAAATTGCACTTCTCTTAAAA CTGTAACTGGCCTTTCTCTTACCTTGCCTTAGGCCTTCTAATCATGAGATCTTGGGGACAAATTG ACTATGTCACAGGTTGCTCCTTGTAACTCATACCTGTCTGCTTCAGCAACTGCTTTGCAATGA TTCAATCACACTTTGTGGAAAAACATTTCCAGGGACTCAAAAATTCCAAAAAGGTGGTCAAAATTC TGGAAGTAAGCATTTCCTCTTTTTTAAAAATTTGGTTTGAGCCTTATGCCCATAGTTTGACATTT

CCCTTTCTTCTTTTGTTTTTTGTGTGGTTCTTGAGCTCTCTGACATCAAGATGCATGTAAA GTCGATTGTATGTTTTGAAGGCAAAGTCTTGGCTTTTGAGACTGAAGTTAAGTGGGCACAGGTG GCCCTGCTGCTGTGCCCAGTCTGAGTACCTTGGCTAGACTCTAGGTCAGGCTCCAGGAGCATG AGAATTGATCCCCAGAAGAACCATTTTAACTCCATCTGATACTCCATTGCCTATGAAATGTAAA CCAGGGCAGAGCCTGCCCTTACTCACGCTCTGCTCTGGTGTCTTGGGAGTTGTGCAGGGACTC TGGCCCAGGCAGGGAAGAAGACCAGGCGGTAGGGGACTGGTCTTGCTGTTAGAGTATAGAG GTTTGTAATGCAGTTTTCTTCATAATGTGTCAGTGATTGTGTGACCAAGGCAGCATCTAGCAGA AAGCCAGGCATGGAGTAGGTGATCGATACTTGTCAATGACTAAATAATAACAATAAAAGAGCA CTTGGGTGAATCTGGGCACCTGATTTCTGAGTTTTGAGTTCTGGAGCTAGTGTTTTGACAATGCT TTGGGTTTTGACATGCCTTTTCCACAAATCTCTTGCCTTTTCAGGGCAAAGTGTATTTGATCAGA AGTGGCCATTTGGATTAGTAGCCTTAGCAATGCTACAGGGTTATAGGCCCCTCTCCCTTTCACAT TCCAGACAATGGAGAGTGTTTATGGTTTCAGGAAAAGAACTTTGTGGCTGAGGGGTCAGTTACC TTATTGAGTGCCGACTGTAGTAAAGCCCTGAAATAGATAATCTCTGTTCTTAACTGATCTAG GATGGGGACGCACCCAGGTCTGCTGAACTTTACTGTTCCTCTGGGAAAGGAGCAGGGACCTCTG GAATTCCCATCTGTTTCACTGTCTCCATTCCATAAATCTCTTCCTGTGTGAGCCACCACACCCAG AGGTGGTTTTAACAGAAAGCATCAGCTCTGCTTCGTGACAGTCTCTGGAGAAATCCCTTAGGAA GACTATGAGAGTAGGCCACAAGGACATGGGCCCACACATCTGCTTTGGCTTTGCCGGCAATTCA GGGCTTGGGGTATTCCATGTGACTTGTATAGGTATATTTGAGGACAGCATCTTGCTAGAGAAAA GGTGAGGGTTGTTTTCTTTCTCTGAAACCTACAGTAAATGGGTATGATTGTAGCTTCCTCAGAA ATCCCTTGGCCTCCAGAGATTAAACATGGTGCAATGGCACCTCTGTCCAACCTCCTTTCTGGTA GATTCCTTTCTCCTGCTTCATATAGGCCAAACCTCAGGGCAAGGGAACATGGGGGTAGAGTGGT GCTGGCCAGAACCATCTGCTTGAGCTACTTGGTTGATTCATATCCTCTTTCCTTTATGGAGACCC GTGACATTTTTTAATTTCAGAGATGCTTTCTGATTTTCCTCTCCCAGGTCACTGTCTCACCTGCA CTCTCCAAACTCAGGTTCCGGGAAGCTTGTGTGTCTAGATACTGAATTGAGATTCTGTTCAGCA CCTTTTAGCTCTATACTCTCTGGCTCCCCTCATCCTCATGGTCACTGAATTAAATGCTTATTGTAT TGAGAACCAAGATGGGACCTGAGGACACAAAGATGAGCTCAACAGTCTCAGCCCTAGAGGAAT AGACTCAGGGATTTCACCAGGTCGGTGCAGTATTTGATTTCTGGTGAGGTGACCACAGCTGCAG TTGTTTGTTTGTTTGAGACAGGGTCTTGCTCTGCTACCCAGGCTGGGGCGCAATGGCACGA TCTTGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCCTGCCACAGCCTCCTGAGGA GCTGGGACTACAGGTGCGTGCTACCACGCCCAGCTACTTCTGTATTTTTAGTAGAGACGGGGTT TCACTGTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCATGATCTGCCCGCCTCAGCCTCCCAA ACGTCTTGTATTTTGTTCTGTGATGGAGGACACTGGAGAGAGTTGCTATTCCAGTCAATCATGTC GAGTCACTGGACTCTGAAAATCCTATTGGTTCCTTTATTTTATTTGAGTTTAGAGTTCCCTTCTG GGTTTGTATTATGTCTGGCAAATGACCTGGGTTATCACTTTTCCTCCAGGGTTAGATCATAGATC TTGGAAACTCCTTAGAGAGCATTTTGCTCCTACCAAGGATCAGATACTGGAGCCCCACATAATA GATTTCATTTCACTCTAGCCTACATAGAGCTTTCTGTTGCTGTCTCTTGCCATGCACTTGTGCGG TGATTACACACTTGACAGTACCAGGAGACAAATGACTTACAGATCCCCCGACATGCCTCTTCCC CTTGGCAAGCTCAGTTGCCCTGATAGTAGCATGTTTCTGTTTCTGATGTACCTTTTTTCTCTTCTT CTTTGCATCAGCCAATTCCCAGAATTTCCCCAGGCAATTTGTAGAGGACCTTTTTGGGGTCCTAT ATGAGCCATGTCCTCAAAGCTTTTAAACCTCCTTGCTCTCCTACAATATTCAGTACATGACCACT GTCATCCTAGAAGGCTTCTGAAAAGAGGGGCAAGAGCCACTCTGCGCCACAAAGGTTGGATCC ATCTTCTCCGAGGTTGTGAAAGTTTTCAAATTGTACTAATAGGCTGGGGCCCTGACTTGGCTG TGGGCTTTGGGAGGGTAAGCTGCTTTCTAGATCTCTCCCAGTGAGGCATGGAGGTGTTTCTGA ATTTTGTCTACCTCACAGGGATGTTGTGAGGCTTGAAAAAGGTCAAAAAATGATGGCCCCTTGAG CTCTTTGTAAGAAAGGTAGATGAAATATCGGATGTAATCTGAAAAAAAGATAAAATGTGACTT CCCCTGCTCTGTGCAGCAGTCGGGCTGGATGCTCTGTGGCNTTTCTTGGGTCCTCATGCCACCCC ACAGCTCCAGGAACCTTGAAGCCAATCTGGGGACTTTCAGATGTTTGACAAAGAGGTACCAGG CAAACTTCCTGCTACACATGCCCTGAATGAATTGCTAAATTTCAAAGGAAATGGACCCTGCTTT TAAGGATGTACAAAAGTATGTCTGCATCGATGTCTGTACTGTAAATTTCTAATTTATCACTGTAC

Figure 34

AGAGTCCTTTCCCTGGAATCCGAGCCCTAACCGTCTCTCCCCAGCCCTATCCGGCGAGGAGCGG AGCGCTGCCAGCGGAGCAGCGCTTCCCGAAGCAGTTTATCTTTGGACGGTTTTCTTTAAAGG GGCGATGGCTCGGCCTGACCCATCCGCGCCCCCCCCTCGCTGTTGCTGCTCCTCGCGCGCAGCTG GTGGGCCGGCGCCGCGTCCAAGGCCCCGGTGTGCCAGGAAATCACGGTGCCCATGTGC GCGGCCTGGAGGTGCACCAGTTCTGGCCGCTGGTGGAGATCCAATGCTCGCCGGACCTGCGCT TCTTCCTATGCACTATGTACACGCCCATCTGTCTGCCCGACTACCACAAGCCGCTGCCGCCCTGC CGCTCGGTGTGCGAGCGCCCAAGGCCGGCTGCTCGCCGCTGATGCGCCAGTACGGCTTCGCCT GGCCCGAGCGCATGAGCTGCGACCGCCTCCCGGTGCTGGGCCGCGACGCCGAGGTCCTCTGCA TGGATTACAACCGCAGCGAGGCCACCACGGCGCCCCCAGGCCTTTCCCAGCCAAGCCCACCCT TCCAGGCCCGCCAGGGGCCCCGGCCTCGGGGGGCGAATGCCCCGCTGGGGGCCCGTTCGTGTG CAAGTGTCGCGAGCCCTTCGTGCCCATTCTGAAGGAGTCACACCCGCTCTACAACAAGGTGCGG ACGGCCAGGTGCCCAACTGCGCGGTACCCTGCTACCAGCCGTCCTTCAGTGCCGACGAGCGC ACGTTCGCCACCTTCTGGATAGGCCTGTGGTCGGTGCTGTGCTTCATCTCCACGTCCACCACAGT GGCCACCTTCCTCATCGACATGGACACGTTCCGCTATCCTGAGCGCCCCATCATCTTCCTGTCAG CCTGCTACCTGTGCGTGTCGCTGGGCCTTCCTGGTGCGTCGTGGGCCATGCCAGCGTGGC CTGCAGCCGCGAGCACAACCACATCCACTACGAGACCACGGGCCCTGCACTGTGCACCATCGT CTTCCTCCTGGTCTACTTCTTCGGCATGGCCAGCTCCATCTGGTGGGTCATCCTGTCGCTCACCT GGTTCCTGGCCGCCGATGAAGTGGGGCAACGAGGCCATCGCGGGCTACGGCCAGTACTTCC ACCTGGCTGCGTGGCTCATCCCCAGCGTCAAGTCCATCACGGCACTGGCGCTGAGCTCCGTGGA CGGGGACCCAGTGGCCGCATCTGCTACGTGGGCAACCAGAACCTGAACTCGCTGCGGCGCTT CGTGCTGGGCCCGCTGGTGCTCTACCTGCTGGTGGGCACGCTCTTCCTGCTGGCGGGCTTCGTGT CGCTCTTCCGCATCCGCAGCGTCATCAAGCAGGGCGGCACCAAGACGGACAAGCTGGAGAAGC TCATGATCCGCATCGGCATCTTCACGCTGCTCTACACGGTCCCCGCCAGCATTGTGGTGGCCTG CTACCTGTACGAGCAGCACTACCGCGAGAGCTGGGAGGCGGCGCTCACCTGCGCCTGCCCGGG CCACGACACCGGCCAGCCGCGCCAAGCCCGAGTACTGGGTGCTCATGCTCAAGTACTTCATG TGCCTGGTGGTGGCATCACGTCGGGCGTCTGGATCTGGTCGGGCAAGACGGTGGAGTCGTGG GCCGCCACCTACCACAAGCAGGTGTCCCTGTCGCACGTGTAGGAGGCTGCCGCCGAGGGACTC GGCCGGAGAGCTGAGGGGGGGGGGGGGGTTTTGTTTGGTAGTTTTGCCAAGGTCACTTCCGTTTA CCTTCATGGTGCTGTTGCCCCCTCCCGCGGCGACTTGGAGAGAGGGGAAGAGGGGCGTTTTCGAG GAAGAACCTGTCCCAGGTCTTCTCCAAGGGGCCCAGCTCACGTGTATTCTATTTTGCGTTTCTTA CCTGCCTTCTTTATGGGAACCCTCTTTTTAATTTATATGTAT

Figure 35

GCAGCTCCAGTCCCGGACGCAACCCCGGAGCCGTCTCAGGTCCCTGGGGGGAACGGTGGGTTA GACGGGGACGGACGGACGGCCTTCGACCGCCCCCCGAGTAATTGACCCAGGACTCATT TTCAGGAAAGCCTGAAAATGAGTAAAATAGTGAAATGAGGAATTTGAACATTTTATCTTTGGAT GGGGATCTTCTGAGGATGCAAAGAGTGATTCATCCAAGCCATGTGGTAAAATCAGGAATTTGA AGAAAATGGAGATGTTTACATTTTTGTTGACGTGTATTTTTCTACCCCTCCTAAGAGGGCACAGT CTCTCACCTGTGAACCAATTACTGTTCCCAGATGTATGAAAAATGGCCTACAACATGACGTTTTT CCCTAATCTGATGGGTCATTATGACCAGAGTATTGCCGCGGTGGAAATGGAGCATTTTCTTCCT CTCGCAAATCTGGAATGTTCACCAAACATTGAAACTTTCCTCTCCAAAGCATTTGTACCAACCT GCATAGAACAATTCATGTGGTTCCACCTTGTCGTAAACTTTGTGAGAAAGTATATTCTGATTG

CAAAAATTAATTGACACTTTTGGGATCCGATGGCCTGAGGAGCTTGAATGTGACAGATTACAA AAACAGAACAAGTCCAAAGAGACATTGGATTTTGGTGTCCAAGGCATCTTAAGACTTCTGGGG GACAAGGATATAAGTTTCTGGGAATTGACCAGTGTGCGCCTCCATGCCCCAACATGTATTTTAA AAGTGATGAGCTAGAGTTTGCAAAAAGTTTTATTGGAACAGTTTCAATATTTTGTCTTTGTGCA ACTCTGTTCACATTCCTTACTTTTTAATTGATGTTAGAAGATTCAGATACCCAGAGAGACCAAT TATATATTACTCTGTCTGTTACAGCATTGTATCTCTTATGTACTTCATTGGATTTTTGCTGGGCGA TAGCACAGCCTGCAATAAGGCAGATGAGAAGCTAGAACTTTGGTGACACTGTTGTCCTAGGCTCT GTGGGTGATTCTTACCATTACTTGGTTCTTAGCTGCAGGAAGAAAATGGAGTTGTGAAGCCATC GAGCAAAAAGCAGTGTGGTTTCATGCTGTTGCATGGGGAACACCAGGTTTCCTGACTGTTATGC TTCTTGCTCTGAACAAGTTGAAGGAGACAACATTAGTGGAGTTTGCTTTGTTGGCCTTTATGA TCTTTTAGCTGGCATTATTTCCTTAAATCATGTTCGACAAGTCATACAACATGATGGCCGGAACC AAGAAAAACTAAAGAAATTTATGATTCGAATTGGAGTCTTCAGCGGCTTGTATCTTGTGCCATT AGTGACACTTCTCGGATGTTACGTCTATGAGCAAGTGAACAGGATTACCTGGGAGATAACTTGG GTCTCTGATCATTGTCGTCAGTACCATATCCCATGTCCTTATCAGGCAAAAGCAAAAGCTCGAC CAGAATTGGCTTTATTTATGATAAAATACCTGATGACATTAATTGTTGGCATCTCTGCTGTCTTC TGGGTTGGAAGCAAAAGACATGCACAGAATGGGCTGGGTTTTTTAAACGAAATCGCAAGAGA GATCCAATCAGTGAAAGTCGAAGAGTACTACAGGAATCATGTGAGTTTTTCTTAAAGCACAATT CTAAAGTTAAACACAAAAAGAAGCACTATAAACCAAGTTCACACAAGCTGAAGGTCATTTCCA AATCCATGGGAACCAGCACAGGAGCTACAGCAAATCATGGCACTTCTGCAGTAGCAATTACTA GCCATGATTACCTAGGACAAGAAACTTTGACAGAAATCCAAACCTCACCAGAAACATCAATGA GAGAGGTGAAAGCGGACGGAGCTAGCACCCCCAGGTTAAGAGAACAGGACTGTGGTGAACCT GCCTCGCCAGCAGCATCCATCTCCAGACTCTCTGGGGAACAGGTCGACGGGAAGGGCCAGGCA GGCAGTGTATCTGAAAGTGCGCGGAGTGAAGGAAGGATTAGTCCAAAGAGTGATATTACTGAC ACTGGCCTGGCACAGACCAATTTGCAGGTCCCCAGTTCTTCAGAACCAAGCAGCCTCAAA GGTTCCACATCTCTGCTTGTTCACCCAGTTTCAGGAGTGAGAAAAGAGCAGGGAGGTGGTTGTC ATTCAGATACTTGAAGAACATTTTCTCTCGTTACTCAGAAGCAAATTTGTGTTACACTGGAAGT GACCTATGCACTGTTTTGTAAGAATCACTGTTACGTTCTTTTTGCACTTAAAGTTGCATTGCC TACTGTTATACTGGAAAAAATAGAGTTCAAGAATAATATGACTCATTTCACACAAAGGTTAATG ACAACAATATACCTGAAAACAGAAATGTGCAGGTTAATAATATTTTTTTAATAGTGTGGGAGGA CAGAGTTAGAGGAATCTTCCTTTTCTATTTATGAAGATTCTACTCTTGGTAAGAGTATTTTAAGA TGTACTATGCTATTTTACCTTTTTGATATAAAATCAAGATATTTCTTTGCTGAAGTATTTAAATCT TATCCTTGTATCTTTTATACATATTTGAAAATAAGCTTATATGTATTTGAACTTTTTTGAAATCC TATTCAAGTATTTTATCATGCTATTGTGATATTTTAGCACTTTGGTAGCTTTTACACTGAATTTC TAAGAAAATTGTAAAATAGTCTTCTTTTATACTGTAAAAAAAGATATACCAAAAAGTCTTATAA TAGGAATTTAACTTTAAAAACCCACTTATTGATACCTTACCATCTAAAATGTGTGATTTTTATAG TCTCGTTTTAGGAATTTCACAGATCTAAATTATGTAACTGAAATAAGGTGCTTACTCAAAGAGT GTCCACTATTGATTGTATTATGCTGCTCACTGATCCTTCTGCATATTTAAAATAAAATGTCCTAA AGGGTTAGTAGACAAAATGTTAGTCTTTTGTATATTAGGCCAAGTGCAATTGACTTCCCTTTTTT AATGTTTCATGACCACCCATTGATTGTATTATAACCACTTACAGTTGCTTATATTTTTTGTTT**TAA** CTTTTGTTTCTTAACATTTAGAATATTACATTTTGTATTATACAGTACCTTTCTCAGACATTTTGT AG

Figure 36

GGGCTGCGAGGCGCTCATGAACAAGTTCGGCTTCCAGTGGCCCGAGCGGCTGCGCTGCGAGAA CTTCCCGGTGCACGGTGCGGGCGAGATCTGCGTGGGCCAGAACACGTCGGACGGCTCCGGGGG CCCAGGCGCCCCACTGCCTACCCTACCGCGCCCTACCTGCCGGACCTGCCCTTCACCGCG CTGCCCCGGGGGCCTCAGATGGCAGGGGGGCGTCCCGCCTTCCCCTTCTCATGCCCCCGTCAGC TCAAGGTGCCCCCGTACCTGGGCTACCGCTTCCTGGGTGAGCGCGATTGTGGCGCCCCGTGCGA ACATGCGGCGCTTCAGCTACCCAGAGCGGCCCATCATCTTCCTGTCGGGCTGCTACTTCATGGT GGCCGTGGCGCACGTGGCCGGCTTCCTTCTAGAGGACCGCGCCGTGTGCGTGGAGCGCTTCTCG GACGATGGCTACCGCACGGTGGCGCAGGGCACCAAGAAGGAGGGCTGCACCATCCTCTTCATG GTGCTCTACTTCTTCGGCATGGCCAGCTCCATCTGGTGGGTCATTCTGTCTCTCACTTGGTTCCT GGCGCCGGCATGAAGTGGGGCCACGAGGCCATCGAGGCCAACTCGCAGTACTTCCACCTGGC CGCGTGGGCCGTGCCGCCGTCAAGACCATCACTATCCTGGCCATGGGCCAGGTAGACGGGGA CCTGCTGAGCGGGGTGTGCTACGTTGGCCTCTCCAGTGTGGACGCGCTGCGGGGCTTCGTGCTG GCGCCTCTGTTCGTCTACCTCTTCATAGGCACGTCCTTCTTGCTGGCCGGCTTCGTGTCCCTCTTC CGTATCCGCACCATCATGAAACACGACGGCACCAAGACCGAGAAGCTGGAGAAGCTCATGGTG CGCATCGGCGTCTTCAGCGTGCTCTACACAGTGCCCGCCACCATCGTCCTGGCCTGCTACTTCTA CGAGCAGGCCTTCCGCGAGCACTGGGAGCGCACCTGGCTCCTGCAGACGTGCAAGAGCTATGC CGTGCCCTGCCCGGCCACTTCCCGCCCATGAGCCCCGACTTCACCGTCTTCATGATCAAG TACCTGATGACCATGATCGTCGGCATCACCACTGGCTTCTGGATCTGGTCGGGCAAGACCCTGC AGTCGTGGCGCCGCTTCTACCACAGACTTAGCCACAGCAGCAAGGGGGAGACTGCGGTATGAG CCCCGGCCCCTCCCCACCTTTCCCACCCCAGCCCTCTTGCAAGAGGAGAGGCACGGTAGGGAAA AGAACTGCTGGGTGGGGCCTGTTTCTGTAACTTTCTCCCCCTCTACTGAGAAGTGACCTGGAA GTGAGAAGTTCTTTGCAGATTTGGGGCGAGGGGTGATTTGGAAAAGAAGACCTGGGTGGAAAAG CGGTTTGGATGAAAAGATTTCAGGCAAAGACTTGCAGGAAGATGATGATAACGGCGATGTGAA TCGTCAAAGGTACGGGCCAGCTTGTGCCTAATAGAAGGTTGAGACCAGCAGAGACTGCTGTGA GTTTCTCCCGGCTCCGAGGCTGAACGGGGACTGTGAGCGATCCCCCTGCTGCAGGGCGAGTGGC CTGTCCAGACCCCTGTGAGGCCCCGGGAAAGGTACAGCCCTGTCTGCGGTGGCTGCTTTGTTGG AAAGAGGGAGGCCTCCTGCGGTGTGCTTGTCAAGCAGTGGTCAAACCATAATCTCTTTTCACT GGGGCCAAACTGGAGCCCAGATGGGTTAATTTCCAGGGTCAGACATTACGGTCTCTCCCCCT GCCCCCCCCCCCTGTTTTTCCTCCCGTACTGCTTTCAGGTCTTGTAAAATAAGCATTTGGAAGT CTTGGGAGGCCTGCCTGCAGAATCCTAATGTGAGGATGCAAAAGAAATGATGATAACATTTTG AGATAAGGCCAAGGAGACGTGGAGTAGGTATTTTTGCTACTTTTTCATTTTCTGGGGAAGGCAG GAGGCAGAAAGACGGGTGTTTTATTTGGTCTAATACCCTGAAAAGAAGTGATGACTTGTTGCTT TTCAAAACAGGAATGCATTTTTCCCCTTGTCTTTGTTGTAAGAGACAAAAGAGGAAACAAAAGT GTCTCCCTGTGGAAAGCATAACTGTGACGAAAGCAACTTTTATAGGCAAAGCAGCGCAAATC TGAGGTTTCCCGTTGGTTGATTTGGTTGAGATAAACATTCCTTTTTAAGGAAAAGTGAAGA GCAGTGTGCTGTCACACACCGTTAAGCCAGAGGTTCTGACTTCGCTAAAGGAAATGTAAGAGG TTTTGTTGTCTGTTTTAAATAAATTTAATTCGGAACACATGATCCAACAGACTATGTTAAAAATAT TCAGGGAAATCTCTCCCTTCATTTACTTTTTCTTGCTATAAGCCTATATTTAGGTTTCTTTTCTAT TTTTTTCTCCCATTTGGATCCTTTGAGGTAAAAAAAACATAATGTCTTCAGCCTCATAATAAAGGA AAGTTAATTAAAAAAAAAAAGCAAAGAGCCATTTTGTCCTGTTTTCTTGGTTCCATCAATCTGT TTATTAAACATCATCCATATGCTGACCCTGTCTCTGTGTGGGTTGGGAGGCGATCAGCAG AAGAAGGTAAACTTCAAAGTGATTCTGGAGTTCTTTGAAATGTGCTGGAAGACTTAAATTTATT AATCTTAAATCATGTACTTTTTTTCTGTAATAGAACTCGGATTCTTTTGCATGATGGGGTAAAGC TTAGCAGAGAATCATGGGAGCTAACCTTTATCCCACCTTTGACACTACCCTCCAATCTTGCAAC ACTATCCTGTTTCTCAGAACAGTTTTTAAATGCCAATCATAGAGGGTACTGTAAAGTGTACAAG TTACTTTATATGTAATGTTCACTTGAGTGGAACTGCTTTTTACATTAAAGTTAAAATCGATCT TGTGTTTCTTCAACCTTCAAAACTATCTCATCTGTCAGATTTTTAAAACTCCAACACAGGTTTTG GCATCTTTTGTGCTGTATCTTTTAAGTGCATGTGAAATTTGTAAAATAGAGATAAGTACAGTAT TTTTTAAATAC

Figure 37

ACAGCATGGAGTGGGGTTACCTGTTGGAAGTGACCTCGCTGCTGGCCGCCTTGGCGCTGCTGCA GCGCTCTAGCGGCGCTGCGGCCCTCGGCCAAGGAGCTGGCATGCCAAGAGATCACCGTGCC GCTGTGTAAGGGCATCGGCTACAACTACACCTACATGCCCAATCAGTTCAACCACGACACGCA AGACGAGGCGGGCCTGGAGGTGCACCAGTTCTGGCCGCTGGTGGAGATCCAGTGCTCGCCCGA TCTCAAGTTCTTCCTGTGCAGCATGTACACGCCCATCTGCCTAGAGGACTACAAGAAGCCGCTG CCGCCCTGCCGCTGTGTGCGAGCGCGCCAAGGCCGGCTGCGCGCCCCTCATGCGCCAGTAC GGCTTCGCCTGGCCCGACCGCATGCGCTGCGACCGGCTGCCCGAGCAAGGCAACCCTGACACG CGCCGCCGCCGCGGGGGCAGCGCCTTCGGGCAGCGGCCACGGCCGCCGGGGGGCCA GTCAAGACAGGCCAGATCGCTAACTGCGCGCTGCCCTGCCACAACCCCTTTTTCAGCCAGGACG AGCGCGCCTTCACCGTCTTCTGGATCGGCCTGTGGTCGGTGCTCTGCTTCGTGTCCACCTTCGCC ACCGTCTCCACCTTCCTTATCGACATGGAGCGCTTCAAGTACCCGGAGCGGCCCATTATCTTCCT CTCGGCCTGCTACCTCTTCGTGTCGGTGGGCTACCTAGTGCGCCTGGTGGCGGGCCACGAGAAG GGGCGCGGGCGCGGGCGCGGGCGGGCGGGCGGGCGGGCGAGTACGAGGAGC TGGGCGCGGTGGAGCACGTGCGCTACGAGACCACCGGCCCCGCGCTGTGCACCGTGGTCT TTCCTGGCGGCCGGTATGAAGTGGGGCAACGAAGCCATCGCCGGCTACTCGCAGTACTTCCACC TGGCCGCGTGGCTTGTGCCCAGCGTCAAGTCCATCGCGGTGCTGGCGCTCAGCTCGGTGGACGG CGACCCGGTGGCGGCATCTGCTACGTGGGCAACCAGAGCCTGGACAACCTGCGCGGCTTCGT GCTGGCGCCGCTGGTCATCTACCTCTTCATCGGCACCATGTTCCTGCTGGCCGGCTTCGTGTCCC TGTTCCGCATCCGCTCGGTCATCAAGCAACAGGACGGCCCCACCAAGACGCACAAGCTGGAGA AGCTGATGATCCGCCTGGGCCTGTTCACCGTGCTCTACACCGTGCCCGCCGCGGTGGTCGCC CTGCCTCTTCTACGAGCAGCACAACCGCCCGCGCTGGGAGGCCACGCACAACTGCCCGTGCCTG CGGGACCTGCAGCCGACCAGGCACGCAGGCCCGACTACGCCGTCTTCATGCTCAAGTACTTCA TGTGCCTAGTGGTGGGCATCACCTCGGGCGTGTGGGTCTGGTCCGGCAAGACGCTGGAGTCCTG GCGGGGGCCGGCGGGGGGCTCCCTCTACAGCGACGTCAGCACTGGCCTGACGTGGC GGTCGGGCACGCGAGCTCCGTGTCTTATCCAAAGCAGATGCCATTGTCCCAGGTCTGAGCGGA ACACTTGATGGGCTGAGGTTCCCACCCCTTCACAGTGTTGATTGCTATTAGCATGATAATGAAC TCTTAATGGTATCCATTAGCTGGGACTTAAATGACTCACTTAGAACAAAGTACCTGGCATTGAA GCCTCCCAGACCCAGCCCCTTTTCCTCCATTGATGTGCGGGGAGCTCCTCCCGCCACGCGTTAAT GGCTGCACTTGGCTGGGTTTGCAGTCAGATACACAGATTTCACCTGGGAGAACCTCTTTTTCTCC CTCGACTCTTCCTACGTAAACTCCCACCCTGACTTACCCTGGAGGAGGGGTGACCGCCACCTG AATGTCTTAATTATACACCCCACGTAAATACGGGTTTCTTACATTAGAGGATGTATTTATATAAT TATTTGTTAAATTGTAAAAAAAAAAAAGTGTAAAATATGTATATATCCAAAGATATAGTGTGTAC ATTTTTTTTTTTAAAAAGTTTAGAGGCTTACCCCTGTAAGAACAGATATAAGTATTCTATTTTGTCA ATAAAATGACTTTTGATAAATGATTTAACCATTGCCCTCTCCCCCGCCTCTTCTGAGCTGTCACC TTTAAAGTGCTTGCTAAGGACGCATGGGGAAAATGGACATTTTCTGGCTTGTCATTCTGTACAC TGACCTTAGGCATGGAGAAAATTACTTGTTAAACTCTAGTTCTTAAGTTGTTAGCCAAGTAAAT ATCATTGTTGAACTGAAATCAAAATTGAGTTTTTGCACCTTCCCCAAAGACGGTGTTTTTCATGG GAGCTCTTTTCTGATCCATGGATAACAACTCTCACTTTAGTGGATGTAAATGGAACTTCTGCAA GGCAGTAATTCCCCTTAGGCCTTGTTATTTATCCTGCATGGTATCACTAAAGGTTTCAAAACCCT GAAAAAAAA

Figure 38 33/41

CCGCCTTCGGCCCGGGCCTCCCGGGATGGCCGTGGCGCCTCTGCGGGGGGGCGCTGCTGTGG CAGCTGCTGGCGCGGCGCGCGCACTGGAGATCGGCCGCTTCGACCCGGAGCGCGGGCGC GGGGCTGCGCCGTGCCAGGCGGTGGAGATCCCCATGTGCCGCGGCATCGGCTACAACCTGACC CGCATGCCCAACCTGCTGGGCCACACGTCGCAGGGCGAGGCGGCTGCCGAGCTAGCGGAGTTC CCATGTGCACCGACCAGGTCTCGACGCCCATTCCCGCCTGCCGGCCCATGTGCGAGCAGGCGCG CGGCTGCCCACGCGCACGCCCCCCCCCGCTGTGCATGGAGGCGCCCGAGAACGCCACGGCC CCCGGAGACCTGGGCCCGGGCGGGCGGCAGTGGCACCTGCGAGAACCCCGAGAAGTTCCAG TACGTGGAGAAGAGCCGCTCGTGCGCACCGCGCTGCGGGCCCCGGCGTCGAGGTGTTCTGGTCC CGGCGCGACAAGGACTTCGCGCTGGTCTGGATGGCCGTGTGGTCGGCGCTGTGCTTCTTCTCCA CCGCCTTCACTGTGCTCACCTTCTTGCTGGAGCCCCACCGCTTCCAGTACCCCGAGCGCCCCATC ATCTTCCTCTCCATGTGCTACAACGTCTACTCGCTGGCCTTCCTGATCCGTGCGGTGGCCGGAGC GCAGAGCGTGGCCTGTGACCAGGAGGCGGGCGCGCTCTACGTGATCCAGGAGGGCCTGGAGAA GTGGTCCTGACGCTCACCTGGTTCCTGGCTGCCGGGAAGAAATGGGGCCACGAGGCCATCGAG GCCCACGCAGCTATTTCCACATGGCTGCCTGGGGCCTGCCCGCGCTCAAGACCATCGTCATCC TGACCCTGCGCAAGGTGGCGGGTGATGAGCTGACTGGGCTTTGCTACGTGGCCAGCACGGATG CAGCAGCGCTCACGGGCTTCGTGCTGGTGCCCCTCTCTGGCTACCTGGTGCTGGGCAGTAGTTT CCTCCTGACCGGCTTCGTGGCCCTCTTCCACATCCGCAAGATCATGAAGACGGGCGGCACCAAC ACAGAGAAGCTGGAGAAGCTCATGGTCAAGATCGGGGTCTTCTCCATCCTCTACACGGTGCCCG CCACCTGCGTCATCGTTTGCTATGTCTACGAACGCCTCAACATGGACTTCTGGCGCCTTCGGGCC ACAGAGCAGCCATGCGCAGCGGCCGGGGGCCCGGAGGCCGGAGGGACTGCTCGCTGCCAGG GGGCTCGGTGCCCACCGTGGCGGTCTTCATGCTCAAAATTTTCATGTCACTGGTGGTGGGGATC ACCAGCGGCGTCTGGGTGTGGAGCTCCAAGACTTTCCAGACCTGGCAGAGCCTGTGCTACCGCA AGATAGCAGCTGGCCGGGCCCAGGCCAGGCCTGCCGCGCCCCCGGGAGCTACGGACGTGGCA CGCACTGCCACTATAAGGCTCCCACCGTGGTCTTGCACATGACTAAGACGGACCCCTCTTTGGA CCACGCCTGCCCCTGCATCCCCTAGAGACAGCTGACTAGCAGCTGCCCAGCTGTCAAGGTCA GGCAAGTGAGCACCGGGGACTGAGGATCAGGGCGGGACCCCGTGAGGCTCATTAGGGGAGAT GGGGGTCTCCCCTAATGCGGGGGCTGGACCAGGCTGAGTCCCCACAGGGTCCTAGTGGAGGAT GTGGAGGGCGGGCAGAGGGGTCCAGCCGGAGTTTATTTAATGATGTAATTTATTGTTGCGTT GGGGAAGGTAGGAGGTGAGGC

Figure 39

ACACGTCCAACGCCAGCATGCAGCGCCCGGGCCCCGCCTGTGGCTGGTCCTGCAGGTGATGG GCTCGTGCGCCGCCATCAGCTCCATGGACATGGAGCGCCCGGGCGACGGCAAATGCCAGCCCA TCGAGATCCCGATGTGCAAGGACATCGGCTACAACATGACTCGTATGCCCAACCTGATGGGCC ACGAGAACCAGCGCGAGGCAGCCATCCAGTTGCACGAGTTCGCGCCGCTGGTGGAGTACGGCT GCCACGGCCACCTCCGCTTCTTCCTGTGCTCGCTGTACGCGCCGATGTGCACCGAGCAGGTCTC TACCCCCATCCCGCCTGCCGGGTCATGTGCGAGCAGGCCCGGCTCAAGTGCTCCCCGATTATG GAGCAGTTCAACTTCAAGTGGCCCGACTCCCTGGACTGCCGGAAACTCCCCAACAAGAACGAC CCCAACTACCTGTGCATGGAGGCGCCCAACAACGGCTCGGACGAGCCCACCCGGGGCTCGGGC CTGTTCCCGCCGCTGTTCCGGCCGCAGCGGCCCCACAGCGCGCAGGAGCACCCGCTGAAGGAC GGGGGCCCCGGCGCGCGCTGCGACAACCCGGGCAAGTTCCACCACGTGGAGAAGAGCGC GTCGTGCGCCCCCTGCACGCCCGGCGTGGACGTGTACTGGAGCCGCGAGGACAAGCGCTT CGCAGTGGTCTGGCCATCTGGGCGGTGCTGTGCTTCTCCCAGCGCCTTCACCGTGCTCA CCTTCCTCATCGACCCGCCCGCTTCCGCTACCCCGAGCGCCCCATCATCTTCCTCTCCATGTGC TACTGCGTCTACTCCGTGGGCTACCTCATCCGCCTCTTCGCCGGCGCCCGAGAGCATCGCCTGCG ACCGGGACAGCGCCAGCTCTATGTCATCCAGGAGGACTGGAGAGCACCGGCTGCACGCTGG TCTTCCTGGTCCTCACTACTTCGGCATGGCCAGCTCGCTGTGGTGGTGGTCCTCACGCTCACC

TGGTTCCTGGCCGCCGGCAAGAAGTGGGGCCACGAGGCCATCGAAGCCAACAGCAGCTACTTC CACCTGGCAGCCTGGGCCATCCCGGCGGTGAAGACCATCCTGATCCTGGTCATGCGCAGGGTG GCGGGGACGAGCTCACCGGGGTCTGCTACGTGGGCAGCATGGACGTCAACGCGCTCACCGGC TTCGTGCTCATTCCCCTGGCCTGCTACCTGGTCATCGGCACGTCCTTCATCCTCTCGGGCTTCGT GGCCCTGTTCCACATCCGGAGGGTGATGAAGACGGGCGGCGAGAACACGGACAAGCTGGAGA AGCTCATGGTGCGTATCGGGCTCTTCTCTGTGCTGTACACCGTGCCGGCCACCTGTGTGATCGCC TGCTACTTTTACGAACGCCTCAACATGGATTACTGGAAGATCCTGGCGGCGCAGCACAAGTGCA AAATGAACAACCAGACTAAAACGCTGGACTGCCTGATGGCCGCCTCCATCCCÇGCCGTGGAGA TCTTCATGGTGAAGATCTTTATGCTGCTGGTGGTGGGATCACCAGCGGGATGTGGATTTGGAC CTCCAAGACTCTGCAGTCCTGGCAGCAGGTGTGCAGCCGTAGGTTAAAGAAGAAGAAGCCGGAG AAAACCGGCCAGCGTGATCACCAGCGGTGGGATTTACAAAAAAGCCCAGCATCCCCAGAAAAAC TCACCACGGGAAATATGAGATCCCTGCCCAGTCGCCCACCTGCGTGTGAACAGGGCTGGAGGG CTTCTTTTTTTTTTTTTATAAAAGCAAAAGAGAAATACATAAAAAAGTGTTTACCCTGAAATTC AGGATGCTGTGATACACTGAAAGGAAAAATGTACTTAAAGGGTTTTGTTTTGTTTTGGTTTTCC AGCGAAGGGAAGCTCCTCCAGTGAAGTAGCCTCTTGTGTAACTAATTTGTGGTAAAGTAGTTGA TTCAGCCCTCAGAAGAAACTTTTGTTTAGAGCCCTCCGTAAATATACATCTGTGTATTTGAGTT GGCTTTGCTACCCATTTACAAATAAGAGGACAGATAACTGCTTTGCAAATTCAAGAGCCTCCCC TGGGTTAACAAATGAGCCATCCCCAGGGCCCACCCCCAGGAAGGCCACAGTGCTGGGCGGCAT CCCTGCAGAGGAAAGACAGGACCCGGGGCCCGCCTCACACCCCAGTGGATTTGGAGTTGCTTA AAATAGACTCTGGCCTTCACCAATAGTCTCTCTGCAAGACAGAAACCTCCATCAAACCTCACAT TTGTGAACTCAAACGATGTGCAATACATTTTTTTCTCTTTCCTTGAAAATAAAAAGAGAAACAA GTATTTTGCTATATAAAGACAACAAAAGAAATCTCCTAACAAAAGAACTAAGAGGCCCAGC CCTCAGAAACCCTTCAGTGCTACATTTTGTGGCTTTTTAATGGAAACCAAGCCAATGTTATAGA CGTTTGGACTGATTTGTGGAAAGGAGGGGGGAAGAGGGAGAAGGATCATTCAAAAGTTACCCA AAGGGCTTATTGACTCTTTCTATTGTTAAACAAATGATTTCCACAAACAGATCAGGAAGCACTA GGTTGGCAGAGACACTTTGTCTAGTGTATTCTCTTCACAGTGCCAGGAAAGAGTGGTTTCTGCG TGTGTATATTTGTAATATATGATATTTTCATGCTCCACTATTTTATTAAAAAATAAAATATGTTCT TTAAAAAAA

Figure 40

GCCGAGGCCGCCACTGGCCGGGGGGACCGGGCAGCAGCTTGCGGCCGCGGAGCCGGGCAAC AGGCGGCGGAGGCAGCCCCGACGTCGCGGAGAACAGGGCGCAGAGCCGGCATGGGCATCGGG CGCAGCGAGGGGCCCCCGCGGGGCCCTGGGCGTGCTGCTGGCGCTGGGCGCGCGCGCTTCTG GCCGTGGGCTCGGCCAGCGAGTACGACTACGTGAGCTTCCAGTCGGACATCGGCCCGTACCAG AGCGGGCGCTTCTACACCAAGCCACCTCAGTGCGTGGACATCCCCGCGGACCTGCGGCTGTGCC ACAACGTGGGCTACAAGAAGATGGTGCTGCCCAACCTGCTGGAGCACGAGACCATGGCGGAGG TGAAGCAGCAGCCAGCAGCTGGGTGCCCCTGCTCAACAAGAACTGCCACGCCGGGACCCAGG TCTTCCTCTGCTCGCTCTTCGCGCCCGTCTGCCTGGACCGGCCCATCTACCCGTGTCGCTGGCTC TGCGAGGCCGTGCGCGACTCGTGCGAGCCGGTCATGCAGTTCTTCGGCTTCTACTGGCCCGAGA TGCTTAAGTGTGACAAGTTCCCGGAGGGGGACGTCTGCATCGCCATGACGCCGCCCAATGCCAC CGAAGCCTCCAAGCCCCAAGGCACAACGGTGTGTCCTCCCTGTGACAACGAGTTGAAATCTGA GGCCATCATTGAACATCTCTGTGCCAGCGAGTTTGCACTGAGGATGAAAATAAAAGAAGTGAA AAAAGAAAATGGCGACAAGAAGATTGTCCCCAAGAAGAAGAAGCCCCTGAAGTTGGGGCCCA TCAAGAAGAAGGACCTGAAGAAGCTTGTGCTGTACCTGAAGAATGGGGCTGACTGTCCCTGCC ACCAGCTGGACAACCTCAGCCACCACTTCCTCATCATGGGCCGCAAGGTGAAGAGCCAGTACTT GCTGACGGCCATCCACAAGTGGGACAAGAAAAACAAGGAGTTCAAAAAACTTCATGAAGAAAA TGAAAAACCATGAGTGCCCCACCTTTCAGTCCGTGTTTAAGTGATTCTCCCGGGGGCAGGGTGG GGAGGGAGCCTCGGGTGGGGGGGAGCGGGGGACAGTGCCCGGGAACCCGTGGTCACACA CACGCACTGCCCTGTCAGTAGTGGACATTGTAATCCAGTCGGCTTGTTCTTGCAGCATTCCC

Figure 41

Figure 42

GCTTCTCCGCGCCCCAGCCGCCGGCTGCCAGCTTTTCGGGGCCCCGAGTCGCACCCAGCGAAGAGAGCGG GCCCGGGÀCAAGCTCGAACTCCGGCCGCCTCGCCCTTCCCCGGCTCCGCTCCCTCTGCCCCCTCGGGGTC $\tt CTCGGCGCGGGGCTCTTCCTCTTTGGCCAGCCCGACTTCTCCTACAAGCGCAGCAATTGCAAGCCCATC$ CCTGCCAACCTGCAGCTGTGCCACGGCATCGAATACCAGAACATGCGGCTGCCCAACCTGCTGGGCCACG AGACCATGAAGGAGGTGCTGGAGCAGGCCGGCGCTTGGATCCCGCTGGTCATGAAGCAGTGCCACCCGGA CACCAAGAAGTTCCTGTGCTCGCTCTTCGCCCCCGTCTGCCTCGATGACCTAGACGAGACCATCCAGCCA TGCCACTCGCTCTGCGTGCAGGTGAAGGACCGCTGCGCCCCGGTCATGTCCGCCTTCGGCTTCCCCTGGC ${\tt CCGACATGCTTGAGTGCGACCGTTTCCCCCAGGACAACGACCTTTGCATCCCCCTCGCTAGCAGCGACCA}$ CCTCCTGCCAGCCACCGAGGAAGCTCCAAAGGTATGTGAAGCCTGCAAAAATAAAAATGATGATGACAAC GACATAATGGAAACGCTTTGTAAAAATGATTTTGCACTGAAAAATAAAAGTGAAGGAGATAACCTACATCA ACCGAGATACCAAAATCATCCTGGAGACCAAGAGCAAGACCATTTACAAGCTGAACGGTGTCCCGAAAG GGACCTGAAGAAATCGGTGCTGTGGCTCAAAGACAGCTTGCAGTGCACCTGTGAGGAGATGAACGACATC AACGCGCCCTATCTGGTCATGGGACAGAAACAGGGTGGGGAGCTGGTGATCACCTCGGTGAAGCGGTGGC AGAAGGGGCAGAGAGAGTTCAAGCGCATCTCCCGCAGCATCCGCAAGCTGCAGTGCTAGTCCCGGCATCC TGATGGCTCCGACAGGCCTGCTCCAGAGCACGGCTGACCATTTCTGCTCCGGGATCTCAGCTCCCGTTCC ${\tt CCAAGCACTCCTAGCTGCTCCAGTCTCAGCCTGGGCAGCTTCCCCCTGCCTTTTGCACGTTTGCATCC}$ CCAGCATTTCCTGAGTTATAAGGCCACAGGAGTGGATAGCTGTTTTCACCTAAAGGAAAAGCCCACCCGA ATCTTGTAGAAATATTCAAACTAATAAAATCATGAATATTTTTATGAAGTTT

Figure 43

36/41

ACGGGCCTGGGCGSAGGGCCGTGGCTGGAGCTCGGTAAAGCTCGTGGGACCCCATTGGGG GAATTTGATCCAAGGAAGCGGTGATTGCCGGGGGAGAAGCTCCCAGATCCTTGTGTCCAC TTGCAGCGGGGAGGCGGAGCGGGCCTTTTGGCGTCCACTGCGCGGCTGCACCCT GCTGCTTGCCTGGCTCTCTGCCTGCTCCGGGTGCCCGGGGCTCGGGCTGCAGCCTGTGAG CCCGTCCGCATCCCCTGTGCAAGTCCCTGCCCTGGAACATGACTAAGATGCCCAACCACCTGC ACCACAGCACTCAGGCCAACGCCATCCTGGCCATCGAGCAGTTCGAAGGTCTGCTGGGCACCC ACTGCAGCCCGATCTGCTCTTCTTCCTCTGTGCCATGTACGCGCCCATCTGCACCATTGACTTC CAGCACGAGCCCATCAACCCCTGTAAGTCTGTGTGCGAGCGGGCCCGGCAGGGCTGTGAGCCC ATACTCATCAAGTACCGCCACTCGTGGCCGGAGAACCTGGCCTGCGAGGAGCTGCCAGTGTAC ATTCTAGTAACGGAAACTGTAGAGGGGCAAGCAGTGAACGCTGTAAATGTAAGCCTATTAGAG CTACACAGAAGACCTATTTCCGGAACAATTACAACTATGTCATTCGGGCTAAAGTTAAAGAGAT AAAGACTAAGTGCCATGATGTGACTGCAGTAGTGGAGGTGAAGGAGATTCTAAAGTCCTCTCT GGTAAACATTCCACGGGACACTGTCAACCTCTATACCAGCTCTGGCTGCCTCTGCCCTCCACTT AATGTTAATGAGGAATATATCATCATGGGCTATGAAGATGAGGAACGTTCCAGATTACTCTTGG TGGAAGGCTCTATAGCTGAGAAGTGGAAGGATCGACTCGGTAAAAAAGTTAAGCGCTGGGATA TGAAGCTTCGTCATCTTGGACTCAGTAAAAGTGATTCTAGCAATAGTGATTCCACTCAGAGTCA GAAGTCTGGCAGGAACTCGAACCCCCGGCAAGCACCCAACTAAATCCCGAAATACAAAAAGTA ACACAGTGGACTTCCTATTAAGACTTACTTGCATTGCTGGACTAGCAAAGGAAAATTGCACTAT TGCACATCATATTCTATTGTTTACTATAAAAATCATGTGATAACTGATTATTACTTCTGTTTCTCT TTTGGTTTCTCTCTCTCTCTCAACCCCTTTGTAATGGTTTGGGGGCAGACTCTTAAGTATA TTGTGAGTTTTCTATTTCACTAATCATGAGAAAAACTGTTCTTTTGCAATAATAATAAATTAAAC ATGCTGTTA

Figure 44

CAGCGGCCGCTGAATTCTAGGGCGGGTTCGCGCCCCGAAGGCTGAGAGCTGGCGCTCGTG CCCTGTGTGCCAGACGGCGGAGCTCCGCGGCCGGACCCCGCGGCCCCGCTTTGCTGCCGACTGG AGTTTGGGGGAAGAACTCTCCTGCGCCCCAGAAGATTTCTTCCTCGGCGAAGGGACAGCGAA AGATGAGGGTGGCAGGAAGAGAGGCGCTTTCTGTCTGCCGGGGTCGCAGCGCGAGAGGGCA GTGCCATGTTCCTCCATCCTAGTGGCGCTGTGCCTGTGGCTGCACCTGGCGCTGGGCGTGCG CGGCGCCCTGCGAGGCGGTGCGCATCCCTATGTGCCGGCACATGCCCTGGAACATCACGCG GATGCCCAACCACCTGCACCACAGCACGCAGGAGAACGCCATCCTGGCCATCGAGCAGTACGA GGAGCTGGTGGACGTGAACTGCAGCGCCGTGCTGCGCTTCTTCTTCTGTGCCATGTACGCGCCC ATTTGCACCCTGGAGTTCCTGCACGACCCTATCAAGCCGTGCAAGTCGGTGTGCCAACGCGCGC GCGACGACTGCGAGCCCCTCATGAAGATGTACAACCACAGCTGGCCCGAAAGCCTGGCCTGCG ACGAGCTGCCTGTCTATGACCGTGGCGTGTGCATTTCGCCTGAAGCCATCGTCACGGACCTCCC GGAGGATGTTAAGTGGATAGACATCACACCAGACATGATGGTACAGGAAAGGCCTCTTGATGT TGACTGTAAACGCCTAAGCCCCGATCGGTGCAAGTGTAAAAAGGTGAAGCCAACTTTGGCAAC GTATCTCAGCAAAAACTACAGCTATGTTATTCATGCCAAAATAAAAGCTGTGCAGAGGAGTGG CTGCAATGAGGTCACAACGGTGGTGGATGTAAAAGAGATCTTCAAGTCCTCATCACCCATCCCT CGAACTCAAGTCCCGCTCATTACAAATTCTTCTTGCCAGTGTCCACACATCCTGCCCCATCAAG ATGTTCTCATCATGTGTTACGAGTGGCGTTCAAGGATGATGCTTCTTGAAAATTGCTTAGTTGAA AAATGGAGAGATCAGCTTAGTAAAAGATCCATACAGTGGGAAGAGAGGGCTGCAGGAACAGCG GAGAACAGTTCAGGACAAGAAGAAAACAGCCGGGCGCACCAGTCGTAGTAATCCCCCCAAACC AAAGGGAAAGCCTCCTGCTCCCAAACCAGCCAGTCCCAAGAAGAACATTAAAACTAGGAGTGC CCAGAAGAGAACAAACCCGAAAAGAGTGTGAGCTAACTAGTTTCCAAAGCGGAGACTTCCGAC TTCCTTACAGGATGAGGCTGGGCATTGCCTGGGACAGCCTATGTAAGGCCATGTGCCCCTTGCC CTAACAACTCACTGCAGTGCTCTTCATAGACACATCTTGCAGCATTTTTCTTAAGGCTATGCTTC AGTTTTCTTTGTAAGCCATCACAAGCCATAGTGGTAGGTTTGCCCTTTGGTACAGAAGGTGAG TTAAAGCTGGTGGAAAAGGCTTATTGCATTGCATTCAGAGTAACCTGTGTGCATACTCTAGAAG TTCAAACAAAACACGTAATTTTTTTACAGTATGTTTTATTACCTTTTTGATATCTGTTGTTGCAAT ATGTTAAAAGATCTTTATGTGTTTATGGTCTGCAGAAGGATTTTTGTGATGAAAGGGGATTTTTT

WO 03/012082 PCT/GB02/03409

37/41

GAAAAATTAGAGAAGTAGCATATGGAAAATTATAATGTGTTTTTTTACCAATGACTTCAGTTTC CAGACAATGTCTGGATTCCTGTTTTTTGGTTACCTGATTTCCATGATCATGATGCTTCTTGTCAA CACCCTCTTAAGCAGCACCAGAAACAGTGAGTTTGTCTGTACCATTAGGAGTTAGGTACTAATT AGTTGGCTAATGCTCAAGTATTTTATACCCACAAGAGAGGTATGTCACTCATCTTACTTCCCAG GACATCCACCCTGAGAATAATTTGACAAGCTTAAAAATGGCCTTCATGTGAGTGCCAAATTTTG TTTTTCTTCATTTAAATATTTTCTTTGCCTAAATACATGTGAGAGGAGTTAAATATAAATGTACA GAGAGGAAAGTTGAGTTCCACCTCTGAAATGAGAATTACTTGACAGTTGGGATACTTTAATCAG AAAAAAAGAACTTATTTGCAGCATTTTATCAACAAATTTCATAATTGTGGACAATTGGAGGCAT TTATTTTAAAAAACAATTTTATTGGCCTTTTGCTAACACAGTAAGCATGTATTTTATAAGGCATT CAATAAATGCACAACGCCCAAAGGAAATAAAATCCTATCTAATCCTACTCTCCACTACACAGA GGTAATCACTATTAGTATTTTGGCATATTATTCTCCAGGTGTTTGCTTATGCACTTATAAAAATGA TTTGAACAAATAAAACTAGGAACCTGTATACATGTGTTTCATAACCTGCCTCCTTTGCTTGGCCC TTTATTGAGATAAGTTTTCCTGTCAAGAAAGCAGAAACCATCTCATTTCTAACAGCTGTGTTATA TTCCATAGTATGCATTACTCAACAAACTGTTGTGCTATTGGATACTTAGGTGGTTTCTTCACTGA CAATACTGAATAAACATCTCACCGGAATTC

Figure 45

AAGCTTGATATCGAATTCGCGGCCGCGTCGACGGGAGGCGCCAGGATCAGTCGGGGCACCCGC AGCGCAGGCTGCCACCCACCTGGGCGACCTCCGCGGCGGCGGCGGCGGCGGCGGCTAGAGTC AGGGCCGGGGCGCACGCCGGAACACCTGGGCCGCCGGGCACCGAGCGTCGGGGGGCTGCGC CTACTATGGCTGGCAGGCCGAGCCGCTGCACGGCCGCTCCTACTCCAAGCCGCCGCAGTGCCTT GACATCCCTGCCGACCTGCCGCTCTGCCACACGGTGGGCTACAAGCGCATGCGGCTGCCCAACC CGGCCCATCTACCCGTGCCGCTCGCTGTGCGAGGCCGTGCGCGCCGGCTGCGCGCCCCTCATGG AGGCCTACGGCTTCCCCTGGCCTGAGATGCTGCACTGCCACAAGTTCCCCCTGGACAACGACCT CTGCATCGCCGTGCAGTTCGGGCACCTGCCCGCCACCGCGCCTCCAGTGACCAAGATCTGCGCC CAGTGTGAGATGGAGCACAGTGCTGACGGCCTCATGGAGCAGATGTGCTCCAGTGACTTTGTG GTCAAAATGCGCATCAAGGAGATCAAGATAGAGAATGGGGACCGGAAGCTGATTGGAGCCCA GAAAAAGAAGAAGCTGCTCAAGCCGGGCCCCCTGAAGCGCAAGGACACCAAGCGGCTGGTGC TGCACATGAAGAATGGCGCGGGCTGCCCCTGCCCACAGCTGGACAGCCTGGCGGCAGCTTCC TGGTCATGGCCGCAAAGTGGATGGACAGCTGCTCATGGCCGTCTACCGCTGGGACAAGA AGAATAAGGAGATGAAGTTTGCAGTCAAATTCATGTTCTCCTACCCCTGCTCCCTCTACTACCCT TTCTTCTACGGGGCGGCAGAGCCCCACTGAAGGGCACTCCTCCTTGCCCTGCCAGCTGTGCCTT GCTTGCCCTCTGGCCCCGCCCCAACTTCCAGGCTGACCCGGCCCTACTGGAGGGTGTTTTCACG AATGTTGTTACTGGCACAAGGCCTAAGGGATGGGCACGGAGCCCAGGCTGTCCTTTTTGACCCA GGGGTCCTGGGGTCCCTGGGATGTTGGGCTTCCTCTCAGGAGCAGGGCTTCTTCATCTGGGT GAAGACCTCAGGGTCTCAGAAAGTAGGCAGGGGAGGAGAGGGTAAGGGAAAGGTGGAGGGGC TCAGGGCACCCTGAGGCGGAGGTTTCAGAGTAGAAGGTGATGTCAGCTCCAGCTCCCCTCTGTC GGTGGTGGGCCTCACCTTGAAGAGGGAAGTCTCAATATTAGGCTAAGCTATTTGGGAAAGTTC TCCCCACCGCCCTGTACGCGTCATCCTAGCCCCCCTTAGGAAAGGAGTTAGGGTCTCAGTGCC TCCAGCCACACCCCTGCCTTCCCCAGCTTGCCCATTTCCCTGCCCCAAGGCCCAGAGCTCCCCC CAGACTGGAGAGCCAGCCCAGCCTCGGCATAGACCCCCTTCTGGTCCGCCCGTGGCTCG ATTCCCGGGATTCATTCCTCAGCCTCTGCTTCTCCCTTTTATCCCAATAAGTTATTGCTACTGCTG TGAGGCCATAGGTACTAGACAACCAATACATGCAGGGTTGGGTTTTCTAATTTTTTAACTTTTT AATTAAATCAAAGGTCGACGCGCGGCCGCGGAATTCCTGCAGCCCGGGGGATCCCCGGGTACC **GAGCTCGAATTC**

Figure 46

Figure 47

TGAGTCCTTCTGAGATGATGGCTCTGGGCGCAGCGGGAGCTACCCGGGTCTTTGTCGCGATGGT AGCGGCGGCTCTCGGCGGCCACCCTCTGCTGGGAGTGAGCGCCACCTTGAACTCGGTTCTCAAT TCCAACGCTATCAAGAACCTGCCCCACCGCTGGGCGCGCTGCGGGGCACCCAGGCTCTGCA GTCAGCGCCGCGCGGAATCCTGTACCCGGGCGGAATAAGTACCAGACCATTGACAACTAC CAGCCGTACCCGTGCGCAGAGGACGAGGAGTGCGGCACTGATGAGTACTGCGCTAGTCCCACC CGCGGAGGGGACGCAGGCGTGCAAATCTGTCTCGCCTGCAGGAAGCGCCGAAAAACGCTGCATG CGTCACGCTATGTGCTGCCCCGGGAATTACTGCAAAAATGGAATATGTGTGTCTTCTGATCAAA ATCATTTCCGAGGAGAAATTGAGGAAACCATCACTGAAAGCTTTGGTAATGATCATAGCACCTT GGATGGGTATTCCAGAAGAACCACCTTGTCTTCAAAAATGTATCACACCAAAGGACAAGAAGG TTCTGTTTGTCTCCGGTCATCAGACTGTGCCTCAGGATTGTGTTGTGCTAGACACTTCTGGTCCA AGATCTGTAAACCTGTCCTGAAAGAAGGTCAAGTGTGTACCAAGCATAGGAGAAAAAGGCTCTC TCACCATCAAGCCAGTAATTCTTCTAGGCTTCACACTTGTCAGAGACACTAAACCAGCTATCCA AATGCAGTGAACTCCTTTTATATAATAGATGCTATGAAAACCTTTTATGACCTTCATCAACTCAA TCCTAAGGATATACAAGTTCTGTGGTTTCAGTTAAGCATTCCAATAACACCTTCCAAAAACCTG GAGTGTAAGAGCTTTGTTTCTTTATGGAACTCCCCTGTGATTGCAGTAAATTACTGTATTGTAAA TTCTCAGTGTGGCACTTACCTGTAAATGCAATGAAACTTTTAATTATTTTTCTAAAGGTGCTGCA TTCTATATTGAACTGAAGTAAATCATTTCAGCTTATAGTTCTTAAAAGCATAACCCTTTACCCCA TTTAATTCTAGAGTCTAGAACGCAAGGATCTCTTGGAATGACAAATGATAGGTACCTAAAATGT AACATGAAAATACTAGCTTATTTTCTGAAATGTACTATCTTAATGCTTAAATTATATTTCCCTTT AGGCTGTGATAGTTTTTGAAATAAAATTTAACATTTAATATCATGAAATGTTATAAGTAGACAT

Figure 48

GCGGGTCTCGCTTGGGTTCCGCTAATTTCTGTCCTGAGGCGTGAGACTGAGTTCATAGGGTCCT
GGGTCCCCGAACCAGGAAGGGTTGAGGGAACACAATCTGCAAGCCCCGCGACCCAAGTGAGG
GGCCCCGTGTTGGGGTCCTCCCTCCCTTTGCATTCCCACCCCTCCGGGCTTTGCGTCTTCCTGGG
GACCCCCTCGCCGGGAGATGGCCGCGTTGATGCGGAGCAAGGATTCGTCCTGCTGCTCCT
ACTGGCCGCGGTGCTGATGGTGGAGAGCTCACAGATCGGCAGTTCGCGGGCCAAACTCAACTC
CATCAAGTCCTCTCTGGGCGGGGAGACGCCTGGTCAGGCCGCCAATCGATCTGCGGGCATGTAC
CAAGGACTGGCATTCGGCGGCAGTAAGAAGAGGCAAAAAACCTGGGGCAGGCCTACCCTTGTAGC
AGTGATAAGGAGTGTGAAGTTGGGAGGTATTGCCACAGTCCCCACCAAGGATCATCGGCCTGC
ATGGTGTCGGAGAAAAAAAGAAGCGCTGCCACCGAGATGGCATGTGCTCCCCAGTACCCGC
TGCAATAATGGCATCTGTATCCCAGTTACTGAAAGCATCTTAACCCCTCACATCCCGGCTCTGG
ATGGTACTCGGCACAGAGATCGAAACCACGGTCATTACTCAAACCATGACTTGGGATGGCAGA
ATCTAGGAAGACCACACACTAAGATGTCACATATAAAAAGGGCATGAAGGAGACCCCTGCCTAC
GATCATCAGACTGCATTGAAGGGTTTTGCTGTCTCGTCATTTCTGGACCAAAATCTGCAAACC

AGTGCTCCATCAGGGGAAGTCTGTACCAAACAACGCAAGAAGGGTTCTCATGGGCTGGAAAT TTTCCAGCGTTGCGACTGTGCGAAGGGCCTGTCTTGCAAAGTATGGAAAGATGCCACCTACTCC TCCAAAGCCAGACTCCATGTGTGTCAGAAAATTTGATCACCATTGAGGAACATCATCAATTGCA GACTGTGAAGTTGTGTATTTAATGCATTATAGCATGGTGGAAAATAAGGTTCAGATGCAGAAG AATGGCTAAAATAAGAAACGTGATAAAGAATATAGATGATCAC

Figure 49

AATTCACAAGATAACCAACAACCAGACTGGACAAATGGTCTTTTCAGAGACAGTTATCACATCT GTGGGAGACGAAGAAGGCAGAAGGAGCCACGAGTGCATCATCGACGAGGACTGTGGGCCCAG TGCACCGGGACAGTGAGTGCTGTGGAGACCAGCTGTGTGTCTGGGGTCACTGCACCAAAATG GCCACCAGGGGCAGCAATGGGACCATCTGTGACAACCAGAGGGACTGCCAGCCGGGGCTGTGC TGTGCCTTCCAGAGAGGCCTGCTGTTCCCTGTGTGCACACCCCTGCCCGTGGAGGGCGAGCTTT GCCATGACCCGCCAGCCGCTTCTGGACCTCATCACCTGGGAGCTAGAGCCTGATGGAGCCTT GGACCGATGCCCTTGTGCCAGTGGCCTCCTCTGCCAGCCCACAGCCACAGCCTGGTGTATGTG TGCAAGCCGACCTTCGTGGGGAGCCGTGACCAAGATGGGGAGATCCTGCTGCCCAGAGAGGTC CCCGATGAGTATGAAGTTGGCAGCTTCATGGAGGAGGTGCGCCAGGAGCTGGAGGACCTGGAG AGGAGCCTGACTGAAGAGATGGCGCTGGGGGAGCCTGCGGCTGCCGCTGCACTGCTGGGA GGGGAAGAGATTTAGATCTGGACCAGGCTGTGGGTAGATGTGCAATAGAAATAGCTAATTTAT TTCCCCAGGTGTGTGCTTTAGGCGTGGGCTGACCAGGCTTCTTCCTACATCTTCTTCCCAGTAAG TTTCCCCTCTGGCTTGACAGCATGAGGTGTTGTGCATTTGTTCAGCTCCCCCAGGCTGTTCTCCA GGCTTCACAGTCTGGTGCTTGGGAGAGTCAGGCAGGGTTAAACTGCAGGAGCAGTTTGCCACC CCTGTCCAGATTATTGGCTGCTTTGCCTCTACCAGTTGGCAGACAGCCGTTTGTTCTACATGGCT TTGATAATTGTTTGAGGGGAGGAGATGGAAACAATGTGGAGTCTCCCTCTGATTGGTTTTGGGG AAATGTGGAGAAGAGTGCCCTGCTTTGCAAACATCAACCTGGCAAAAATGCAACAAATGAATT TTCCACGCAGTTCTTTCCATGGGCATAGGTAAGCTGTGCCTTCAGCTGTTGCAGATGAAATGTTC TGTTCACCCTGCATTACATGTGTTTATTCATCCAGCAGTGTTGCTCAGCTCCTACCTCTGTGCCA GGGCAGCATTTTCATATCCAAGATCAATTCCCTCTCTCAGCACAGCCTGGGGAGGGGGTCATTG TTCTCCTCGTCCATCAGGGATCTCAGAGGNCTCAGAGACTGCAAGCTGCTTGCCCAAGTCACAC AGCTAGTGAAGACCAGAGCAGTTTCATCTGGTTGTGACTCTAAGCTCAGTGCTCTCCACTAC TGAGGCATGCACATCTGGAATTAAGGTCAAACTAATTCTCACATCCCTCTAAAAGTAAACTACT GTTAGGAACAGCAGTGTTCTCACAGTGTGGGGCAGCCGTCCTTCTAATGAAGACAATGATATTG ACACTGTCCCTCTTTGGCAGTTGCATTAGTAACTTTGAAAGGTATATGACTGAGCGTAGCATAC AGGTTAACCTGCAGAAACAGTACTTAGGTAATTGTAGGGCGAGGATTATAAATGAAATTTGCA **AAATCACTTAGCAGCAACTGAAGACAATTATCAACCACGTGGAGAAAATCAAACCGAGCAGGG** CTGTGTGAAACATGGTTGTAATATGCGACTGCGAACACTGAACTCTACGCCACTCCACAAATGA TGTTTTCAGGTGTCATGGACTGTTGCCACCATGTATTCATCCAGAGTTCTTAAAGTTTAAAGTTG CACATGATTGTATAAGCATGCTTTCTTTGAGTTTTAAATTATGTATAAACATAAGTTGCATTTAG AAATCAAGCATAAATCAC

Figure 50

GACTTTGCTGTGCTCGTCATTTTTGGACGAAAATTTGTAAGCCAGTCCTTTTGGAGGGACAGGT CTGCTCCAGAAGAGGGCATAAAGACACTGCTCAAGCTCCAGAAATCTTCCAGCGTTGCGACTGT GGCCCTGGACTACTGTCGAAGCCAATTGACCAGCAATCGGCAGCATGCTCGATTAAGAGTAT GCCAAAAAATAGAAAAGCTATAAATATTTCAAAATAAAGAAGAATCCACATTGC

Figure 51

AGGCAGAATACTTCTATGAATTCCTGTCCTTGCGCTCCCTGGATAAAGGCATCATGGCAGATCC AACCGTCAATGTCCCTCTGCTGGGAACAGTGCCTCACAAGGCATCAGTTGTTCAAGTTGGTTTC CCATGTCTTGGAAAACAGGATGGGGTGGCAGCATTTGAAGTGGATGTGATTGTTATGAATTCTG AAGGCAACACCATTCTCCAAACACCTCAAAATGCTATCTTCTTTAAAACATGTCAACAAGCTGA GTGCCCAGGCGGTGCCGAAATGGAGGCTTTTGTAATGAAAGACGCATCTGCGAGTGTCCTGA TGGGTTCCACGGACCTCACTGTGAGAAAGCCCTTTGTACCCCACGATGTATGAATGGTGGACTT TGTGTGACTCCTGGTTTCTGCATCTGCCCACCTGGATTCTATGGAGTGAACTGTGACAAAGCAA ACTGCTCAACCACCTGCTTTAATGGAGGGACCTGTTTCTACCCTGGAAAATGTATTTGCCCTCCA GGACTAGAGGGAGAGCAGTGTGAAATCAGCAAATGCCCACAACCCTGTCGAAATGGAGGTAA ATGCATTGGTAAAAGCAAATGTAAGTGTTCCAAAGGTTACCAGGGAGACCTCTGTTCAAAGCCT GTCTGCGAGCCTGGCTGTGCACATGGAACCTGCCATGAACCCAACAATGCCAATGTCAA GCAGCAGCCCCAGCTCAGGCAGCACCCCTTCACTTAAAAAGGCCGAGGAGCGGCGGCATC CACCTGAATCCAATTACATCTGGTGAACTCCGACATCTGAAACGTTTTAAGTTACACCAAGTTC ATAGCCTTTGTTAACCTTTCATGTGTTGAATGTTCAAATAATGTTCATTACACTTAAGAATACTG GCCTGAATTTTATTAGCTTCATTATAAATCACTGAGCTGATATTTACTCTTCCTTTTAAGTTTTCT AAGTACGTCTGTAGCATGATGGTATAGATTTTCTTGTTTCAGTGCTTTGGGACAGATTTTATATT ATGTCAATTGATCAGGTTAAAATTTTCAGTGTGTGTGGCAGATATTTTCAAAATTACAATGC ATTTATGGTGTCTGGGGGCAGGGGAACATCAGAAAGGTTAAATTGGGCAAAAATGCGTAAGTC ACAAGAATTTGGATGGTGCAGTTAATGTTGAAGTTACAGCATTTCAGATTTTATTGTCAGATAT TTAGATGTTTGTTACATTTTTAAAAATTGCTCTTAATTTTTAAACTCTCAATACAATATATTTTGA AAACAATATAATATTCTAAACACAATGAAATAGGGAATATAATGTATGAACTTTTTGCATTG GCTTGAAGCAATATAATATTGTAAACAAAACACAGCTCTTACCTAATAAACATTTTATACTG TTTGTATGTATAAAATAAAGGTGCTGCTTTAGTTTTC

Figure 52

 $\tt CGCTTCTGGCCGTGGGCTCGGCCAGCGAGTACGACTACGTGAGCTTCCAGTCGGACATCGGCCCGTACCA$ GAGCGGGCGCTTCTACACCAAGCCACCTCAGTGCGTGGACATCCCCGCGGACCTGCGGCTGTGCCACAAC GTGGGCTACAAGAAGATGGTGCTGCCCAACCTGCTGGAGCACGAGACCATGGCGGAGGTGAAGCAGCAGG CGCGCCCGTCTGCCTGGACCGGCCCATCTACCCGTGTCGCTGGCTCTGCGAGGCCGTGCGCGACTCGTGC GAGCCGGTCATGCAGTTCTTCGGCTTCTACTGGCCCGAGATGCTTAAGTGTGACAAGTTCCCCGAGGGGG ACGTCTGCATCGCCATGACGCCGCCCAATGCCACCGAAGCCTCCAAGCCCCAAGGCACAACGGTGTGTCC TCCCTGTGACAACGAGTTGAAATCTGAGGCCATCATTGAACATCTCTGTGCCAGCGAGTTTGGGCTGAGT TTAAAGATGATTGTGGGTAGCTCCCATAACTCATGCTGCACGCTGGGTCCTTCTCATCCCAACTCCTCAA AGCGGCAGGAGCAGGAACTGGGGACTCCTGAGAGAAGGCTTGGATATGGCCTTTTATTACACTTCATCCA AGGAAATCTGCCCCACCCTGTGCCCAGGCCCGATCACGCATGAGGCCTAAAGACGGAGGCCACTCCGCTG GCTCTGGGTAGATCTGCCCCTGGACTGTTTGCCGACTGCCCGGAGCGCCCTCTGCCGGTCTGCAGCTTCC CACACCACACGGAAGAAGTGGGGAAACTGAGGATACATTCTTTCCTCCTCCAGGTAAAGGGATTCTCAAT GAAGGGCTTGTGCACCTTCCACACTTAGATACCTCTACTACCTGAAAACCAGCATGCAGCATGTACAT CAAGAGTACCAGGCACATAGTGCTCAAGTCTGGGCTAATATGCCÁCCTGCAGAGAGATGTAAAGATGAAG AAGACAAAGCCATGTTTTCAAAGTGA

WO 03/012082 PCT/GB02/03409

Figure 53 41/41

GGCGGGTTCGCGCCCCGAAGGCTGAGAGCTGGCGCTGCTCGTGCCCTGTGTGCCAGACGGCGGAGCTCCG $\tt CGGCCGGACCCCGCGGCCCGCTTTGCTGCCGACTGGAGTTTGGGGGGAAGAACTCTCCTGCGCCCCAGA$ GGGGTCGCAGCGCGAGAGGGCAGTGCCATGTTCCTCTCCATCCTAGTGGCGCTGTGCCTGTGGCTGCACC TGGCGCTGGGCGTGCGCGCGCCCTGCGAGGCGGTGCGCATCCCTATGTGCCGGCACATGCCCTGGAA CATCACGCGGATGCCCAACCACCTGCACCACAGCACGCAGGAGAACGCCATCCTGGCCATCGAGCAGTAC GAGGAGCTGGTGGACGTGAACTGCAGCGCCGTGCTGCGCTTCTTCTTCTGTGCCATGTACGCGCCCATTT CGAGCCCCTCATGAAGATGTACAACCACAGCTGGCCCGAAAGCCTGGCCTGCGACGAGCTGCCTGTCTAT GACCGTGGCGTGTGCATTTCGCCTGAAGCCATCGTCACGGACCTCCCGGAGGATGTTAAGTGGATAGACA TCACACCAGACATGATGGTACAGGAAAGGCCTCTTGATGTTGACTGTAAACGCCTAAGCCCCGATCGGTG CAAGTGTAAAAAGGTGAAGCCAACTTTGGCAACGTATCTCAGCAAAAACTACAGCTATGTTATTCATGCC AAAATAAAAGCTGTGCAGAGGAGTGGCTGCAATGAGGTCACAACGGTGGTGGATGTAAAAGAGATCTTCA AGTCCTCATCACCCATCCCTCGAACTCAAGTCCCGCTCATTACAAATTCTTCTTGCCAGTGTCCACACAT CCTGCCCCATCAAGATGTTCTCATCATGTGTTACGAGTGGCGTTCAAGGATGATGCTTCTTGAAAATTGC TTAGTTGAAAAATGGAGAGATCAGCTTAGTAAAAGATCCATACAGTGGGAAGAGAGGCTGCAGGAACAGC GGAGAACAGTTCAGGACAAGAAGAAAACAGCCGGGCGCACCAGTCGTAGTAATCCCCCCAAACCAAAGGG AAAGCCTCCTGCTCCCAAACCAGCCAGTCCCAAGAAGAACATTAAAACTAGGAGTGCCCAGAAGAAACA AACCCGAAAAGAGTGTGAGCTAACTAGTTTCCAAAGCGGAGACTTCCGACTTCCTTACAGGATGAGGCTG GGCATTGCCTGGGACAGCCTATGTAAGGCCATGTGCCCCTTGCCCTAACAACTCACTGCAGTGCTCTTCA TAGACACATCTTGCAGCATTTTTCTTAAGGCTATGCTTCAGTTTTTCTTTGTAAGCCATCACAAGCCATA GTGGTAGGTTTGCCCTTTGGTACAGAAGGTGAGTTAAAGCTGGTGGAAAAGGCTTATTGCATTGCATTCA GAGTAACCTGTGTGCATACTCTAGAAGAGTAGGGAAAATAATGCTTGTTACAATTCGACCTAATATGTGC ATTGTAAAATAAATGCCATATTTCAAACAAAACACGTAATTTTTTTACAGTATGTTTTATTACCTTTT**GA** AGTGGAATGAATGTTAAAAGATCTTTATGTGTTTATGGTCTGCAGAAGGATTTTTGTGATGAAAGGGGAT GTCTGGATTCCTGTTTTTTGGTTACCTGATTTCCATGATCATGATGCTTCTTGTCAACACCCTCTTAAGC AGCACCAGAAACAGTGAGTTTGTCTGTACCATTAGGAGTTAGGTACTAATTAGTTGGCTAATGCTCAAGT ATTTTATACCCACAAGAGAGGTATGTCACTCATCTTACTTCCCAGGACATCCACCCTGAGAATAATTTGA CAAGCTTAAAAATGGCCTTCATGTGAGTGCCAAATTTTGTTTTTCTTCATTTAAATATTTTCTTTGCCTA AATACATGTGAGAGGAGTTAAATATAAATGTACAGAGAGGAAAGTTGAGTTCCACCTCTGAAATGAGAAT TACTTGACAGTTGGGATACTTTAATCAGAAAAAAAGAACTTATTTGCAGCATTTTATCAACAAATTTCAT AATTGTGGACAATTGGAGGCATTTATTTTAAAAAACAATTTTATTGGCCTTTTGCTAACACAGTAAGCAT GTATTTATAAGGCATTCAATAAATGCACAACGCCCAAAGGAAATAAAATCCTATCTAATCCTACTCTCC ACTACACAGAGGTAATCACTATTAGTATTTTTGGCATATTATTCTCCAGGTGTTTTGCTTATGCACTTATAA AATGATTTGAACAAATAAAACTAGGAACCTGTATACATGTGTTTCATAACCTGCCTCCTTTGCTTGGCCC TTTATTGAGATAAGTTTTCCTGTCAAGAAGCAGAAACCATCTCATTTCTAACAGCTGTGTTATATTCCA TAGTATGCATTACTCAACAAACTGTTGTGCTATTGGATACTTAGGTGGTTTCTTCACTGACAATACTGAA TAAACATCTCACCGGAATTC

Figure 54

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 13 February 2003 (13.02.2003)

PCT

(10) International Publication Number WO 2003/012082 A3

(51) International Patent Classification⁷: 15/11, A61K 48/00, 31/70

C12N 5/06,

(21) International Application Number:

PCT/GB2002/003409

(22) International Filing Date:

25 July 2002 (25.07.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0118223.7

26 July 2001 (26.07.2001) GB

- (71) Applicant (for all designated States except US): AXOR-DIA LIMITED [GB/GB]; Firth Court, Western Bank, Sheffield S10 2TN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ANDREWS, Peter [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB). WALSH, James [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB). GOKHALE, Paul [GB/GB]; University of Sheffield, Western Bank, Sheffield S10 2TN (GB).

- (74) Agent: HARRISON GODDARD FOOTE; 31 St Saviourgate, York YO1 8NO (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report:

 10 June 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

2003/012082 A3

(54) Title: METHOD FOR MODULATING STEM CELL DIFFERENTIATION USING STEM LOOP RNA

(57) Abstract: This invention relates to a method to promote the differentiation of stem cells, typically embryonic stem cells, through the use of RNA interference, by the introduction of stem loop RNA into a cell.

International Application No PCT/GB 02/03409

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N5/06 C12N15/11 A61K31/70 A61K48/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Category 9 WO 01 03743 A (GEHRING WALTER; ARTAVANIS X TSAKONAS SPYRIDON) 18 January 2001 (2001-01-18) page 39 -page 45 page 52 -page 60 WO 01 36646 A (CANCER RES CAMPAIGN TECHN Y LIM (GB) ZERNIČKA-GOETZ WIANNY EVANS GLOVER) 25 May 2001 (2001-05-25) page 6, line 29 -page 7, line 12 page 11, line 28 page 20, line 21 -page 21, line 26 Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "O" document referring to an oral disclosure, use, exhibition or document published prior to the international filing date but tater than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 1.2 08. 2003 21 May 2003 Name and mailing address of the ISA Authorized offices European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Macchia, G Fax: (+31-70) 340-3016

Form PCT/ISA/210 (second sheet) (July 1992)

International Application No
PCT/GB 02/03409

| | | FC1/GD 02/03409 | |
|-------------|---|----------------------------------|---|
| C.(Continua | ation) DOCUMENTS CONSIDERED TO BE RELEVANT | | _ |
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to daim No. | |
| Υ | WO 01 25422 A (AVI BIOPHARMA, INC. (US); BARTELMEZ STEPHEN H.; IVERSEN PATRICK L.) 12 April 2001 (2001-04-12) | 1-5, 7-22, 25-28, 30,33 | |
| | page 4 page 16 -page 17 | | |
| Ρ,Χ | WO 02 16620 A (UNIVERSITY OF SHEFFIELD (GB); ANDREWS PETER; WALSH JAMES; GOKHALE PAUL) 28 February 2002 (2002-02-28) the whole document | 1,4-8, 12-23, 25-32 | |
| 4 | WO 98 58958 A (WASHINGTON UNIV PHILADELPHIA CHILDREN'S HOSPITAL; LI HOOD KRANTZ SPINN) 30 December 1998 (1998-12-30) | | |
| | WO 97 45143 A (NATL US RED CROSS; UNIV GENEVE; ZIMRIN; MACIAG; PEPPER; MONTESANO WONG) 4 December 1997 (1997-12-04) page 9, line 14-25 page 15, line 30 -page 36, line 4 | | |
| 1 | WO 00 25809 A (SMITH & NEPHEW PLC (GB); SKERRY T.M.; DALLAS D.J.; WOLOWACZ R.G.) 11 May 2000 (2000-05-11) the whole document | | • |
| 1 | WO 99 32619 A (CARNEGIE INST WASHINGTON; FIRE XU MONTGOMERY KOSTAS TIMMONS TABARA ET) 1 July 1999 (1999-07-01) page 10, line 28 -page 11, line 13 page 13, line 1-29 page 14, line 26-30 page 16, line 23 | 8-23,26, 27,32,33 | • |
| | WO 00 63364 A (AMERIĆAN HOME PRODUCTS CORPORATION; PACHUK CATHERINE SATISHCHANDRAN C.) 26 October 2000 (2000-10-26) | | |
| | - | | |
| | | | |
| ļ | | | |
| } | | | |
| | | | |
| | | | • |
| | | | |
| . [| | · | |
| • | · | | |
| Į | | } | |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

International application No. PCT/GB 02/03409

| Boxi | Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) |
|----------------|---|
| This Inte | ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: |
| 1. X | Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: |
| - . | Although claims 1-7 and 25 (for claims 1-7, insofar as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. |
| 2. X | Claims Nos.: 1-6, 8-16, 18-33 all in part because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: |
| | see FURTHER INFORMATION sheet PCT/ISA/210 |
| | |
| | |
| . з. [] | Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). |
| | Observations where unity of invention is lacking (Continuation of item 2 of first sheet) |
| Box II | Observations where unity of invention is facking (continuation of item 2 of first sheet) |
| This Inte | rnational Searching Authority found multiple inventions in this international application, as follows: |
| | see additional sheet |
| | See additional Sheet |
| | |
| 1. | As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. |
| | |
| 2. | As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. |
| | or any adminoral ree. |
| | |
| з. 🗌 | As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: |
| | |
| • | |
| | |
| 4. X | No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: |
| • | 1-33 (all partially) |
| | 1-55 (att paretaris) |
| | |
| Remark | on Protest |
| I | No protest accompanied the payment of additional search fees. |
| | |

BNSDOCID: <WO____03012082A3_I_>

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

International Application No
PCT/GB 02/03409

| (Continua | tion) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|-----------|---|--------|----------------------------------|
| tegory ° | Citation of document, with indication, where appropriate, of the relevant passages | | Relevant to dalm No. |
| | WO 01 25422 A (AVI BIOPHARMA, INC. (US); BARTELMEZ STEPHEN H.; IVERSEN PATRICK L.) 12 April 2001 (2001-04-12) | | 1-5, 7-22, 25-28, 30,33 |
| | page 4 page 16 -page 17 | • | |
| ,х | WO 02 16620 A (UNIVERSITY OF SHEFFIELD (GB); ANDREWS PETER; WALSH JAMES; GOKHALE PAUL) 28 February 2002 (2002-02-28) the whole document | | 1,4-8, 12-23, 25-32 |
| | WD 98 58958 A (WASHINGTON UNIV PHILADELPHIA CHILDREN'S HOSPITAL; LI HOOD KRANTZ SPINN) 30 December 1998 (1998-12-30) | | |
| | WO 97 45143 A (NATL US RED CROSS; UNIV GENEVE; ZIMRIN; MACIAG; PEPPER; MONTESANO WONG) 4 December 1997 (1997-12-04) page 9, line 14-25 page 15, line 30 -page 36, line 4 | | |
| | WO 00 25809 A (SMITH & NEPHEW PLC (GB); SKERRY T.M.; DALLAS D.J.; WOLOWACZ R.G.) 11 May 2000 (2000-05-11) the whole document | | |
| | WO 99 32619 A (CARNEGIE INST WASHINGTON; FIRE XU MONTGOMERY KOSTAS TIMMONS TABARA ET) 1 July 1999 (1999-07-01) page 10, line 28 -page 11, line 13 page 13, line 1-29 page 14, line 26-30 page 16, line 23 | | 8-23,26, 27,32,33 |
| · | WO 00 63364 A (AMERICAN HOME PRODUCTS CORPORATION; PACHUK CATHERINE SATISHCHANDRAN C.) 26 October 2000 (2000-10-26) | | ÷ |
| | | | |
| | | | |
| | | · · | |
| - | | | |
| | | | |

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

International application No. PCT/GB 02/03409

| Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) | |
|--|----|
| This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | |
| 1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: | |
| Although claims 1-7 and 25 (for claims 1-7, insofar as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, t search has been carried out and based on the alleged effects of the compound/composition. | he |
| 2. X Claims Nos.: 1-6, 8-16, 18-33 all in part because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: | |
| see FURTHER INFORMATION sheet PCT/ISA/210 | |
| | |
| 3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). | |
| | |
| Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet) | |
| This International Searching Authority found multiple inventions in this international application, as follows: | |
| | |
| see additional sheet | |
| | · |
| | • |
| As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. | |
| | |
| 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did hot invite payment of any additional fee. | |
| or any adminoral ree. | |
| | |
| 3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: | |
| | |
| | ٠. |
| | |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: | |
| | |
| 1-33 (all partially) | |
| | • |
| · | |
| Remark on Protest The additional search fees were accompanied by the applicant's protest. | |
| No protest accompanied the payment of additional search fees. | |
| | |

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)